Document:

EX 10.5 - First Amendment to HQ Lease

FIRST AMENDMENT TO LEASE
This FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of the _9__ day of July, 2015, by and between SFI PLEASANTON, LLC, a Delaware limited liability company ("Landlord"), and ELLIE MAE, INC., a Delaware corporation ("Tenant").
R E C I T A L S :
A.    Landlord and Tenant entered into that certain Lease dated July 14, 2014 (the "Lease"), whereby Landlord leased to Tenant and Tenant leased from Landlord those certain premises consisting of 105,452 rentable square feet ("Existing Premises") commonly known as Suites 300, 400 and 500 and located on the entire third (3rd), fourth (4th) and fifth (5th) floors of that certain office building located at 4420 Rosewood Drive, Pleasanton, California ("Building").
B.    Pursuant to Section 46 of the Lease, Tenant has exercised its right of first offer with respect to the First Floor Offer Space, to expand the Existing Premises to include that certain space consisting of 31,717 rentable square feet of space commonly known as Suite 100 and located on the first (1st) floor of the Building (the "Expansion Premises"), as delineated on Exhibit A attached hereto and made a part hereof, and to make other modifications to the Lease, and in connection therewith, Landlord and Tenant desire to amend the Lease as hereinafter provided.
A G R E E M E N T :
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
1.Capitalized Terms.  All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this First Amendment.
2.Modification of Premises.  Effective as of January 1, 2016 (the "Expansion Commencement Date"), Tenant shall lease from Landlord and Landlord shall lease to Tenant the Expansion Premises.  Consequently, effective upon the Expansion Commencement Date, the Existing Premises shall be increased to include the Expansion Premises.  Landlord and Tenant hereby acknowledge that such addition of the Expansion Premises to the Existing Premises shall, effective as of the Expansion Commencement Date, increase the size of the Premises to 137,169 rentable square feet.  The Existing Premises and the Expansion Premises may hereinafter collectively be referred to as the "Premises." 
3.Expansion Term.  The term of Tenant's lease of the Expansion Premises (the "Expansion Term") shall commence on the Expansion Commencement Date and shall expire coterminously with Tenant's Lease of the Existing Premises on the Termination Date, subject to extension as provided in Section 44 of the Lease (Option to Renew), unless sooner terminated as provided in the Lease, as hereby amended.
4.Rent.
4.1.Existing Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, Tenant shall continue to pay Monthly Installments of Rent for the Existing Premises in accordance with the terms of Article 3 of the Lease.  
4.2.Expansion Premises.  Commencing on the Expansion Commencement Date and continuing throughout the Expansion Term, Tenant shall pay to Landlord Monthly Installments of Rent for the Expansion Premises as follows:

	
				
	Period During Expansion Term
	Annual Rent
	Monthly Installment of Rent
	Approximate Monthly Rental Rate per Rentable Square Foot

	1/1/16 - 3/31/2016*
	$951,510.00*
	$79,292.50*
	$2.50*

	4/1/2016 - 3/31/2017
	$980,055.36 
	$81,671.28 
	$2.58

	4/1/2017 - 3/31/2018
	$1,009,456.92 
	$84,121.41 
	$2.65

	4/1/2018 - 3/31/2019
	$1,039,740.72 
	$86,645.06 
	$2.73

	4/1/2019 - 3/31/2020
	$1,070,932.92 
	$89,244.41 
	$2.81

	4/1/2020 - 3/31/2021
	$1,103,060.88 
	$91,921.74 
	$2.90

	4/1/2021 - 3/31/2022
	$1,136,152.68 
	$94,679.39 
	$2.99

	4/1/2022 - 3/31/2023
	$1,170,237.24 
	$97,519.77 
	$3.07

	4/1/2023 - 3/31/2024
	$1,205,344.44 
	$100,445.37 
	$3.17

	4/1/2024 - 12/31/2024
	$1,241,504.76 
	$103,458.73 
	$3.26

*The Monthly Installment of Rent for the period commencing on January 1, 2016 and ending on March 31, 2016 is subject to abatement pursuant to Section 4.3 of this First Amendment.
On or before the Expansion Commencement Date, Tenant shall pay to Landlord the Monthly Installment of Rent payable for the Expansion Premises for the first full month of the Expansion Term.
4.3.Abated Base Rent.  Notwithstanding anything in this Lease to the contrary, so long as there exists no uncured monetary or material non-monetary Event of Default, Tenant shall be entitled to an abatement of Monthly Installment of Rent with respect to the Expansion Premises in the amount of $79,292.50 per month (and prorated for any partial month) for the period commencing on January 1, 2016 and continuing through March 31, 2016 (the “Rent Abatement Period”).  The maximum total amount of Monthly Installment of Rent abated with respect to the Expansion Premises in accordance with the foregoing shall equal $237,877.50 (the “Abated Monthly Installment of Rent”).  If Landlord terminates this Lease following the occurrence of an Event of Default, then all unamortized Abated Monthly Installment of Rent (i.e. based upon the amortization of the Abated Monthly Installment of Rent in equal monthly amounts, without interest, during the period commencing on the day immediately following the expiration of the Rent Abatement Period and ending on the original Termination Date) shall immediately become due and payable.  Only Monthly Installment of Rent shall be abated pursuant to this Section, as more particularly described herein, and Tenant’s Proportionate Share of Expenses, Insurance Costs and Taxes and all other rent and other costs and charges specified in the Lease, as amended, shall remain as due and payable pursuant to the provisions of the Lease, as amended.  If there exists any uncured monetary or material non-monetary Event of Default at any time during the Rent Abatement Period, then Tenant’s right to receive the Abatement Monthly Installment of Rent shall toll (and Tenant shall be required to pay Monthly Installment of Rent during such period of uncured Event of Default) until Tenant has cured such Event of Default in accordance with this Lease.
5.Tenant's Proportionate Share of Expenses, Insurance Costs and Taxes.  
5.1.Existing Premises.  Tenant shall continue to pay Tenant's Proportionate Share of Expenses, Insurance Costs and Taxes in connection with the Existing Premises in accordance with the terms of the Lease.  
5.2.Expansion Premises.  Except as specifically set forth in this Section 5.2, commencing on the Expansion Commencement Date, Tenant shall pay Tenant's Proportionate Share of Expenses, Insurance Costs and Taxes in connection with the Expansion Premises in accordance with the terms of Article 4 of the Lease, provided that with respect to the calculation of Tenant's Proportionate Share of Expenses, Insurance Costs and Taxes in connection 

with the Expansion Premises, Tenant's Proportionate Share shall equal 18.19% for the Building and 3.08% for the Project.
6.Expansion Improvements.  Except as specifically set forth in the Tenant Work Letter attached hereto as Exhibit B, Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Expansion Premises, and Tenant shall accept the Expansion Premises in its presently existing, "as-is" condition.  Tenant also acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises or Building or with respect to the suitability of the Premises or Building for the conduct of Tenant's business.  For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project, Building and Premises have not undergone inspection by a Certified Access Specialist (CASp).
7.Broker.  Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this First Amendment other than Cushman & Wakefield of California, Inc. and Jones Lang LaSalle (the "Broker"), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this First Amendment.  Each party agrees to indemnify and defend the other party against and hold the other party harmless from and against any and all claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys' fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of the indemnifying party's dealings with any real estate broker or agent, other than the Broker, occurring by, through, or under the indemnifying party.  The terms of this Section 7 shall survive the expiration or earlier termination of the term of the Lease, as hereby amended.
8.No Further Right of First Offer for First Floor Offer Space.  Notwithstanding anything to the contrary set forth in the Lease, effective as of the Expansion Space Commencement Date, Tenant shall have leased the entirety of the "First Floor Offer Space" (as defined in Section 46 of the Lease), and therefore, effective as of the date hereof, Landlord and Tenant acknowledge and agree that Tenant's right of first offer set forth in Section 46 of the Lease with respect to the First Floor Offer Space only is hereby deleted and of no further force or effect.
9.No Further Modification.  Except as set forth in this First Amendment, all of the terms and provisions of the Lease shall apply with respect to the Expansion Premises and shall remain unmodified and in full force and effect.  
[signatures follow on next page]

IN WITNESS WHEREOF, this First Amendment has been executed as of the day and year first above written.   
	
		
	"LANDLORD"
	"TENANT"

	 
	 

	SFI PLEASANTON, LLC,
	ELLIE MAE, INC.,

	a Delaware limited liability company
	a Delaware Corporation

	 
	 

	By:  SFI Mezz Pleasanton, LLC,
	 

	        a Delaware limited liability company,
	 

	        its member
	 

	 
	 

	        By: Swift Fund I GP, LLC,
	 

	               a Delaware limited liability company,
	 

	               its manager
	 

	 
	 

	               By: /s/ Craig Firpo                          
	By: /s/ Jonathan Corr                      

	 
	 

	               Name: Craig Firpo                          
	Name: Jonathan Corr                      

	 
	 

	               Its: VP                                             
	Its: President & CEO                      

EXHIBIT A
4420 ROSEWOOD DRIVE
OUTLINE OF EXPANSION PREMISES

           

EXHIBIT B
4420 ROSEWOOD DRIVE
TENANT WORK LETTER
On September 1, 2015, Landlord shall deliver the Expansion Premises and "Base, Shell, and Core," as that term is defined below, to Tenant for purposes of Tenant's commencement of construction of the "Tenant Improvements," as that term is defined below, and installing Tenant's furniture, fixtures and equipment, prior to the Expansion Commencement Date, and Tenant shall accept the Expansion Premises and Base, Shell, and Core from Landlord in their presently existing, "as-is" condition.  The "Base, Shell, and Core" shall consist of those portions of the Expansion Premises which were in existence prior to the construction of the tenant improvements in the Expansion Premises.  
Notwithstanding the foregoing, Tenant shall be entitled to a one-time tenant improvement allowance (the "Tenant Improvement Allowance") equal to One Million Three Hundred Eighty-Seven Thousand Sixteen and 00/100 Dollars ($1,387,016.00) for the costs relating to the initial design and construction of Tenant's improvements which are permanently affixed to the Expansion Premises (the "Tenant Improvements").  The Tenant Improvement Allowance will be disbursed in accordance with Landlord's standard disbursement procedures, including, without limitation, following Landlord's receipt of (i) evidence (i.e., invoices, contracts or other documentation reasonably satisfactory to Landlord) of payment for the Tenant Improvements, and (ii) fully executed, unconditional lien releases from all contractors, subcontractors, laborers, materialmen, and suppliers used by Tenant in connection with the Tenant Improvements.  If the estimated cost of the Tenant Improvements exceeds the Tenant Improvement Allowance, Tenant shall be entitled to the Tenant Improvement Allowance in accordance with the terms hereof, but each individual disbursement of the Tenant Improvement Allowance shall be disbursed in the proportion that the Tenant Improvement Allowance bears to the total cost for the Tenant Improvements (less the percentage of any retainage withheld by Landlord).  The Tenant Improvements shall be constructed in accordance with the terms and conditions of Article 6 of the Lease.  
Further notwithstanding the foregoing, Landlord shall be obligated to upgrade the men's and women's restrooms exclusively serving the Expansion Premises in accordance with the terms of  Exhibit B, Paragraph B(1)(A) to the Lease (the "Landlord Work").  
In no event shall Landlord be obligated to disburse any portion of the Tenant Improvement Allowance subsequent to August 31, 2016, nor shall Landlord be obligated to disburse any amount in excess of the Tenant Improvement Allowance in connection with the construction of the Tenant Improvements.  No portion of the Tenant Improvement Allowance, if any, remaining after the construction of the Tenant Improvements shall be available for use by Tenant.EXHIBIT 10.1

 

ASSET PURCHASE AGREEMENT

 

 

 

THIS ASSET PURCHASE
AGREEMENT (this “Agreement”) is entered into as of July 31, 2015 (the “Effective Date”)
by and among MEDAC HEALTH SERVICES, P.A., a North Carolina professional corporation (“Seller”),
the shareholders of Seller listed on the signature page to this Agreement (“Shareholders” and together
with Seller, “Seller Parties”), KEVIN E. POTTS, MD, (in his capacity as a Shareholder,
“Dr. Potts” and in his capacity as attorney-in-fact of Seller Parties, “Seller Representative”),
and ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability company (“Buyer”).

 

RECITALS

 

A.Seller owns and
operates (i) a medical practice administration and staffing business that contracts exclusively with an emergency department physician
staffing business conducted by an Affiliate (the “ER Business”) and (ii) a medical business involved
in the delivery and management of urgent care, occupational medicine and similar services rendered on an episodic, walk-in basis
(the “Urgent Care Business” and together with the ER Business, the “Business”)
from centers located at 4402 Shipyard Boulevard Wilmington, North Carolina 28403 (the “Shipyard Center”),
1442 Military Cutoff Road, Wilmington, North Carolina 28403 (the “Military Cutoff Center”), 8115 Market
Street Wilmington, North Carolina 28411 (the “Porter’s Neck Center”), and 5245 South College Road,
Wilmington, North Carolina 28412 (the “Monkey Junction Center” and together with the Shipyard Center,
the Military Cutoff Center, and the Porter’s Neck Center, collectively, the “Centers”);

 

B.Shareholders
own all of the outstanding shares of the capital stock of Seller (the “Shares”);

 

C.Shareholders
desire to appoint Dr. Potts, as their agent, attorney-in-fact and authorized representative, and Dr. Potts desires to accept such
appointment, to take certain action and effectuate certain aspects of the Transactions on behalf of the Shareholders; and

 

D.This Agreement
and all other agreements, instruments, certificates and other documents executed and delivered in connection with the transactions
contemplated by this Agreement (collectively, the “Transaction Documents”), contemplate that upon the
terms and subject to the conditions set forth herein, the following will occur at Closing: (i) Buyer will purchase all the Purchased
Assets from Seller and Seller will assign, transfer, and convey all of the Purchased Assets to Buyer; (ii) immediately thereafter,
the Net Closing Proceeds will be distributed to the Shareholders in accordance with each Shareholder’s respective Sharing
Percentage, (iii) immediately thereafter, Seller will distribute the Excluded Assets listed on Schedule 1.3 and will assign
those rights and obligations under the Transaction Documents to a North Carolina limited liability company organized for the purpose
of accepting such rights and obligations (“Newco”) that accrue or will accrue to the Seller Parties (including,
without limitation, the rights under the Escrow Agreements and the Note) or are necessary for the Shareholders to enjoy the benefits
of the Transactions (collectively, the “APA Rights”), which Newco was formed for the purpose of accepting
such assignment and is owned by the Shareholders in accordance with the Sharing Percentage, and (iv) immediately thereafter,
the Shareholders other than Michael P. Moulton, MD (collectively, the “Redeemed Shareholders”) will assign,
transfer, and convey (the “Redemption”) all their Shares (collectively, the “Redeemed Shares”)
to the Seller. The transactions contemplated by this Agreement and the other Transaction Documents, including those described in
the preceding sentence, are referred to in this Agreement and the other Transaction Documents collectively as the “Transactions.”

 

    	 

    	 

    

AGREEMENT

 

In consideration of
the above Recitals and the promises and provisions set forth in this Agreement, the adequacy and sufficiency of which the parties
acknowledge, the parties, intending to be bound, agree as follows:

 

Article
1

PURCHASE AND SALE

 

1.1Purchase
and Sale of Redeemed Shares. On the terms and subject to the conditions of this Agreement and the Stock Redemption Agreement
(defined below), at the closing of the Transactions (“Closing” and the date on which Closing occurs in
accordance with this Agreement, the “Closing Date”), but immediately after the consummation of the transactions
contemplated by Section 1.2, and the distribution by Seller of the Net Closing Proceeds and the APA Rights to Shareholders,
each Redeemed Shareholder shall sell, assign, transfer, and deliver to Seller, and Seller shall purchase and redeem from such Redeemed
Shareholder, all of the Redeemed Shares owned by such Redeemed Shareholder as set forth on Schedule 1.1. Additional terms
and conditions relating to the purchase, sale and transfer of the Redeemed Shares are set forth in a stock redemption agreement
by and among Seller and the Redeemed Shareholders executed and delivered contemporaneously with this Agreement and attached hereto
as Exhibit A (the “Stock Redemption Agreement”). Notwithstanding the contemporaneous execution
and delivery of this Agreement, the obligation of the Seller Representative (on behalf of the Redeemed Shareholders) to close the
transactions contemplated by the Stock Redemption Agreement shall be conditioned on the consummation of the transactions contemplated
by Section 1.2 of this Agreement and distribution of the Net Closing Proceeds (defined in Section 1.3(a)) and the APA Rights.

 

1.2Purchase
and Sale of Assets. On the terms and subject to the conditions of this Agreement, at Closing, but prior to the consummation
of the Redemption, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, all
of Seller’s right, title and interest in and to the following assets, but in any event excluding the Excluded Assets (collectively,
the “Purchased Assets”), free and clear of all Liens (defined in Section 1.10(b)) other than Permitted
Liens (as defined in Section 1.10(b)):

 

(a)All of Seller’s
tangible and intangible property used or held for use in the operation or ownership of the Business, whether or not such property
is located at the Centers, including all furniture, fixtures, instruments, inventory, office supplies, medical supplies, signage,
general equipment, medical equipment, computer hardware, computer software, telecommunications equipment, telephone (including
cell phone) and fax numbers, post office boxes, advertising and marketing materials, business plans and other items of tangible
and intangible personal property owned by Seller or, to the extent assignable, leased or licensed by Seller, together with any
express or implied warranty by the manufacturer, seller or lessor of any item or component part thereof, to the extent such warranties
may be assigned without consent or upon the obtainment of any requisite consent, and all maintenance records and other documents
related thereto (which property shall include, by way of illustration and without limitation, all property described in Schedule
1.2(a));

 

(b)An amount of cash
and cash equivalents equal to $100,000;

 

(c)All accounts receivable
attributable to goods sold (including pharmaceutical and durable medical equipment) or services rendered in the operation of the
Business prior to Closing (the “Accounts Receivable”), whether proceeds from the Accounts Receivable
are to be deposited, transferred or paid to a lockbox, deposit account, or any other account under the control of Seller or any
of its Affiliates. For purposes of this Agreement, the term “Affiliate”
means any individual or entity that directly or indirectly through one or more intermediaries, controls, is controlled by,
or is under common control with, a specified person, entity, or group of common persons or entities, which, in the case of Seller,
shall include Seamist Management, LLC, a North Carolina limited liability company (“Seamist”);

 

    	2

    	 

    

(d)All data, books,
and records created or maintained in connection with the Business (other than the Medical Records (defined in Section 4.3)
and the books and records relating to the Seller’s corporate organization and existence as described in Section 1.3(e)),
including compliance materials, policies and procedures, creative materials, and financial and accounting records;

 

(e)All contracts,
leases, licenses (to the extent assignable), corporate health arrangements, commitments, or other binding arrangements relating
to the Business to which any Seller Party is a party, whether written or oral, and all rights therein and thereunder (collectively,
the “Contracts”) in effect as of Closing, including all right, title, and interests in, to, and under
all vendor agreements, supplier agreements, and subcontractor agreements in favor of Seller, including the Contracts listed on
Schedule 1.2(e) (the “Assumed Contracts”);

 

(f)All intellectual
and other intangible property, including web pages, URLs, blogs, social media pages and accounts, email addresses, domain names,
websites and content contained therein, hosting agreements and arrangements, trademarks, trade names, business names, service marks,
mascots, emblems, logos, letterheads, trade secrets and copyrights including all property described on Schedule 1.2(f);

 

(g)All claims and
all rights related to such claims that Seller has or may in the future have relating to the Purchased Assets, the Centers, the
Assumed Contracts or the Business, whether such claims are choate or inchoate, known or unknown, legal or equitable, contingent
or non-contingent;

 

(h)All rights relating
to advance payments, prepayments, prepaid expenses, claims for refunds, security deposits and similar payments previously made
by Seller, except as are set forth on Schedule 1.3(h); and

 

(i)All goodwill associated
with the Business, the Assumed Contracts, the Centers (to the extent arising out of the Leases assumed by Buyer), and the Purchased
Assets.

 

1.3Excluded
Assets. Notwithstanding anything in this Agreement to the contrary, the following assets, properties, Contracts, rights and
interests of Seller (collectively, the “Excluded Assets”) are excluded from the Purchased Assets and
shall remain the property of Seller after Closing:

 

(a)All cash and cash
equivalents in excess of $100,000;

 

(b)All rights, title
and interest in and to the Medical Records except as described in Section 4.3;

 

(c)All right, title
and interest in and to real property, except those rights relating to or arising under any leases assumed by Buyer in connection
with the Transactions;

 

(d)All Benefit Plans
(defined in Section 2.21) and all assets attributable thereto;

 

(e)Seller’s
corporate seals, organizational documents, minute books, stock books, tax returns, and all other books of account and other records
having to do with the corporate organization of Seller;

 

    	3

    	 

    

(f)Seller’s
tax identification number, provider numbers, and Certificate of Registration issued by the North Carolina Medical Board;

 

(g)All Payor Contracts
(defined in Section 2.11(b)) and all other Contracts related to the Business to which Seller is a party and which are described
on Schedule 1.3(g) (collectively, the “Operating Contracts”);

 

(h)All
rights relating to advance payments, prepayments, prepaid expenses, claims for refunds, security deposits and similar
payments previously made by Seller and set forth on Schedule 1.3(h);

 

(i)All rights that
accrue or will accrue to Seller Parties or Seller Representative under the Transaction Documents; and

 

(j)All of the assets
listed on Schedule 1.3(j) and any other personal effects of the Shareholders and similar items of nominal value.

 

It is the intent of
the parties that the Excluded Assets listed in Sections 1.3(a), (c), (h), (i) and (j) shall
be distributed by Seller to Newco for the benefit of the Shareholders prior to the consummation of the Redemption.

 

1.4Purchase
Price. The aggregate consideration for the sale, assignment, transfer and delivery of the Purchased Assets, subject to the
adjustments described herein, is $5,600,000 (as adjusted, the “Purchase Price”). The Purchase Price shall
be paid at Closing as follows:

 

(a)Buyer will pay
Seller by wire transfer of immediately available funds, an amount calculated as follows (as calculated, the “Net
Closing Proceeds”): $5,600,000, minus the sum of (i) the amount necessary to satisfy all outstanding
Liabilities (defined in Section 1.6) of Seller at Closing, including the Assumed Payables (defined in Section 1.5(b)),
the Assumed Payroll and the Benefit Accrual (each as defined in Section 1.5(d)) and any unpaid legal expenses, accounting
expenses, or other costs or expenses of Seller incurred in connection with the negotiation and implementation of the Transactions
(the “Transaction Expenses”); (ii) the initial principal balance of the Note (defined in Section 1.4(b));
(iii) the Escrow Amount (defined in Section 1.4(c)); (iv) the amount of Seller’s share of any prorated expenses described
in Section 1.7; and (v) any other adjustments specifically provided in this Agreement. The calculation of the Net Closing
Proceeds, and the parties to whom and accounts to which payment shall be made at Closing, shall be set forth on a closing statement
prepared by Buyer and delivered to Seller no less than two business days before Closing (the “Closing Statement”).
The Closing Statement shall, among other things, include the portion of the Net Closing Proceeds to be distributed to each Shareholder,
which each Shareholder agrees shall be equal to one-twelfth (1/12) (the “Sharing Percentage”) of the
total Net Closing Proceeds.

 

(b)The amount of
$560,000, as may be adjusted pursuant to this Agreement, shall be paid by delivery to Seller Representative of a promissory note
in such initial principal amount executed by Buyer in favor of Seller in substantially the form attached as Exhibit B (the
“Note”). Simple interest shall accrue on the outstanding principal balance of the Note at the rate of
5% per annum. The Note shall mature, at which time all outstanding balance of principal and accrued but unpaid interest shall be
due and payable, 18 months after the Closing Date, subject to any claims asserted by Buyer Indemnitees pursuant to Article 6
hereof. The Note shall be guaranteed by American CareSource Holdings, Inc. The parties acknowledge and agree that following the
Closing, the Note shall be assigned by Seller to Newco for the benefit of the Shareholders, and that Buyer will be instructed to
make all payments on the Note directly to Newco.

 

    	4

    	 

    

(c)The amount of
$610,000 (the “Escrow Amount”) to Branch Banking and Trust Company (the “Escrow Agent”),
by wire transfer of immediately available funds to be held, invested, and distributed by the Escrow Agent pursuant to the terms
and conditions of an Escrow Agreement to be entered into at Closing among Buyer, Seller, Seller Representative (on behalf of Shareholders),
and the Escrow Agent in substantially the form attached hereto as Exhibit C (the “Escrow Agreement”).
Subject to claims or potential claims of the Buyer Indemnitees pursuant to Article 6 and the other terms and conditions
set forth in the Escrow Agreement, the Escrow Agreement will provide for the distribution of the Escrow Amount (disregarding any
earned interest or appreciation) as follows, (i) $110,000 (the “Regulatory Escrow”), which will be distributed
on or about the date that is 18 months after the Closing Date, and (ii) $500,000 (the “Payor Escrow”),
$250,000 of which will be distributed on or about the date that is 9 months after the Closing Date and the remainder of which will
be distributed on or about the date that is 18 months after the Closing Date.

 

1.5Assumed Liabilities.
After Closing, Buyer shall pay, fulfill, perform and otherwise discharge prior to delinquency, the following debts, liabilities,
obligations, expenses, contracts and commitments of Seller relating to the Business and the Purchased Assets (collectively, the
“Assumed Liabilities”):

 

(a)The payment and
performance obligations arising under the Assumed Contracts, but only to the extent such obligations do not relate to or arise
from (i) any action, omission or occurrence taking place prior to Closing or (ii) a breach or failure to perform when due any of
the terms of the Assumed Contracts prior to Closing; 

 

(b)The trade accounts
payable accrued and not overdue as of the Closing Date, incurred by Seller in the ordinary course of operating the Business, consistent
with past practice and included in the schedule delivered pursuant to Section 1.10(b) (the “Assumed Payables”);

 

(c)Any Liabilities
for which the Purchase Price is reduced pursuant to clause (i) of Section 1.4(a) and which are not otherwise assumed under
this Section 1.5; and

 

(d)The amounts set
forth on Schedule 1.5(d) representing the Liabilities as of the Closing Date attributable to: (i) accrued but unpaid salary,
wages, bonuses, and any other amounts owed to any person or entity (including Seller’s portion of any applicable withholding
taxes related thereto) on account of services rendered to or for the benefit of Seller, which shall include services of the physicians
employed by Wilmington Health who perform services at the Centers and the clinical employees of Seller that perform services for
ECEP II (collectively, the “Assumed Payroll”), (ii) accrued but unused personal and vacation time of
any Seller Employee (defined in Section 2.20(a)), and (iii) accrued but unpaid employer contribution for which Seller is
or will be obligated to pay to any retirement plan maintained for the benefit of any Seller Employee relating to the period prior
to Closing (clauses (i), (ii), and (iii) collectively, the “Benefit Accrual”); provided that the portion
of the Benefit Accrual described in clauses (ii) and (iii), on a person-by-person basis, shall be limited to the maximum potential
accrual for similarly situated employees under Buyer’s employee benefit plans.

 

1.6Retained
Liabilities. Buyer shall not assume, and Seller Parties shall pay, perform and discharge when due, any and all debts, liabilities,
obligations, expenses, taxes, contracts or commitments of any Seller Party or their Affiliates, whether the same are known or unknown,
choate or inchoate, disclosed or undisclosed, matured or unmatured, accrued, absolute or contingent (“Liabilities”)
of any Seller Party or their Affiliates (including any Liability arising out of the Transaction Documents) other than the Assumed
Liabilities (collectively, the “Retained Liabilities”). Notwithstanding that Seller Parties shall remain
solely liable for all Retained Liabilities, Buyer or any of its Affiliates (on their own behalf or on behalf of Seller Parties)
may elect at any time after Closing, to pay any such Retained Liability that is due and payable and not reasonably being contested
by Seller or Newco directly to the party to whom payment is due and shall be entitled to reimbursement or such other remedies in
accordance with Article 6. Without limiting the generality of the foregoing, the following Liabilities of any Seller Party
or their Affiliates (to the extent not specifically among the Assumed Liabilities) shall constitute Retained Liabilities:

 

    	5

    	 

    

(a)Liabilities of
any type whatsoever (whether arising in tort, contract or otherwise) relating to or arising from actions, omissions or occurrences
taking place prior to Closing, including Liabilities relating to or arising from the provision of (or failure to provide) professional
medical or other health care services (including patient refunds);

 

(b)Liabilities accrued
at Closing under any Contract (including any Assumed Contract), whether or not (i) such Contract has been disclosed to Buyer or
(ii) such Liability relates to any breach or failure to perform any term of such Contract;

 

(c)Liabilities for
indebtedness of Seller Parties or any of their Affiliates, or relating to any Center or any equipment used in the Business, including
(i) indebtedness for borrowed money, whether or not evidenced in writing and whether secured or unsecured, (ii) obligations under
conditional sale or other title retention agreements relating to purchased property, (iii) the portion of any capital lease obligations
(which includes equipment subject to a lease-to-purchase option for nominal or below-market consideration), (iv) guarantees of
any such indebtedness referred to in clauses (i)-(iii) of any other individual or entity (all of the foregoing collectively, “Indebtedness”);

 

(d)Liabilities relating
to or arising from the Excluded Assets;

 

(e)Liabilities for
federal, state or local income, excise, sales, use, property, franchise or other taxes or assessments relating to periods prior
to Closing (whether or not required to be paid or escrowed pursuant to any leases for the Centers) and those arising at any time
from or by reason of the Transactions;

 

(f)Liabilities for
all compensation and employee benefits to any Seller Employee including unpaid payroll taxes, salary or wage expense, bonuses,
termination pay or severance obligations, and sick, personal or vacation time, earned or accrued prior to Closing, other than the
Benefit Accrual and the Assumed Payroll;

 

(g)Liabilities arising
from Seller’s failure to provide timely notice or to obtain any third-party consent required prior to or in connection with
the execution and delivery of any Transaction Document or the consummation of any of the Transactions;

 

(h)Liabilities resulting
from any violation, alleged violation, or any investigation or audit the purpose of which is to determine whether a violation occurred
by any Seller Party, the Business, any Clinical Provider, ECEP II, P.A. (“ECEP II”), any of their respective
Affiliates or predecessors-in-interest, of any Law (including any Health Care Law (defined in Section 2.13(c))), if such
violation, alleged violation or potential violation (in the case of an audit or investigation) relates to or arises from actions,
omissions or occurrences taking place prior to Closing; and

 

(i)Liabilities, damages,
obligations, overpayments, false claims, penalties, fines, assessments, repayments, refunds (payable to patients, Payors, or any
other party), recoupments, offsets, recoveries, adjustments or similar Liabilities of any Seller Party or their Affiliates due
or that may become due to any Governmental Authority (defined in Section 2.13(c)), Payor, corporate health client, patient
or any other third party relating to or arising from the provision of, failure to provide, or billing or coding on account of professional
medical or other health care services by or on behalf of Seller, any Clinical Provider, ECEP II, or any other party prior to Closing.

 

    	6

    	 

    

1.7Operating
Contracts and Prorations. At Closing, Buyer and Seller shall prorate between them, as of the Closing Date, all amounts
that relate in whole or in part to any period beginning prior to and ending after Closing, including any applicable taxes, lease
payments, utility payments or other expenses (regardless when due) relating to or arising out of the operation of the Business,
the Centers, the Assumed Contracts or the Purchased Assets, based on the respective number of days before and after the Closing
Date as to which such amounts relate. Unless the actual amount to be prorated is immediately determinable, such expenses shall
be reasonably estimated by the parties and apportioned between Buyer and Seller based on the number of days of the applicable tax
or billing period. As soon as reasonably practicable after Closing, Buyer shall report to Seller’s Representative any increase
or decrease in the Closing estimate and Buyer and Seller’s Representative shall work in good faith to correct such inaccuracies.
Notwithstanding the foregoing, the Retained Liabilities shall be the exclusive obligation and liability of the Seller Parties.

 

1.8Allocation
of Purchase Price. The Purchase Price shall be allocated among the Purchased Assets for all tax purposes in the manner set
forth in Schedule 1.8. Each of the parties shall make all appropriate tax and other filings, including but not limited
to IRS Form 8594, on a basis consistent with such allocation. Neither the Buyer nor any Seller Party shall take any position with
respect to taxes (whether in audits, tax returns, refunds or otherwise) inconsistent with such allocation determined under this
Agreement unless required to do so by applicable Law.

 

1.9Closing and
Closing Disbursements. Closing will occur by delivery of originally executed documents or scanned copies of originally executed
documents; provided that all conditions precedent and other matters required to be completed as of Closing, including those identified
in Article 5, have been or will be completed or waived in writing by the party to whom performance is owed by such date.
The Closing Date shall be automatically extended from time to time for so long as any of the conditions set forth in Article
5 are not satisfied or waived, subject, however, to the termination provisions of Section 5.1. Notwithstanding anything
in the Transaction Documents to the contrary, each of the following transactions shall be deemed to occur as of 11:59 p.m., Atlanta,
Georgia time on the Closing Date and in the following sequence: (a) the consummation of the purchase and sale of Purchased Assets;
(b) the distribution of the Net Closing Proceeds by Seller to the Shareholders; (c) the assignment of the APA Rights to Newco;
and (d) the consummation of the Redemption.

 

1.10Seller Parties’
Deliveries.

 

(a)On the Effective
Date, Seller Parties shall duly execute and deliver, or cause to be executed and delivered, to Buyer or such other party as indicated
below, the following:

 

(i)A counterpart
to this Agreement;

 

(ii)The Stock Redemption
Agreement, duly executed by Seller Parties;

 

(iii)To Seller
Representative, certificates representing all of the issued and outstanding Redeemed Shares duly endorsed in blank or accompanied
by stock powers or other instruments of transfer duly executed in blank, with all required stock transfer tax stamps affixed thereto;
and

 

(iv)To Seller Representative,
counterparts to Restrictive Covenant Agreements (the “Restrictive Covenant Agreement”)
executed by each of the Shareholders, in substantially the form of Exhibit D, the effectiveness and enforceability of which
shall be conditioned on the closing of the Transactions.

 

    	7

    	 

    

(b)At Closing, Seller
Representative (on behalf of the Seller Parties) shall duly execute and deliver, or cause to be executed and delivered, to Buyer
or such other party as indicated below, the following:

 

(i) A Bill of Sale
in substantially the form of Exhibit E;

 

(ii)A counterpart
to the Escrow Agreement;

 

(iii)The following,
collectively referred to as the “Service Agreements”: (A) a counterpart to a consulting agreement between
Buyer and Dr. Moulton, reasonably acceptable in form and substance to Dr. Moulton, duly executed by Dr. Moulton, and (B) a counterpart
to a consulting agreement between Buyer and Dr. Potts, reasonably acceptable in form and substance to Dr. Potts, duly executed
by Dr. Potts;

 

(iv)A counterpart
to an Assignment and Assumption Agreement relating to the Assumed Contracts in substantially the form of Exhibit F (the
“Assumed Contracts Assignment Agreement”);

 

(v) A counterpart
to an assignment and assumption of lease agreement (and any amendments Buyer reasonably determines to be necessary), relating to
the Military Cutoff Center and the Monkey Junction Center, each in forms acceptable to Buyer (the “Lease Assumption
Agreements”);

 

(vi)Counterparts
to a new lease agreement between Buyer and Seamist relating to the Porters Neck Center;

 

(vii)Evidence that
Seller and Newco have entered into an Assignment and Assumption Agreement relating to Seller’s assignment of the APA Rights
to Newco;

 

(viii)A Closing
Certificate in substantially the form of Exhibit G (a “Closing Certificate”);

 

(ix)A schedule
setting forth the Accounts Receivable, the Assumed Payables and the Assumed Payroll, each as of the Closing Date;

 

(x)Payoff letters,
issued by the holders of any Seller Indebtedness and the creditors to whom Transaction Expenses are owed not earlier than two business
days prior to the Closing Date, in form and substance reasonably acceptable to Buyer, setting forth the amounts required to repay
in full any such Indebtedness and any Transaction Expenses at Closing, together with wire transfer instructions;

 

(xi)Evidence satisfactory
to Buyer of the release of all liens, security interests, equipment financing, conditional or installment sales contracts, conditions,
claims, charges, or restrictions of any kind relating to or encumbering any of Seller’s assets (including the Purchased Assets)
or the Business (collectively, the “Liens”), other than (i) any mechanic’s, materialmen’s
or similar statutory Lien incurred in the ordinary course of business for monies not yet due, and (ii) any Lien for Taxes not yet
due (together, “Permitted Liens”), either at or in connection with Closing;

 

(xii)A counterpart
to the Closing Statement;

 

(xiii)Copies of
all consents, authorizations, waivers, and approvals from all Governmental Authorities and other third parties (pursuant to any
Contract or otherwise) necessary for Seller Parties to execute, deliver and perform their obligations under this Agreement and
the other Transaction Documents and to consummate the Transactions;

 

    	8

    	 

    

(xiv)A certified
copy of the articles of incorporation of Seller issued by the North Carolina Secretary of State, together with copies of all Bylaws
and any other governance document of Seller;

 

(xv)A certificate
of existence of Seller issued not earlier than ten days prior to the Closing Date by the North Carolina Secretary of State; and

 

(xvi)Copies of
such officers’ certificates, good standing certificates, corporate approval documents, incumbency certificates and other
customary closing documents as Buyer may reasonably request.

 

1.11Buyer’s
Deliveries.

 

(a)On the Effective
Date, Buyer shall deliver or cause to be delivered to Seller Representative, an executed counterpart to this Agreement.

 

(b)At Closing, Buyer
shall deliver or cause to be delivered to Seller Representative or such other party as indicated below, the following:

 

(i)The Net Closing
Proceeds to be distributed by Buyer to Shareholders on behalf of Seller, in accordance with their Sharing Percentage and the other
instructions set forth in the Closing Statement;

 

(ii)The Note, duly
executed by Buyer;

 

(iii)A guaranty
of the Note, duly executed by American CareSource Holdings, Inc., in form and substance reasonably acceptable to Seller;

 

(iv)A counterpart
to the Escrow Agreement;

 

(v)The amount set
forth in the Closing Statement to be distributed to the creditors, service providers, brokers and other third parties, by wire
transfer of immediately available funds in accordance with the instructions set forth in the Closing Statement;

 

(vi)A counterpart
to the Closing Statement;

 

(vii)A counterpart
to each of the Service Agreements;

 

(viii)A counterpart
to the Assumed Contracts Assignment Agreement;

 

(ix)A counterpart
to the Lease Assumption Agreements;

 

(x)A counterpart
to a new lease agreement between Buyer and Seamist relating to the Porters Neck Center.

 

(xi)A counterpart
to the Restrictive Covenant Agreements;

 

(xii)A Closing
Certificate;

 

(xiii)A certified
copy of the certificate of formation of Buyer issued by the Delaware Secretary of State, together with copies of the Buyer’s
operating agreement and any other governance document of Buyer;

 

(xiv)A certificate
of good standing of Buyer issued not earlier than ten days prior to the Closing Date by the Delaware Secretary of State; and

 

    	9

    	 

    

(xv)Copies of such
officers’ certificates, good standing certificates, corporate approval documents, incumbency certificates and other customary
closing documents as Seller may reasonably request.

 

1.12Nonassignment
of Contracts and Authorizations. If any Assumed Contract may not be assigned or transferred without the consent or waiver of
one or more Governmental Authorities or other third parties, and such consent or waiver has not been given, or if such assignment
or transfer or attempted assignment or transfer would constitute a breach thereof or a violation of any Law, this Agreement shall
not constitute an assignment or transfer thereof, or an attempted assignment or transfer of any such Assumed Contract. Notwithstanding
the foregoing, Seller Parties shall take all commercially reasonable action, at their sole expense, to obtain the consent or waiver
of any third party required to assign or transfer an Assumed Contract to Buyer.

 

Article
2

REPRESENTATIONS AND WARRANTIES OF SELLER PARTIES

 

Seller Parties, jointly
and severally, hereby make the following representations and warranties to Buyer:

 

2.1Organization;
Qualification. Seller is a professional corporation duly incorporated and validly existing under the Laws of North Carolina.
Seller is (a) qualified to do business in North Carolina, (b) qualified to conduct the Business as presently conducted, and (c)
is in good standing in North Carolina and in each other jurisdiction in which the nature of the Business or the character of Seller’s
assets makes such qualification necessary. Seller has all requisite power and authority to operate the Business as presently conducted.

 

2.2Authority
and Binding Effect. Each Seller Party has all requisite capacity, power and authority to execute, deliver and perform each
of their respective obligations under this Agreement and all other Transaction Documents. Upon execution and delivery by Seller
Parties and the other parties thereto, this Agreement and the other Transaction Documents (assuming, in each case, the due and
valid authorization, execution and delivery thereof by the other parties thereto) will constitute legal, valid and binding obligations
of the applicable Seller Parties or Seller Representative, as applicable, enforceable against the applicable Seller Parties subject
to and in accordance with the terms of such Transaction Documents, except as such enforceability may be limited by applicable Law.
Upon execution and delivery by Seller Parties and Buyer of this Agreement, Seller Representative, as attorney-in-fact of each Shareholder
(as described in Article 7), shall be vested with the right, power, and authority, to, among other things, consummate the
Transactions on behalf of the Shareholders in accordance with the terms set forth in Article 7.

 

2.3Authority
and Status of Shares. Each Shareholder owns the Shares listed opposite such Shareholder’s name on Schedule 1.1,
free and clear of all Liens other than the Permitted Liens and the liens described on Schedule 2.3. All of the Shares have
been duly authorized, are validly issued, fully paid and non-assessable, and are owned of record and beneficially by Shareholders,
free and clear of all Liens other than the Permitted Liens. All of the Shares were issued, have been owned, and all prior transfers
of the Shares (if any) were effectuated, in compliance with all applicable Law, and the redemption of the Redeemed Shares by Seller
will not violate any applicable Law. Seller’s corporate books and records accurately reflect all transactions involving the
Shares and the current ownership of the Shares. None of the Shares were issued either in violation of any agreement, arrangement
or commitment to which any Seller Party is a party or are subject to or in violation of any preemptive or similar rights of any
third party. The Shares represent all of the issued and outstanding shares of capital stock of Seller, and, except as set forth
in Schedule 2.3, there are no outstanding or authorized (i) classes of stock other than that of the Shares, (ii) options,
warrants, convertible securities or other rights, agreements, arrangements or commitments of any character relating to equity interests
in Seller or obligating any Seller Party to issue, transfer or assign any of the Shares or any other interest in Seller; (iii)
equity appreciation, phantom equity, profit participation or other similar rights; or (iv) voting trusts, operating agreement,
rights of first refusal, shareholders agreements, proxies or other agreements or understandings in effect with respect to the voting
or transfer of any of the Shares. 

 

    	10

    	 

    

2.4Governing
Documents. Seller Parties have delivered to Buyer copies of Seller’s governing documents, including its Articles of Incorporation
and Bylaws, each of which is complete, correct and now in effect in the form delivered. Except as disclosed to Buyer in writing,
there have been no amendments, restatements or other modifications to such documents. No Shareholders is a party to any shareholder
agreement or any other similar agreement or arrangement governing the relationship of the Shareholders as shareholders of Seller,
other than as set forth in Schedule 2.4. 

 

2.5Title
and Condition of Assets. The Purchased Assets set forth in Schedule 1.2(a) (together with the Medical Records, Payor
Contracts, and the assets the ownership of which is limited to entities entitled to employ physicians to engage in the practice
of medicine under applicable Law, the Excluded Assets, and assets provided to Seller by Wilmington Health, PLLC (“Wilmington
Health”) pursuant to the terms of the Professional Services and Management Agreement by and between Seller and Wilmington
Health (the “PSMA”)), are all of the assets used or held for use in the operation of the Business. All
of Seller’s assets are in operating condition. Neither the Centers nor any item of tangible personal property among the Seller’s
assets is in need of maintenance or repair except for any ordinary, routine maintenance and repair that is not material in nature
or cost. Seller has or will have at Closing, good, valid and marketable title to, a valid leasehold interest in, or a valid and
enforceable license or right to use, as the case may be, all Seller’s assets (including the Purchased Assets) free and clear
of all Liens, other than Permitted Liens. Seller does not own any beneficial interest in any stock, securities or any other equity
of any entity.

 

2.6No
Violation. Except as set forth on Schedule 2.6, the execution, delivery and performance by Seller Parties and Seller
Representative of this Agreement and the other Transaction Documents and the consummation of the Transactions will not (a) constitute
a violation of, conflict with or constitute a default under any term or provision of Seller’s organizational documents, including
its Articles of Incorporation or Bylaws; (b) with respect only to the Redemption, constitute or result in a violation of any Law
or Permit; (c) result in a violation or breach by any Seller Party of, conflict with, constitute (with or without due notice or
lapse of time or both) a default by any Seller Party (or give rise to any right of termination, cancellation, payment or any acceleration
of rights or obligations) under, or result in the creation of any Lien upon any of Seller’s assets, including the Purchased
Assets, under any of the terms, conditions, or provisions of any Contract, note, bond, mortgage, indenture, license to which any
Seller Party or their Affiliates is a party or by which any Seller Party or their Affiliates may be bound or encumbered, (d) result
in the creation of any Lien upon any of Seller’s assets (including the Purchased Assets), or (e) violate any other restrictions
or covenants of any kind to which any Seller Party or the Shares are subject. Notwithstanding the foregoing or any other contrary
provision in this Agreement, Seller Parties make no representations or warranties, express or implied, regarding or with respect
to the management and operation of the Business by Buyer and Seller from and after the Closing, and such management and operation
of the Business by Buyer and Seller from and after the Closing is expressly excluded from all representations and warranties made
by Seller Parties herein, including but not limited to as set forth in this Section 2.6 and in Section 2.7.

 

    	11

    	 

    

2.7Consents
and Approvals. Except as set forth in Schedule 2.7(a), the execution and delivery of, and performance under, the Transaction
Documents and the consummation of the Transactions have been or will be at Closing duly authorized by all appropriate parties,
and no other action, approval, notice or consent on the part of Seller, the Shareholders or any third party is necessary for Seller
Parties to consummate the Transactions or to perform Seller Parties’ obligations in the Transaction Documents. Except as
set forth in Schedule 2.7(b), no consent, approval, waiver, authorization or other action is required by or of, and no notice
is required to be given to, any Governmental Authority or other third party in order to duly execute, deliver and perform the obligations
under the Transaction Documents or to consummate the Transactions, including (a) the assignment and assumption of the Assumed Contracts,
(b) the purchase, sale, transfer or assignment of the Redeemed Shares, and (c) the purchase, sale and transfer of the Purchased
Assets.

 

2.8Litigation.
Except as set forth in Schedule 2.8, there is no action, lawsuit, administrative proceeding, condemnation, arbitration,
mediation, audit, investigation or other proceeding (each, a “Legal Proceeding”) pending or, to the knowledge
of Seller Parties, threatened against, involving, or affecting any of the Seller Parties, the Shares, the Seller’s assets,
the Centers, the Business, or any of the Clinical Providers (as defined in Section 2.20(e)), at law or in equity, before
any Governmental Authority, and, to the knowledge of Seller Parties, no basis for any Legal Proceeding exists that could reasonably
be expected to affect the Shares, the Seller Parties, the Seller’s assets, the Centers, the Business or the Clinical Providers.

 

2.9Material
Vendors. Schedule 2.9 sets forth a complete and correct list of the names of the top ten (based on amounts paid) suppliers
and vendors to whom Seller has paid consideration for goods received or services rendered in the 12-month period immediately preceding
the Effective Date (collectively, the "Material Vendors"). Seller has not received any written notice and
Seller Parties have no knowledge (a) that a dispute of any kind exists or could reasonably be expected to arise as a result of
events or occurrences that took place prior to Closing that involve or affect any of the Material Vendors, or (b) that any of the
Material Vendors have ceased or intend to cease to supply goods or services to Seller or to otherwise terminate or materially modify
the terms in which such goods or services are provided to Seller.

 

2.10Contracts.
Schedule 2.10 contains the party names, effective date, a brief description of the subject matter of each Contract, and
if applicable, a description of the matters set forth in the remainder of this Section 2.10. Each Contract has been delivered
to Buyer (to the extent in writing) or disclosed and described in reasonable detail to Buyer (to the extent oral). Except as otherwise
indicated on Schedule 2.10, (a) no Contract involves consideration determined based in whole or in part on (i) the revenue
or profit of the Business, or (ii) the volume of patients treated or the value of amounts billed for treatment rendered in connection
with the Business whose service is paid or is payable in whole or in part by Medicare, Medicaid, or any other governmental reimbursement
program; (b) all of the Contracts are in full force and effect and are valid and enforceable in accordance with their terms, subject
to the application of general principles of equity and the effect of bankruptcy, insolvency, reorganization, moratorium or any
similar Laws affecting creditors’ rights; (c) Seller and, to the knowledge of Seller Parties, each other party to the Contracts
is in compliance with all terms and requirements of such Contracts and all applicable conditions to continued performance at levels
and on terms now existing are satisfied in full; (d) neither Seller nor, to the knowledge of Seller Parties, any party to any of
the Contracts has violated or will violate any applicable Law simply by performing such party’s respective obligations under
such Contract in a manner consistent with past practice; (e) to the knowledge of Seller Parties, no event has occurred or circumstance
exists that (with or without notice or lapse of time) may contravene, conflict with or result in a default, violation or breach
of, or give Seller or any other party to any Contract the right to declare a default, to exercise any remedy under, to accelerate
the maturity of, or any rights or obligations under, or to cancel, terminate or modify the terms of or performance under any Contract;
(f) there are no renegotiations, attempts to renegotiate or outstanding rights to negotiate any amount to be paid or payable to
or by Seller under any Contract, and no third party has made a written or oral demand to any Seller Party for such renegotiation;
and (g) no Seller Party has released or waived any of its rights under any Contract.

 

    	12

    	 

    

2.11Payors
and Payor Contracts. 

 

(a)Schedule 2.11(a)
sets forth a complete and correct list of (i) the name and amount received by every governmental payor (including Medicare, Medicaid
and Tricare), every commercial insurance company, and the top ten (based on amount paid) corporate health clients (collectively,
the “Payors”) who has paid consideration to or on account of Seller Parties or Clinical Providers for
goods sold or services rendered by or on behalf of Seller during the immediately preceding 12-month period. Seller has good, working
relationships with all Payors, and no Seller Party has received any written notice, and no Seller Party has knowledge, that any
Payor is considering discontinuing its relationship with any Seller Party or Clinical Provider, adjusting any fee or reimbursement
schedule now in effect, or denying or disputing any claims submitted to such Payor by Seller or any Clinical Provider for services
provided for the benefit of Seller.

 

(b)Seller and each
Clinical Provider is certified, licensed, and eligible in all respects, and each Clinical Provider is appropriately credentialed,
as applicable, to participate in and to bill and collect for goods sold and services rendered on behalf of Seller pursuant to the
terms and conditions of each Payor’s network, plan, Contract, or program maintained by Payor for payment or reimbursement
for such goods and services (collectively, “Payor Programs”). Seller and each Clinical Provider
maintain, to the extent required to bill and collect under any Payor Program, all valid provider numbers and provider agreements,
and except as set forth in Schedule 2.11(b), are in compliance with the requirements of such Payor Programs. To the
knowledge of Seller Parties, except as set forth in Schedule 2.11(b), no condition exists or event has occurred which in
itself or with the giving of notice or the lapse of time or both would result in the breach, default or other material amendment
to any rights or obligations of either party (including the modification of any reimbursement schedule or fee schedule) to any
Contract pertaining to any Payor Program in which Seller or any Clinical Provider Participates in connection with the Business
(“Payor Contract”) or in the suspension, revocation, impairment, forfeiture or non-renewal of Seller’s
or any Clinical Provider’s eligibility to bill and collect under any Payor Contract or Payor Program. Neither the execution
and delivery of this Agreement nor the consummation of the Transactions will result in the termination, suspension, revocation,
violation or material modification of any Payor Contract.

 

2.12Intellectual
Property Rights. Except as set forth on Schedule 2.12, Seller does not possess any rights in or to, does not own, and
is not a licensee in respect of any patents, websites, URLs, webpages, software (except for off-the-shelf software licenses), trademarks,
service marks, trade names, copyrights, inventions, specialized treatment protocols, or other intellectual property. No Legal Proceeding
is pending or, to the knowledge of Seller Parties, has been threatened alleging that any act of Seller infringed or is infringing
upon or conflicting with the asserted rights of others to any patents, patent rights, trade names, trademarks, service marks, copyrights,
inventions, specialized treatment protocols or other intellectual property. Seller has the sole and exclusive right to use the
items described on Schedule 2.12 as currently being used by Seller without infringing on or violating the rights of any
third party.

 

2.13Compliance
With Laws. 

 

(a)With
respect to the Centers, the Seller’s assets (including the Purchased Assets) and the Business, Seller and the Business are
in compliance with all applicable Laws, and except as set forth in Schedule 2.13(a), (i) in the past five years, no material
violation of any applicable Law by any Seller Party has occurred in connection with the operation of the Business, (ii) in the
past five years, neither Seller nor any Shareholder has received any notice of any violation or alleged violation of any applicable
Laws by a Clinical Provider, Seller or any Shareholder or any other party in connection with, or that could reasonably be expected
to affect, the Business, (iii) to Seller Parties’ knowledge, in the past five years, no Clinical Provider has violated any
applicable Laws, and (iv) there is no pending or, to the knowledge of Seller Parties, any present intent of any Governmental Authority
to pursue any, inspection, audit, review or other Legal Proceeding involving the Business or any Seller Party in connection with
such Seller Party’s role in the Business. 

 

    	13

    	 

    

(b)Seller
has made available to Buyer true, complete, and correct copies of all Contracts under which Seller is a “business associate”
or “covered entity” (each, a “Business Associate Agreement”), as such terms are defined in
45 C.F.R. § 160.103. Seller is not in breach of any Business Associate Agreement, and there is no information, security or
privacy breach event that has occurred that would require current or future notification under HIPAA or any comparable state Laws
for which Seller has not provided the notification required under such Laws.

 

(c)The
term “Law” and “Laws” mean, individually and collectively, all laws (including
the Health Care Laws), ordinances, regulations, rules, orders, common laws, injunctions, guidelines, professional standards, ethical
standards, restrictions, requirements, procedures, decrees or other requirements of any Governmental Authority. The term “Governmental
Authority” means any federal, state, local or any political subdivision thereof, and any department, commission,
board, body, bureau, agency, court, tribunal, panel, or other instrumentality exercising executive, legislative, judicial, regulatory
or administrative functions. The term “Health Care Laws” means each of the following, individually and
collectively, as currently in effect, (i) the Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), (ii) the Federal Physician
Self-Referral Law (42 U.S.C. 1395nn et seq., commonly referred to as the Stark Law), (iii) the Federal Civil Money Penalty Provisions
(42 U.S.C. § 1320a-7a and 31 U.S.C. § 3801 et seq.), (iv) the Federal False Claim Acts (31 U.S.C. § 3729, et seq.),
(v) Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Act, (vii) the Health
Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d, et seq.) (“HIPAA”), (viii)
all state Law counterparts to the Laws described in clauses (i)-(vii) and all federal and state regulations promulgated thereunder,
(ix) all Laws applicable to the ownership, custody and retention of medical records, (x) all Laws applicable to the prescription,
dispensation, maintenance and custody of pharmaceuticals, (xi) all Laws applicable to the splitting of medical fees by a Clinical
Provider with nonlicensed persons, (xii) all Laws applicable to the corporate practice of medicine, and (xiii) all Laws applicable
to a physician’s supervision of, collaboration with, and delegation of authority to, advanced practice registered nurses,
nurse practitioners, physician assistants and other nonphysician healthcare providers. 

 

2.14Licenses
and Permits.

 

(a)Seller
owns and maintains in good standing and in full force and effect, all licenses, registrations, permits, accreditations, provider
numbers, provider agreements, qualifications, certifications, and approvals granted or issued by any Governmental Authority or
accreditation bodies (collectively, “Permits”), a true, complete and correct list of which is set forth
on Schedule 2.14(a), that are necessary for Seller to participate in all Payor Programs in which it currently participates
and to otherwise operate the Business at the Centers in compliance with all applicable Laws. No Seller Party has been notified
by any Governmental Authority or other third party during the immediately preceding 24-month period that such Governmental Authority
or other third party has or intends to rescind, restrict, limit, suspend or not renew any Permit or that penalties or other adverse
action has been, is threatened to, or will be assessed or taken against Seller or any Clinical Provider or that any audit, investigation
or other Legal Proceeding that could lead to such adverse action is being threatened with respect to any Permit. Each Permit is
renewable by the appropriate Seller Party in the ordinary course of operating the Business without the need to comply with any
special qualification procedures or to pay any amounts other than routine taxes or filing fees.

 

    	14

    	 

    

(b)The
Clinical Providers maintain in good standing in full force and effect, all professional licenses and other Permits required by
all applicable Governmental Authorities (including state licensing boards), under applicable Laws in order to engage in the professional
activities for which such Clinical Provider is engaged or employed. Seller Parties have delivered or made available to Buyer true
and correct copies of the medical licenses, DEA certificates, Medicare NPI and/or UPIN numbers, and any other identifying information
maintained by each Clinical Provider in connection with such Clinical Provider’s professional practice. Each of the Clinical
Providers is duly licensed to practice their respective profession in North Carolina and at no time during the last five years
has any such Clinical Provider (i) had his or her professional license, DEA number (if applicable), or any other professional certificate
or provider number suspended or revoked, (ii) been reprimanded, sanctioned or disciplined by any state licensing board or other
Governmental Authority, professional society, hospital, Payor, or specialty board, (iii) been excluded from participation in any
Payor Program, or (iv) had a final judgment or settlement without judgment entered against him or her in connection with a matter
alleging professional malpractice. 

 

2.15Real
Property; Environmental Matters. Seller owns no right, title or interests in any real property. No action or omission by or
on behalf of Seller or any of its Affiliates, has resulted in any party’s material noncompliance with any applicable Laws
or binding determinations by any Governmental Authority relating to environmental, health and safety matters (including, without
limitation, those relating to toxic or hazardous substances), including, without limitation, the Clean Air Act, the Clean Water
Act, the Solid Waste Management Act (as amended by the Resource Conservation and Recovery Act), the Comprehensive Environmental
Response, Compensation and Liability Act (“CERCLA”) (as amended by the Superfund Amendments and Reauthorization
Act), the Emergency Planning and Community Right-to-Know Act, the Toxic Substances Control Act and the Occupational Safety and
Health Act. None of the Business, Seller’s assets or any real property currently or formerly owned, leased or managed by
Seller is listed on, or, to the knowledge of Seller Parties, has been proposed for listing on, the National Priorities List under
CERCLA, or any similar state list. No conditions or circumstances exist with respect to the Centers, the Business, Seller’s
assets or any real property currently or formerly owned, leased or managed by Seller that could reasonably be expected to give
rise to any remedial action under, or impose any Liability on Buyer or Seller Parties or their Affiliates with respect to, any
applicable Law or binding determination by any Governmental Authority regarding any environmental, health or safety matters.

 

2.16Financial
Condition. Schedule 2.16 contains audited financial statements of Seller consisting of its balance sheets for the years
ended December 31, 2013 and December 31, 2014 and the related statements of income and cash flow for such periods (collectively,
the “Audited Financial Statements”), and unaudited financial statements consisting of Seller’s
balance sheet for the six months ended June 30, 2015, and the related statements of income and cash flow for each such period (collectively,
“Unaudited Financial Statements” and together with the Audited Financial Statements, collectively, the
“Year-End Financial Statements”). Within 21 days after the close of each calendar month after the Effective
Date until Closing, Seller shall prepare and deliver unaudited financial statements consisting of a balance sheet and the related
statement of profit and loss as of the end of each such calendar month (the “Interim Financial Statements”
and together with the Year-End Financial Statements, the “Financial Statements”). The Financial Statements
(a) do and will fairly present in all material respects, the financial position of Seller as of the respective dates thereof and
the results of operations of the Business for the respective periods therein, and (b) are and will be true, complete and correct
in all material respects as of the respective dates and for the respective periods to which they relate.

 

    	15

    	 

    

2.17Undisclosed
Liability. No Liabilities exist affecting Seller, the Business, the Centers, or Seller’s assets (including the Purchased
Assets), except for those which (a) have been incurred in the ordinary course of Seller’s operating the Business subsequent
to the date of the Unaudited Financial Statements, not in excess of $2,500, (b) are reflected in the Unaudited Financial Statements,
or (c) are disclosed in Schedule 2.17. No facts or circumstances have occurred or exist that could reasonably be expected
to lead to any such Liabilities except for such Liabilities that may arise in the ordinary course of operating the Business consistent
with past practice. 

 

2.18Reimbursement;
Accounts Receivable; Accounts Payable. 

 

(a)Except
as set forth in Schedule 2.18(a), since January 1, 2009: (i) Seller has timely filed all claims for reimbursement under
Payor Programs (“Reimbursement Claims”); (ii) all such Reimbursement Claims have complied with all Laws
and all Payor requirements for prompt payment and are true, complete and correct, and none contain any material errors, omissions
or disallowable costs or expenses; and (iv) Seller and, to Seller Parties’ knowledge, Clinical Providers have not received
notice of any denial, overpayment claim, or other dispute between or among either or both of them and any Payor, Governmental Authority
or Medicare administrative contractor regarding such Reimbursement Claims, and there are no facts or circumstances that may reasonably
be expected to give rise to any material disallowance under any such Reimbursement Claims. Seller has never failed to return an
overpayment in accordance with applicable Law. All funds received in connection with the Seller’s operation of the Business
are, have been and will be deposited in an account or lockbox that currently is, and at Closing will remain, under the exclusive
dominion and control of Seller and which Seller is the sole account holder.

 

(b)The
Accounts Receivable as of the Closing Date are (or will be at Closing) set forth on Schedule 2.18(b). All Accounts Receivable
(i) have arisen from bona fide transactions involving the sale of goods or the rendition of services in the ordinary course of
Seller’s operation of the Business, consistent with past practice; (ii) constitute only valid, undisputed claims of Seller;
(iii) are not subject to patient or payor refund, recoupment, or any other claims, set-offs, defenses or counterclaims; (iv) reflect
gross charges for services rendered and goods sold; and (v) subject to a reduction equal to 35% of the Accounts Receivable attributable
to commercial insurance Payors for contractual adjustments and bad debts, are collectible in full within 90 days after the date
the goods were sold or services were rendered. 

 

(c)The
Assumed Payables as of the Closing Date are (or will be at Closing) set forth on Schedule 2.18(c). Each of the Assumed Payables
arose in the ordinary course of operating the Business, consistent with past practice, and none of the Assumed Payables are overdue
or delinquent.

 

2.19Inventory.
All inventory owned by Seller, whether or not reflected in the Financial Statements, consists of a quality and quantity usable
and salable in the ordinary course of Business, consistent with past practice, except for obsolete, damaged, spoiled, or slow-moving
items that have been written off or for which adequate reserves have been established in the Financial Statements. All such inventory
is owned by Seller free and clear of all Liens other than Permitted Liens, and no inventory is held on a consignment basis. The
quantities of each item of inventory are neither deficient nor materially excessive, but are reasonable in the present circumstances
of Seller, consistent with past practice, when considered together with any items of inventory supplied by Wilmington Health pursuant
to the terms of the PSMA. Seller is not responsible for the provision or procurement of any inventory or supplies in connection
with the ER Business.

 

    	16

    	 

    

2.20Service
Providers. 

 

(a)Schedule 2.20(a)
contains (i) a current, correct and complete list of all Service Providers; (ii) a summary of each Service Provider’s current
compensation rate, any bonus paid in the immediately preceding calendar year, any bonus accrued or paid for the current calendar
year, additional compensation whether current, deferred, promised, accrued, or payable to each such Service Provider for services
rendered or to be rendered through the period ending as of the Closing Date and an explanation of the applicable formula or calculation
method used to arrive at such bonus or additional compensation; (iii) a list of all Service Providers party to a written employment
agreement, independent contractor agreement, or other written agreement with or on behalf of Seller; (iv) a list of any Contract
or arrangement that provides for severance or termination pay by Seller to Wilmington Health, ECEP II, or any Service Provider,
and a description of such obligations; (v) a list of any Service Providers who will be entitled to any transaction bonuses, change-in-control
payments, or other rights or cash compensation that arise or accelerate as a result of the Transactions, and a description of such
compensation, rights or benefits; and (vi) a list of all Service Providers that have given notice to any Seller Party of a present
intention to terminate such Service Provider’s relationship with Seller. Seller has delivered to Buyer copies of all written
agreements between Seller and any Service Provider (including any exhibits, amendments or schedules thereto) and all of Seller’s
employee or contractor manuals, materials, policies, procedures and work-related rules applicable to employees or independent contractors
providing services to or for the Business.

 

(b)Seller has obtained
and has in its files a Form I-9 and all other new-hire documentation required under applicable Law, and all such documentation
is validly and properly completed in accordance with applicable Law for each Seller Employee. Except as set forth in the written
agreements described in Schedule 2.20(a), all Seller Employees are employed on an “at will” basis. To the extent
such classification is required to be made by Seller, each Service Provider has been correctly classified and treated (for withholding
and all other purposes) by Seller as an employee or independent contractor, as the case may be, and no Service Provider classified
by Seller as an independent contractor is entitled to overtime, benefits, or compensation of any kind, under any Seller Plan or
applicable Law. Each Seller Employee classified and treated as “exempt” from overtime under the Fair Labor Standards
Act and any applicable state laws governing wages, hours, and overtime pay, has been properly classified as such, and each non
“exempt” Seller Employee has been properly classified in accordance therewith and has been paid overtime wages consistent
with applicable Law. No physician that renders healthcare services in connection with the Urgent Care Business is required to be
classified as an employee of Seller. No physician that renders healthcare services in connection with the business of ECEP II is
required to be classified as an employee of Seller.

 

(c)Seller is and
to Seller Parties’ knowledge at all times since January 1, 2009 has been in compliance with all applicable Laws pertaining
to employment and employment practices, including all Laws relating to labor relations, equal employment opportunities, fair employment
practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration,
wages, hours, overtime compensation, employee classification, child labor, hiring, promotion and termination of employees, working
conditions, meal and break periods, privacy, health and safety, workers' compensation, leaves of absence and unemployment insurance.
There are no actions or other Legal Proceedings pending or, to the knowledge of Seller Parties, threatened against Seller by or
with any Governmental Authority or arbitrator in connection with the employment or retention of any current or former Service Provider,
including, without limitation, any claim relating to unfair labor practices, employment discrimination, harassment, retaliation,
equal pay, wage and hours or any other employment related matter arising under applicable Laws.

 

    	17

    	 

    

(d)Seller does not,
nor to Seller’s knowledge, does any Clinical Provider, have any financial relationship (whether investment interest, compensation
interest, or otherwise) with any entity to which any of such individual refers patients, except for such financial relationships
that qualify for exceptions to state and federal Laws restricting physician referrals to entities in which they have a financial
interest. Seller Parties have reviewed the following government sponsored website: http://exclusions.oig.hhs.gov and neither Seller
nor any of the Clinical Providers has been excluded, or is currently pending exclusion, from participation in any federal or state-funded
Payor Programs (including Medicare, Medicaid and Tricare) or any federal procurement or non-procurement program.

 

(e)Certain Definitions.

 

(i)“Clinical
Provider” means each physician and or non-physician (such as physician assistants, nurse practitioners and nurses)
provider of clinical services who has rendered clinical services for or on behalf of Seller in connection with the Business, whether
employed or engaged, directly or indirectly, by Seller (including (A) the clinical providers of Wilmington Health who render services
at the Centers for Seller’s benefit and (B) the clinical providers employed by Seller who render services to or for the benefit
of ECEP II); provided that any such person is considered to be a Clinical Provider only with respect to and to the extent of his
or her provision of clinical services for or on behalf of Seller (collectively as a group, the “Clinical Providers”).

 

(ii)“Seller
Employee” means each clinical or non-clinical employee of Seller (collectively as a group, the “Seller
Employees”).

 

(iii)“Service
Provider” means each individual or entity employed or engaged (as an independent contractor) by or on behalf of Seller
in connection with the Business, including all Clinical Providers and Seller Employees (collectively as a group, the “Service
Providers”).

 

2.21Employee
Benefit Plans. Except as set forth on Schedule 2.21, neither Seller nor any of its Affiliates has established, sponsored,
contributed to, or maintained, nor is Seller obligated to make contributions to or under or otherwise participate in, (a) any bonus
or other type of incentive compensation plan, program, agreement, policy, commitment, contract or arrangement (whether or not set
forth in a written document); (b) any pension, profit sharing, retirement or other plan, program or arrangement; or (c) any other
benefit plan, fund or program, including, but not limited to, those described in Section 3(3) of ERISA. All such plans listed on
Schedule 2.21 (collectively, the “Benefit Plans”) have been established, operated and administered
in accordance with all applicable Laws, including ERISA, the Code, Title VII of the Civil Rights Act of 1964, as amended, the Equal
Pay Act of 1967, as amended, the Age Discrimination in Employment Act of 1967, as amended, and the related rules and regulations
adopted by those federal agencies responsible for the administration of such laws. Except with respect to any qualification failures
as may have been corrected in accordance with applicable Law, each Benefit Plan that is intended to be qualified under Section
401(a) of the Internal Revenue Code of 1986, as amended (the “Code”) is so qualified and its related
trust or group annuity contract is exempt from taxation under Section 501(a) of the Code. No act or failure to act by Seller or
any of its Affiliates has resulted in or constituted a “prohibited transaction” or a “reportable event”
(each, as defined in ERISA) with respect to any of the Benefit Plans. Seller has not previously made, is not currently making and
is not obligated in any way to make, any contributions to any multi-employer plan within the meaning of the Multi-Employer Pension
Plan Amendments Act of 1980. Except as described in Schedule 2.21, no provision under any of the Benefit Plans could, as
a result of the execution of this Agreement or the consummation of the Transactions: (i) result in the payment to any employee,
director or consultant of any money or other property; or (ii) accelerate the vesting of or provide any additional rights or benefits
(including funding of compensation or benefits through a trust or otherwise) to any employee, director or consultant, except as
a result of any partial plan termination resulting from this Agreement. 

 

    	18

    	 

    

2.22Related
Parties Transactions. Except as set forth in Schedule 2.22: (i) no Seller Party has entered into any agreements, Contracts,
arrangements or other business relationships with any Related Party (defined below) relating to the Business; (ii) Seller is not
owed and does not owe any amount from or to the Related Parties in connection with the Business other than ordinary non-delinquent
compensation and other ordinary non-delinquent incidents of employment; and (iii) no property or interest in any property that
relates to and is or will be necessary or useful in the present or Seller Parties’ presently contemplated future operation
of the Business, is owned or leased by or to any Related Party. “Related Party” means any of the Seller
Parties, or any of Seller’s present directors, managers, officers, members, shareholders (including former shareholders)
and partners, and their respective Affiliates and immediate family members.

 

2.23Insurance.

 

(a)Schedule
2.23 contains a true, complete, and correct list and description (including insurer, coverage, deductibles, limitations and
expiration dates) of all insurance policies (including fire and casualty, general liability, professional liability, theft, life,
workers’ compensation, directors and officers, business interruption and all other forms of insurance) that are owned or
maintained by Seller or that name any Seller Party or Clinical Provider as an insured (or loss payee) as a result of such Seller
Party’s or Clinical Provider involvement with the Business, including those that pertain to the assets, employees (including
independent contractors), or operations of Seller. The insurance policies are and have been in all respects sufficient to comply
with all insurance requirements set forth in the Contracts and under applicable Law. With respect to each insurance policy: (i)
such policy is valid, binding and in full force and effect; (ii) neither Seller nor, to Seller Parties’ knowledge, any other
party, is in breach or default (including with respect to the payment of premiums or the giving of notices), and, to the knowledge
of Seller Parties, no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or
permit termination or modification of such policy; and (iii) no party to such policy has provided Seller with written repudiation
of any provision of the policy. Seller does not participate in any self-insurance or other similar program. None of the Clinical
Providers have ever been denied coverage for professional liability insurance by Seller’s insurers, and there are no pending
claims that have been denied insurance coverage or with respect to which a coverage determination has yet to be made. 

 

(b)Seller
has maintained Malpractice Coverage for all non-physician Clinical Providers who are Seller Employees (including those working
exclusively for the ER Business) for the entire period in which the Business has operated. Prior to March 1, 2014, Seller maintained
Malpractice Coverage for all past and present Clinical Providers. Seller maintains an Extended Reporting Endorsement (tail policy),
providing Malpractice Coverage relating to the period prior to March 1, 2014 for the Clinical Providers now employed by Wilmington
Health. To the knowledge of Seller Parties based solely on certificates of insurance evidencing coverage, from and after March
1, 2014, Wilmington Health has maintained uninterrupted Malpractice Coverage for each of the physician Clinical Providers. Upon
the termination or expiration of the Malpractice Coverage maintained by Wilmington Health for the physician Clinical Providers
engaged by Seller through Wilmington Health, each such physician Clinical Provider employed by Wilmington Health is bound to obtain
an Extended Reporting Endorsement (tail policy), covering the period beginning March 1, 2014 and ending on the applicable termination
or expiration date. ECEP II maintains (and Seller is not obligated to maintain) uninterrupted and adequate professional liability
coverage for all physicians rendering medical services in connection with the business of ECEP II. Seller is named as an additional
insured on the policies referenced in this Section 2.23(b), maintained by Wilmington Health and ECEP II. “Malpractice
Coverage” means uninterrupted professional liability insurance for the acts and omissions of Clinical Providers occurring
in the operation of the Business at minimum annual policy limits of $1,000,000 per occurrence and $3,000,000 in the aggregate.

 

    	19

    	 

    

(c)Schedule
2.23(c) sets forth a list of all claims filed and all notices given in connection with any potential claims against any insurance
policy maintained by or on behalf of Seller, Wilmington Health or ECEP II in connection with any Clinical Provider or the Business
during the immediately preceding 60 months. No Seller Party has failed to give any notice or present any claim under any insurance
policy in due and timely fashion or as required by any policy and, to the knowledge of Seller Parties, no actions, omissions or
occurrences have taken place that could reasonably be expected to give rise to a claim against any such insurance policies for
which notice has not yet been given. With respect to Seller’s Malpractice Coverage, all premiums due prior to the Closing
Date for periods prior to and including the Closing Date with respect to such policies have been timely paid. During the immediately
preceding 24-month period, there has been no notice from or on behalf of any insurance carrier providing Seller’s Malpractice
Coverage to the effect that insurance rates will thereafter be materially increased, that there will thereafter be no renewal of
an existing policy or that material alteration of any owned or leased personal or real property or material modification of any
of the Seller’s methods of doing business will be required or is suggested.

 

2.24Absence
of Certain Changes. Except as set forth on Schedule 2.24, since the cutoff date of the most recent Audited Financial
Statements, Seller Parties have operated the Business in the ordinary course, consistent with past practice, and except as set
forth on Schedule 2.24, Seller Parties have not: 

 

(a)Paid any expense
(including any capital expenditure) or incurred any Liability (other than for Transaction Expenses) in excess of $10,000 or which
could reasonably be expected to exceed $10,000, other than in the ordinary course of operating the Business, consistent with past
practice;

 

(b)Experienced any
termination, revocation, expiration, lapse or suspension of any Permit;

 

(c)Sold, transferred
or contracted to sell or transfer any of Seller’s assets other than in the ordinary course of operating the Business, consistent
with past practice;

 

(d)Mortgaged, pledged
or subjected to any Lien, any of the Shares or Seller’s assets;

 

(e)Except for normal
annual increases consistent as to timing and amount with past practice, granted, paid, or promised to pay any bonus or increase
in the salary or rate of pay of any Service Provider;

 

(f)Except for the
Transaction Documents, entered into any Contract or transaction other than in the ordinary course of operating the Business, consistent
with past practice;

 

(g)Authorized, declared,
or paid any dividends or distributions, in cash or in kind, or otherwise transferred any assets to any Shareholder or any third
party on account of rights in or to securities of Seller;

 

    	20

    	 

    

(h)Issued, granted,
awarded or assigned any shares or other securities, profit-sharing interest or voting interest in Seller, or any rights, units,
warrants or options to acquire (or which are convertible into) any equity interest in Seller; or

 

(i)Experienced, and
Seller Parties do not reasonably expect Seller to experience, any damage, destruction, loss (whether or not covered by insurance)
or other material adverse change (including the loss or termination of any patient, customer or supplier) that had or may have,
individually or in the aggregate, a material adverse effect on Seller’s assets (including the Purchased Assets), the Business,
the Centers or the financial condition of Seller.

 

2.25Books
and Records. The minute books and corporate records of Seller, copies of which have been delivered to Buyer, are complete
and correct in all material respects and contain accurate and complete records of all meetings and actions taken by written consent
of the shareholders, directors, officers, governing body or committee of Seller during the immediately preceding two years, and
no meeting or action taken by such written consent occurring during the immediately preceding two years has been held for which
minutes have not been prepared and are not contained in such record books. 

 

2.26Taxes.

 

(a)Seller has timely
filed all tax returns required to be filed by Seller in the past three (3) years and has timely made all payments of taxes, including
any interest, penalty or addition thereto, (whether or not reflected on any such tax return) with respect to income taxes, real
and personal property taxes, sales taxes, use taxes, employment taxes, excise taxes and all other taxes due and payable on or before
the Closing Date. All such tax returns are complete and accurate in all respects and each properly reflects the transactions consummated
and the relevant taxes for the periods covered by such tax returns in accordance with applicable tax Law. Seller has no outstanding
tax liability, except for taxes attributable to the portion of the tax year immediately preceding the Closing Date, which tax is
not yet due and payable. Seller has not received any notice that any tax deficiency or delinquency has been asserted against or
in connection with Seller, Seller’s assets (including the Purchased Assets), the Business, the Centers or the Shares. Except
as disclosed on Schedule 2.26(a), there are no pending or, to the knowledge of Seller Partiers, threatened audits relating
to taxes of Seller, and Seller is not currently the beneficiary of any waiver of any statute of limitations in respect of taxes
nor of any extension of time within which to file any tax return or to pay any tax assessment or deficiency. There are no Liens
other than Permitted Liens relating to taxes on or, threatened against Seller, any of Seller’s assets (including the Purchased
Assets), the Business, the Shares or the Centers. All taxes required by law to have been withheld or collected by or on behalf
of Seller have been timely withheld and collected, and to the extent required, have been timely remitted to the proper Governmental
Authority. Seller has not been a party to any tax allocation or sharing agreement or a member of any affiliated group of corporations
filing a consolidated federal income tax return.

 

(b)No Seller Party
has relied on Buyer, or any of its respective Affiliates, directors, managers, officers, shareholders, employees, or agents for
any advice concerning federal or state tax consequences resulting from the Transactions, including the transfer of the Redeemed
Shares. Seller Parties will be responsible for the full amount of any federal, state and any other tax Liability resulting from
the Transactions, including the Seller’s sale of the Purchased Assets and each Redeemed Shareholder’s sale of his or
her Redeemed Shares.

 

2.27Brokers.
No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the
transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Seller.

 

    	21

    	 

    

2.28No
Misrepresentations. No representation or warranty by any Seller Party in this Agreement (including the statements made in the
Schedules to this Agreement) or in any other Transaction Document contains any untrue statement of a material fact, or omits to
state a material fact necessary to make the statements contained herein or therein, in light of the circumstances in which they
are made, not misleading. 

 

2.29Knowledge.
Certain of the representations set forth in this Agreement are qualified by the “knowledge” of Seller Parties. For
purposes of this Agreement, Seller Parties’ “knowledge” shall mean the knowledge of each Seller Party and their
respective officers, directors, shareholders, managers, after due and reasonable inquiry. 

 

Article
3

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer makes the following
representations and warranties to Seller:

 

3.1Organization.
Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.

 

3.2Authority
and Binding Effect. Buyer has all requisite power and authority to execute, deliver and perform its obligations under each
of the applicable Transaction Documents and to consummate the Transactions. The execution and delivery of, and performance under,
the Transaction Documents and the consummation of the Transactions have been duly authorized, and no other action, approval, notice
or consent on the part of Buyer in order for Buyer to consummate the Transactions or to execute, deliver or perform Buyer’s
obligations set forth in the Transaction Documents. Upon execution and delivery by Buyer, this Agreement will constitute (assuming,
in each case, the due and valid authorization, execution and delivery thereof by the other party thereto) legal, valid and binding
obligations of Buyer, enforceable against Buyer in accordance with its terms except as such enforceability may be limited by applicable
law or equitable principles.

 

3.3Brokers.
No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the
Transactions based upon arrangements made by or on behalf of Buyer.

 

3.4No
Misrepresentations. No representation or warranty made by Buyer in this Agreement or any other Transaction Document contains
any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained herein or
therein, in light of the circumstances in which they are made, not misleading. 

 

Article
4

COVENANTS

 

4.1Access
to Information; No Waiver. For separate consideration, the receipt and sufficiency of which is acknowledged by Seller, from
the Effective Date until Closing, Seller shall (a) afford Buyer and the directors, officers, employees, consultants, financial
advisors, counsel, brokers, and accountants (collectively, “Representatives”) of Buyer full and free
access to inspect all of Seller’s properties, assets, premises, books and records, Contracts and other documents and data
that Buyer or its Representatives deem relevant to their investigation and review of the Business, the Centers and Seller’s
assets; (b) furnish Buyer and its Representatives with such financial, operating and other data and information related to the
Business as Buyer or any of its Representatives may reasonably request; and (c) instruct the Representatives of Seller to cooperate
with Buyer and its Representatives in their investigation and review of the Business, the Centers and Seller’s assets. Any
investigation pursuant to this Section 4.1 shall be conducted in such a manner as not to unreasonably interfere with the
conduct of the Business. No investigation by Buyer or its Representatives or information furnished by Seller or their Representatives
to Buyer or its Representatives shall operate as a waiver or otherwise affect any representation, warranty or agreement given or
made by Seller in this Agreement or the other Transaction Documents.

 

    	22

    	 

    

4.2Service
Providers. 

 

(a)Immediately after
Closing, Seller shall continue the employment of substantially all non-clinical Seller Employees on substantially the same terms,
at substantially the same rates of pay, and with the same benefits as immediately prior to the Closing; provided that Buyer may
request that the terms of any employment agreement between Seller and any officer of Seller be renegotiated prior to Closing, and
to the extent permissible under applicable Law, Seller, in cooperation with Buyer, shall attempt in good faith to renegotiate such
terms in accordance with Buyer’s request.

 

(b)Immediately after
Closing, Seller shall continue the employment of all Clinical Providers employed by Seller at Closing and shall continue the engagement
of any Clinical Providers who render services for the benefit of Seller at Closing. The continued employment and engagement of
such Clinical Providers shall be on substantially the same terms, at substantially the same compensation levels or rates of pay,
and with respect to the employed Clinical Providers, at the same benefits as immediately prior to the Closing.

 

(c)Any Seller Employees
who continue employment with Seller following the Closing are referred to as “Continuing Employees”.
If Buyer changes the entity employing any Continuing Employee following the Closing (e.g., to Buyer or any of its Affiliates),
or separately transitions any Continuing Employee to a Buyer benefit plan, Buyer shall give to each such Continuing Employee full
service credit (including for vesting, eligibility, and future contributions) under all Buyer benefit plans for such Continuing
Employee’s years of service with Seller.

 

(d)With respect to
the physician Clinical Providers who render services to Seller under the PSMA, the parties intend that immediately after Closing
such physician Clinical Providers will continue to render such services to Seller under the PSMA without modification to the terms
existing immediately prior to the Closing.

 

(e)To the maximum
extent permissible under applicable law, Seller shall provide Buyer with access to all Seller’s records related to the Service
Providers, including background checks, OIG exclusion checks, drug tests and records relating to performance reviews, disciplinary
actions, and grievances.

 

4.3Medical
Records. The parties acknowledge and agree that Seller shall retain ownership and custody of, and legal title to, all notes,
charts and other information constituting “medical records” as such term is used in applicable North Carolina Law (the
”Medical Records”), and such records shall remain with Seller. Seller shall use commercially reasonable
care at all times in the retention, maintenance, confidentiality, privacy, security, access and copying of the Medical Records
and agrees to comply with all applicable Law regarding custody, ownership, retention, maintenance, confidentiality, privacy, security,
access and copying of the Medical Records, including without limitation HIPAA and all other Health Care Laws. 

 

4.4Conduct
Prior to Closing. From the Effective Date until Closing, except as otherwise provided in this Agreement or as consented to
in writing by Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), Seller Parties shall conduct the
Business in the ordinary course, consistent with past practice, and shall use commercially reasonable efforts to maintain and preserve
intact the Business, the Centers, Seller’s assets and the relationships with the Service Providers, patients, employers,
lenders, suppliers, regulators and others having commercial relationships with the Business. Without limiting the foregoing, from
the Effective Date until Closing, Seller shall, in a manner consistent with past practices, use commercially reasonable efforts
to: 

 

    	23

    	 

    

(a)Preserve and maintain
all Permits necessary to operate the Business in compliance with applicable Law;

 

(b)Pay the debts,
taxes and other Liabilities of the Business when due;

 

(c)Bill for goods
sold and services rendered, and collect accounts receivable on account thereof;

 

(d)Manage its working
capital, including not delaying payment of accounts payable; accelerating the collection of accounts receivable; accelerating the
sale or disposal of inventory; or offering patients inconsistent transaction terms (including discounts or delayed payment arrangements);

 

(e)Maintain the Centers
and tangible assets of the Business in the same condition as they were on the Effective Date, subject to reasonable wear and tear;

 

(f)Timely perform
all Seller Parties’ obligations under the Contracts in effect relating to the Business, and maintain such Contracts in full
force and effect without modification;

 

(g)Maintain the books
and records (including the Medical Records) of the Business;

 

(h)Comply with all
Laws and the terms of any Contract applicable to the Centers, the Business and the ownership and use of Seller’s assets;

 

(i)Not take any action,
commit to take any action, or permit any action to be taken that could reasonably be anticipated to (i) cause any of the changes,
events or conditions to occur, which Seller Parties would be required to disclose in Schedule 2.24 as of Closing or (ii)
prevent Seller Parties from performing or cause Seller Parties not to perform one or more covenants required hereunder to be performed
by such Seller Parties; and

 

(j)Promptly notify
Buyer of any fact, circumstance, event or action the existence, occurrence or taking of which has had, or could reasonably be expected
to have, individually or in the aggregate, a material adverse effect on the Centers, Seller’s assets (including the Purchased
Assets) or the Business.

 

4.5Public
Announcement. Prior to Buyer’s filing of the Form 8-K or press release reporting or announcing the entry into this Agreement,
which Buyer may do without consent of or notice to Seller Parties (provided, however, that Buyer shall give Seller not less than
three days prior notice of such filing and an opportunity to review and comment on such filing, which comments Buyer shall consider
in good faith), neither Seller, the Shareholders nor Buyer shall make, or permit any agent or Affiliate to make, any public statements,
including any press release or public statement with respect to the Transactions without the prior written consent of the other
party (which consent will not be unreasonably withheld or delayed) except as required by applicable Law or the requirements of
any applicable stock exchange based on the reasonable advice of counsel. 

 

4.6Consents.
No later than ten calendar days after the Effective Date, Seller Parties shall give all notices required to be given as a result
of the prospective consummation of the Transaction (notwithstanding the fact that notice may not technically be due as a result
of the period of time between the Effective Date and Closing) under all Payor Contracts and shall use commercially reasonable efforts
to obtain all consents described in Schedule 2.7 prior to Closing. The form and substance of any written notice shall be
subject to the prior approval of Buyer, which shall not be unreasonably withheld, conditioned or delayed.

 

    	24

    	 

    

4.7Restrictive
Covenants. Each Seller Party acknowledges (a) the covenants set forth in the Restrictive Covenant Agreements are an essential
part of this Agreement and that, but for the agreement of each Shareholder to comply with such covenants, Buyer would not have
entered into this Agreement, and (b) that the restrictions set forth in the Restrictive Covenant Agreements are reasonable and
necessary to protect the legitimate business interests of Buyer after Closing and the goodwill being purchased by Buyer.

 

4.8Tax
Matters. All transfer, documentary, sales, use, stamp, registration, and other such taxes and fees (including any penalties
and interest) incurred in connection with the Transactions, this Agreement and the other Transaction Documents (including any real
property transfer tax and any other similar tax) shall be borne and paid by Shareholders when due. Promptly following Closing,
the tax books of Seller shall be closed, and Terri Miller, CPA for Seller, shall allocate items of income, gain, loss, deduction
and credit to the short taxable year in which such items are recognized under the cash basis method of accounting, and not pro
rata across the entire calendar year. Using the information prepared by Terri Miller and the purchase price allocation set forth
in Section 1.8, Seller Representative, at Shareholders’ sole cost and expense, shall cause for the timely preparation
and filing of the Seller’s final tax return on Form 1120 and corresponding Forms K-1 for the period ending on the Closing
Date. Except as described in this Section 4.8, Buyer shall bear the reasonable and customary costs and expenses relating
to the taxable events arising from the operation of the Business after Closing.

 

4.9Payment
of Expenses. Except with respect to the audit of the Seller’s financial statements, the cost of which shall be paid by
Buyer, Buyer and each of the Seller Parties shall bear their own Transaction Expenses. 

 

4.10Updates
to Schedules. Buyer and Seller Parties shall promptly supplement and amend the Schedules to this Agreement for which they are
responsible to reflect those events and circumstances, if any, that occur between the Effective Date and the Closing Date, which,
if existing or known on the Effective Date (or occurring on or before the Effective Date) would have been required to be set forth
or described in the Schedules or which are necessary to correct any information in the Schedules that has been rendered inaccurate
or incomplete by such events or circumstances.

 

4.11No-Shop.

 

(a)In consideration
of the substantial time and expense to Buyer in analyzing the Business and the Purchased Assets, conducting its due diligence investigation,
and preparing the Transaction Documents, for the Covered Period (defined below), neither Seller, Shareholders, nor any of their
Affiliates, Representatives, or their respective equity owners shall, directly or indirectly, without the prior written consent
of Buyer, contact, respond to, negotiate with, or initiate or engage in discussions with any person, corporation, partnership,
or other entity (other than Buyer) regarding (i) the sale or other disposition of all or substantially all of Seller’s assets,
(ii) the issuance, sale or other dispossessory or other dilutive action involving of any capital stock or other equity interests
in Seller, (iii) the merger or consolidation of Seller with or into any other entity, or (iv) the management of all or any material
portion of the Business or Seller’s assets. Upon receipt during the Covered Period of any communication to any Seller Party
from any corporation, partnership, person, or other entity regarding any transaction described in clauses (i)-(iv) of the previous
sentence, Seller Representative shall promptly provide written notice to Buyer of such communication, identifying the communicant
(each, a “Soliciting Party”) and the subject matter and substance of the communication. Seller Representative
also shall promptly inform the Soliciting Party that Seller is not free to discuss the matter and that any further effort to do
so would interfere with Seller’s obligations under an existing contract. Notwithstanding the preceding sentences of this
Section 4.11, the term “Soliciting Party” shall not include any corporation, partnership, person, or other entity
with whom Seller has previously entered into a confidentiality or nondisclosure agreement for the purposes of discussing any transaction
described in clauses (i)-(iv) prior to the commencement of the Covered Period; provided that Seller shall deliver the written notice
required in the previous sentence (including all information therein to the extent permissible under any applicable confidentiality
or nondisclosure agreement) with respect to such unsolicited communication from any such party. For purposes of this Section
4.11, the term “Covered Period” means the period beginning April 9, 2015 (the date of the full execution
and delivery of the Letter of Intent contemplating the Transactions) and ending on the Closing Date or the earlier expiration or
termination of this Agreement.

 

    	25

    	 

    

(b)If Seller enters
into a binding agreement to consummate any of the transaction described in clauses (i)-(iv) of Section 4.11(a) with any
Soliciting Party during the nine-month period immediately after the termination or expiration of this Agreement, Seller shall pay
Buyer $50,000 in immediately available funds by wire transfer no later than three business days after such agreement becomes binding.

 

4.12Access
to Information after Closing. Buyer agrees that, for a period of three (3) years after the Closing Date, upon the delivery
by any Seller Party of a written request for records in accordance with this Section 4.12, Buyer shall provide Seller Parties
during normal business hours reasonable access to and shall permit Seller Parties to make reasonable numbers of copies, at Seller
Parties’ expense, of any of the data, books and records of the Business generated by Seller in the course of its operation
of the Business prior to Closing. The written request for records shall be delivered no later than three business days in advance
of the proposed record review date and shall state the purpose for which the Seller Party intends to use the records. Buyer may
decline access to such records if, in Buyer’s reasonable discretion, it determines that the stated purpose of the Seller
Party is improper, overly broad, or is made other than in good faith. In any case, such Seller Party’s access shall be limited
to the records created prior to Closing, which are germane to the stated purpose. 

 

4.13Further
Assurances. Each party to this Agreement, from and after Closing, upon the reasonable request of any other party hereto and
without further consideration, shall (a) execute and deliver to the requesting party such documents and further assurances and
(b) take such other actions (without cost to the requesting party) in order to carry out the purposes and intentions of this Agreement
and the other Transaction Documents.

 

Article
5

TERMINATION AND Conditions to closing

 

5.1Termination.

 

(a)This Agreement
shall terminate automatically without any further action of any party at 5:00 p.m., Atlanta, Georgia time on October 4, 2015. This
Agreement may be terminated at any time (i) by the mutual written agreement of Buyer and Seller, (ii) by Buyer, upon delivery of
written notice of termination to Seller if there has been a material adverse change to the Business, or (iii) by Buyer or Seller
if the terminating party is not then in material breach of any provision of this Agreement and there has been a material breach,
inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by the other party and such breach,
inaccuracy or failure has not been cured by the breaching party within ten days after the non-breaching party’s delivery
of written notice of such breach, inaccuracy or failure to perform or would render satisfaction of the conditions to Closing set
forth in this Agreement impossible; or (iv) by Buyer or Seller upon delivery of written notice of termination to the other party
if (A) the other party commences a voluntary case, or any third party commences an involuntary case against the other party, under
any chapter of the federal bankruptcy laws, and the case is not dismissed by midnight of the 60th day after commencement, (B) a
court of competent jurisdiction appoints, or the other party makes an assignment of any portion of its assets to, a custodian,
or (C) the other party fails generally to pay its debts as they become due (unless those debts are subject to a good-faith dispute
as to liability or amount) or acknowledges in writing that it is unable to do so.

 

    	26

    	 

    

(b)If this Agreement
is terminated pursuant to Section 5.1(a)(iii), upon the expiration of the cure period, if any, the breaching party shall
reimburse the non-breaching party for up to $40,000 for the non-breaching party’s out-of-pocket costs reasonably incurred
in connection with the Transactions, including, but not limited to, fees paid or payable to lawyers, accountants, consultants,
and advisors. Such reimbursement shall be payable in immediately available funds by wire transfer no later than five business days
after such termination.

 

5.2Seller
Conditions. Seller Parties’ obligation to close the Transactions shall be subject to the satisfaction of each of the
following conditions on or prior to the Closing Date, unless specifically waived in writing by Seller Representative in whole or
in part at or prior to Closing:

 

(a)All obligations
of Buyer to be performed in this Agreement or the other Transaction Documents through and including the Closing Date (including
all closing deliveries required under Section 1.11 and all other obligations Buyer would be required to perform at the Closing
if the Transactions were consummated) shall have been performed in all material respects;

 

(b)All of the representations,
warranties, covenants and agreements of Buyer contained in this Agreement shall in all material respects be true, correct and not
breached as of the Effective Date and the Closing Date; provided that Seller Representative’s decision to proceed with Closing
shall not serve as a waiver of any deficiency therein or breach thereof;

 

(c)Seller shall have
obtained all consents, including those set forth in Schedule 2.7, required to enter into the Transaction Documents and consummate
the Transactions; and

 

(d)The provisions
of all Schedules to this Agreement that were not included on the Effective Date, or to the extent updated by Buyer after the Effective
Date, shall be acceptable to Seller Representative in his reasonable discretion.

 

5.3Buyer
Conditions. Buyer’s obligation to close the Transactions shall be subject to the satisfaction of each of the following
conditions on or prior to the Closing Date, unless specifically waived in writing by Buyer, in whole or in part, at or prior to
Closing:

 

(a)All obligations
of Seller Parties to be performed in this Agreement or the other Transaction Documents through and including the Closing Date (including
all closing deliveries required under Section 1.10 and all other obligations Seller Parties would be required to perform
at the Closing if the Transactions were consummated) shall have been performed in all material respects;

 

(b)All of the representations,
warranties, covenants and agreements of Seller Parties contained in this Agreement shall in all material respects be true, correct
and not breached as of the Effective Date and the Closing Date; provided that Buyer’s decision to proceed with Closing shall
not serve as a waiver of any deficiency or breach thereof;

 

    	27

    	 

    

(c)Buyer shall have
received financing in an amount no less than the Purchase Price;

 

(d)Seller shall have
entered into an Amended and Restated Professional Services Management Agreement with Wilmington Health in a form reasonably acceptable
to Buyer;

 

(e)Buyer shall have
entered into a new lease agreement or assumed Seller’s existing lease providing for Buyer’s use and occupancy of the
Shipyard Center, in form and substance reasonably acceptable to Buyer;

 

(f)ECEP II shall
have renewed its Services and Staffing Agreement, dated January 1, 2000 and most recently amended on June 1, 2014, with Seller
for another one-year term;

 

(g)Buyer shall have
obtained all Permits from any Governmental Authority, approvals under any Payor Contracts, and entered into all agreements with
third parties, each as Buyer deems necessary, in its reasonable discretion, to consummate the Transactions, to perform its obligations
under the Transaction Documents, and to manage the non-clinical aspects of the Business after Closing;

 

(h)Seller shall have
given all notices and obtained all consents, including those set forth in Schedule 2.7, required to enter into the Transaction
Documents and consummate the Transactions;

 

(i)There shall not
have been any Lien (other than Permitted Liens) on, or material adverse change in or to Seller’s assets (including the Purchased
Assets) other than the distribution of real property located in Brunswick County, NC by Seller to Seamist, the Business or the
Centers since the cutoff date of the most recent Audited Financial Statements;

 

(j)Buyer and Seller
shall have entered into a management services agreement governing the relationship of the parties after Closing pursuant to which
Buyer will, among other things, perform substantially all nonclinical services related to the Business in exchange for a monthly
management fee; and

 

(k)The provisions
of all Exhibits and Schedules attached to this Agreement that were not attached at the Effective Date or to the extent updated
by Seller after the Effective Date shall be acceptable to Buyer in its reasonable discretion.

 

Article
6

INDEMNIFICATION

 

6.1Survival.
Except in the case of fraud, intentional misrepresentation, or willful misconduct and as otherwise indicated in this Section
6.1, (a) all of the representations and warranties in this Agreement (other than the Fundamental Representations (defined below))
shall survive Closing and shall remain in full force and effect for a period of 12 months after the Closing Date; (b) all of the
representations and warranties set forth in Sections 2.5 (with respect only to title of the Purchased Assets), 2.6, 2.7,
2.10, 2.11, 2.13, 2.15 and 2.23 shall survive Closing and shall remain in full force and effect for a period of 24 months
after the Closing Date; and (c) the Fundamental Representations shall survive Closing and shall remain in full force for the period
of the applicable statute of limitations plus any extensions or waivers thereof. All covenants, agreements and obligations of the
parties contained in this Agreement and the other Transaction Documents shall survive Closing until fully performed or satisfied.
The term “Fundamental Representations” means the representations of Seller Parties set forth in Sections
2.1, 2.2, 2.3, 2.26 and 2.27, and the representations of Buyer set forth in Sections 3.1, 3.2 and 3.3.
Notwithstanding the foregoing, any claims for indemnification asserted in writing and in good faith, with reasonable specificity
(to the extent known at such time), and in accordance with the procedures set forth in Section 6.11, prior to the expiration
date of the applicable survival period shall not be barred by the expiration of the relevant representation or warranty and any
such claims shall survive until finally resolved. 

 

    	28

    	 

    

6.2Indemnification
by Shareholders. Subject to the limitations set forth in this Article 6, the Shareholders shall, jointly and severally,
indemnify, defend, protect, and hold harmless Buyer and its Affiliates and their respective directors, managers, officers, members,
shareholders, partners, agents, Representatives, successors and permitted assigns (collectively, the “Buyer Indemnitees”)
for, from, and against, and be liable for, and pay on behalf of or reimburse such Buyer Indemnitees for, as and when incurred,
any and all liabilities, losses, damages, claims, actions, suits, demands, causes of action, costs, expenses, interest, awards,
judgments and penalties of any nature whatsoever (including, without limitation, reasonable legal costs and expenses) (“Losses”),
that any such 

Buyer Indemnitee may suffer, sustain, or become subject to, directly or indirectly caused by, relating
to, arising out of, resulting from, attributable to, or in any way incidental to the occurrence of:

 

(a)Any
breach or inaccuracy of any representation or warranty made by any Seller Party in this Agreement or any other Transaction Document;

 

(b)Any
breach or nonperformance of any covenant, agreement or obligation to be performed by any Seller Party pursuant to this Agreement
(including the obligations set forth in this Article 6) or any other Transaction Document (excluding the Restrictive Covenant
Agreements); 

 

(c)Any
Excluded Asset or any Retained Liability;

 

(d)Action
taken by Blue Cross Blue Shield of North Carolina (“BCBSNC”) to discontinue or reduce Seller’s
reimbursement under Schedule 1 of the Reimbursement Exhibit to the First Amendment to Network Participation Agreement – Professional,
dated effective April 1, 2014 (“Reimbursement Exhibit”) or to terminate such agreement, but only if (i)
such action by BCBSNC is the result of or is prompted by the failure to satisfy one or more of the conditions set forth in the
Reimbursement Exhibit and (ii) such condition was unsatisfied at Closing; or

 

(e)Any
Legal Proceeding or Liability (except for those relating to the enforcement of this Agreement) arising out of or relating to (i)
the ownership or operation the Business or Seller’s assets (including the Purchased Assets) prior to Closing, (ii) the ownership
or transfer of any shares in Seller prior to the Redemption or the sale or transfer of the Shares as part of the Redemption, or
(iii) the assets owned or formerly owned by Seller or any of Seller’s Affiliates on or prior to Closing.

 

6.3Indemnification
by Buyer. Subject to the limitations set forth in this Article 6, Buyer shall indemnify, defend, protect and hold harmless
Shareholders, and their Affiliates and respective Representatives (collectively, the “Seller Indemnitees”)
for, from and against, and be liable for, and pay on behalf of or reimburse such Seller Indemnitees for, as and when incurred,
any and all Losses that any such Seller Indemnitee may suffer, sustain, or become subject to, directly or indirectly caused by,
relating to, arising out of, resulting from, attributable to, or in any way incidental to the occurrence of:

 

(a)Any
breach or inaccuracy of any representation or warranty made by Buyer in this Agreement or any other Transaction Document;

 

(b)Any
breach or nonperformance of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement (including
the obligations set forth in this Article 6) or any other Transaction Document; 

 

(c)Any
Assumed Liability; or

 

    	29

    	 

    

(d)Any
Legal Proceeding or Liability (except for those relating to the enforcement of this Agreement) arising out of or relating to the
ownership or operation of the Business or the Purchased Assets after Closing.

 

6.4Indirect
Losses; Escrow Amount. Shareholders acknowledge and agree that (a) Buyer is relying and will rely on the accuracy and completeness
of the representations, warranties and agreements set forth in this Agreement in closing the Transactions and in its management
of the Business after Closing, (b) as manager of the Business, Buyer indirectly will suffer damages from any Losses for which indemnification
is available under Section 6.2, and (c) in determining whether any Buyer Indemnitee is entitled
to indemnification under this Agreement, any release, waiver or discharge by Seller of any Shareholder or such Shareholder’s
successors, assigns, heirs or agents (including the waiver and release set forth in Section 4 of the Stock Redemption Agreement)
shall be disregarded. For the avoidance of doubt, (x) Shareholders agree that Buyer Indemnitees shall be entitled to indemnification
for Losses in accordance with the terms of this Article 6 (without reduction for or limitation by any release or waiver
of any Shareholder by Seller) as if Buyer suffered or sustained such Losses directly, and (y) the Escrow Amount is intended to
be available to reimburse Buyer Indemnitees for any Losses they may incur (subject to the limitations otherwise set forth in this
Article 6) and is not intended as a source of payment for any obligation owing by the Seller or Shareholders.

 

6.5Limitations
of Liability. 

 

(a)Generally
Applicable Caps. Notwithstanding anything to the contrary contained herein, except with respect to Excluded Claims (as defined
in Section 6.5(d)), (i) the maximum aggregate liability under this Article 6 of all Shareholders to all Buyer Indemnitees,
and of Buyer to all Seller Indemnitees, shall not in either case exceed (A) with respect to any inaccuracy in or breach of any
Fundamental Representation, the Purchase Price, (B) with respect to all other claims for indemnification under this Article
6, $2,240,000 (the “Overall Cap”), and (ii) the maximum liability under this Article 6 of
any Shareholder individually to all Buyer Indemnitees shall be an amount equal to (X) for claims made during the 12-month period
immediately after the Closing Date, (a) the Overall Cap multiplied by (b) 125% of such Shareholder’s Sharing Percentage,
and (Y) for claims made after the 12-month period immediately after the Closing Date, (a) the Overall Cap multiplied by
(b) such Shareholder’s Sharing Percentage. The term “Indemnified Party” means, with respect to
a particular matter, the party (either Buyer Indemnitee or Seller Indemnitee) who is entitled or is alleging entitlement to indemnification
from the other party pursuant to this Article 6. The limitations set forth in this Section 6.5(a) are in addition
to any other limitations herein and in no event shall such limitations be read or understood to diminish or detract from the limiting
effect of the indemnification limitations set forth in Section 6.5(b) or any other provision of this Article 6.

 

(b)Basket.
Except as expressly set forth herein, no Shareholder shall be liable under this Article 6 to any Buyer Indemnitee, and Buyer
shall not be liable under this Article 6 to any Seller Indemnitee, unless and until the amount of Losses incurred by the
Indemnified Party exceeds $56,000.00 in the aggregate (the “Deductible”), after which the applicable
Indemnified Party shall be entitled to reimbursement for all Losses in excess of the Deductible, subject to the limitations provided
herein. Notwithstanding the foregoing, Shareholders shall be jointly and severally liable for all Losses from the first dollar
relating to or arising from the following claims and matters, without limitation by or reduction of the Deductible: (i) the Excluded
Claims (defined in Section 6.5(d)), (ii) claims for or relating to any inaccuracy in or breach of any Fundamental Representation,
(iii) claims for or relating to the matters for which indemnification is secured by the Payor Escrow or the Regulatory Escrow,
(iv) Seller Parties’ failure to pay (or Buyer’s election to pay on behalf of Seller Parties in accordance with Section
1.6) any Retained Liability described in paragraphs (b), (c), (e), (f) or (i) of Section 1.6 or any other trade account
payable that would have been properly defined as an Assumed Payable had it been disclosed on Schedule 1.10(b). 

 

    	30

    	 

    

(f)Specific
Issue Limitations. Notwithstanding anything to the contrary contained herein, (i) with respect to any claim for indemnification
arising out of or relating to the matter described in Section 6.2(d) for which indemnification is secured by the Payor Escrow,
(A) the maximum aggregate liability of all Shareholders to all Buyer Indemnitees shall be limited to $1,000,000, (B) as set forth
in Section 6.5(b), any Losses incurred by Buyer Indemnitees in connection with such matter shall be jointly and severally
reimbursable by Shareholders from the first dollar, without limitation by or reduction of the Deductible, and (C) any amount paid
in connection with such matter shall be included for purposes of calculating the Overall Cap; and (ii) Buyer shall have no right
to indemnification for any payment or performance obligations arising after Closing under any Operating Contract unless such payment
or performance arises as a result of a breach or failure to perform when due any of the terms of the Operating Contracts prior
to Closing. 

 

(c)Excluded
Claims. The limitations set forth in Sections 6.5(a), (b), and (c), shall not apply to or otherwise affect
any parties ability to make claims or recover Losses with respect to claims for indemnification for fraud, intentional misrepresentation
or willful misconduct (collectively, the “Excluded Claims”). In addition, the amount of Losses with respect
to the Excluded Claims will be disregarded in determining whether the Overall Cap has been met and any Losses subject to the Deductible
will be disregarded in determining whether any limitation on Losses has been met. 

 

(d)Duty
to Mitigate. Nothing in this Agreement shall be construed to relieve the Indemnified Party from its duty, if any, under law
to mitigate or otherwise act reasonably upon the occurrence of any event giving rise to any claim or Losses.

 

(e)Waiver
of Consequential Damages. No party hereto shall be liable to any Buyer Indemnitee or Seller Indemnitee, as applicable, for
any unforeseeable loss of profits, business interruption, or any special, exemplary, punitive, consequential or similar damages
of any nature, whether based on contract, tort, negligence, or any other theory of recovery or cause of action, in law or in equity,
arising out of or otherwise relating to this Agreement other than indemnification for amounts paid or payable to third parties
in respect of any Third Party Claim for which indemnification hereunder is otherwise required. 

 

6.6Materiality.
Notwithstanding anything in this Agreement to the contrary, for purposes of determining the amount of any Losses that are the subject
matter of an indemnification claim, each representation and warranty contained in this Agreement is to be read without regard and
without giving effect to any materiality, material adverse effect or similar standard or qualification contained in such representation
or warranty (as if such standard or qualification were deleted from such representation and warranty).

 

6.7Exclusive
Remedy. The parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than
claims arising from fraud, intentional misrepresentation or willful misconduct on the part of a party in connection with the Transactions)
for any breach of any representation, warranty, covenant, agreement or obligation set forth in this Agreement or otherwise relating
to the subject matter of this Agreement (other than the subject matter contained in the Restrictive Covenant Agreements), shall
be pursuant to the indemnification provisions set forth in this Article 6. Nothing in this Section 6.7 shall inhibit
or restrict the parties’ rights to injunctive relief as set forth in Section 6.9. 

 

    	31

    	 

    

6.8Payments;
Recourse; Set Off. 

 

(a)The
outstanding balance of the Note and the Escrow Amount (to the limited extent set forth in this Article 6), will secure the
indemnification obligations of the Shareholders under this Agreement. Except as set forth in this Section 6.8, to the extent
a Buyer Indemnitee is entitled to indemnification under this Agreement, it shall obtain such indemnification, first, by offsetting
the then-existing outstanding balance of the Note. Once the balance of the Note is exhausted, the Buyer Indemnitees may make claims
against the Shareholders, directly or through the Seller Representative, to be paid in cash, by wire transfer of immediately available
funds to an account designated by the applicable Buyer Indemnitees within 10 days after final determination of the Loss as set
forth in Section 6.11. Notwithstanding the foregoing, if Seller Representative fails to make any payment pursuant to this
Article 6 within the time period required herein, then Buyer Indemnitees will have the option, in their sole discretion,
in addition to any other rights or remedies Buyer or any Buyer Indemnitee may have in this Agreement or at law or in equity, to
recover such amounts by offsetting such amounts against any amount payable to any of the Seller Parties or their Affiliates under
any of the Transaction Documents. Any indemnification obligation owed to the Seller Indemnitees pursuant to this Article 6
shall be made by Buyer by wire transfer of immediately available funds in accordance with written instructions provided by the
Seller Representative within 10 days after final determination of such Loss as set forth in Section 6.11;

 

(b)To
the extent any Buyer Indemnitee suffers Losses relating to, arising out of, resulting from, attributable to, or in any way incidental
to the Settlement Agreement, entered into in December 2001, between the United States of America, acting through the Department
of Justice (acting on behalf of several other Governmental Authorities), ECEP II, and Eastern Carolina Emergency Physicians, P.A.
(predecessor to Medac Health Services, P.A.), or the matters giving rise thereto, the Buyer Indemnitee shall obtain indemnification
first by offsetting the outstanding balance of the Regulatory Escrow. Once the Regulatory Escrow has been exhausted, any Buyer
Indemnitee may pursue such claims in accordance with this Article 6;

 

(c)To
the extent any Buyer Indemnitee is entitled to indemnification for Losses arising out of or relating to Section 6.2(d),
the Buyer Indemnitee shall obtain such indemnification, first, by offsetting the outstanding balance of the Payor Escrow. Once
the Payor Escrow has been exhausted, any Buyer Indemnitee may pursue such claims in accordance with this Article 6, subject
to the $1,000,000 limitation set forth in Section 6.5(c); and

 

(d)To
the extent any Buyer Indemnitee is entitled to indemnification for Losses directly or indirectly caused by, relating to, arising
out of, resulting from, attributable to, or in any way incidental to Seller’s prior ownership of real property, which property
was transferred to Seamist, including with respect to indebtedness or Liens related thereto, the Buyer Indemnitee may, in addition
to any other rights or remedies the Buyer Indemnitee may have under this Agreement or at law or in equity, offset amounts payable
to Seamist.

 

6.9Injunctive
Relief. Notwithstanding the provisions of Article 6, the parties agree that irreparable damage would occur in the event
that any of the provisions in this Agreement were not performed by Seller Parties or Seller Representative in accordance with their
specific terms or were otherwise breached. Accordingly, Buyer shall be entitled to seek an injunction or injunctions, without the
posting of any bond, to prevent breaches of this Agreement by Seller Parties or Seller Representative and to enforce specifically
the terms and provisions in this Agreement, in addition to any other remedy to which Buyer is entitled at law or in equity. 

 

    	32

    	 

    

6.10Other
Matters. Any liability for indemnification under this Article 6 shall be determined without duplication of recovery
by multiple parties and by reason of the state of facts giving rise to such liability constituting a breach of more than one representation,
warranty, covenant or agreement. The amount of any Losses for which indemnification is entitled under this Article 6 shall
be reduced by any amounts actually recovered by the Indemnified Party (or any other person or entity that receives payment on account
of amounts payable to the Indemnified Party) under insurance policies or any other source.

 

6.11Notice;
Indemnification Procedures. 

 

(a)Any
party seeking indemnification under this Article 6 shall give the party from whom indemnification is being sought notice
of any matter which such Indemnified Party has determined to give rise to or to potentially give rise to a right of indemnification
under this Agreement as soon as practicable after the party entitled to indemnification becomes aware of any fact, condition or
event that would be reasonably likely to give rise to Losses for which indemnification may be sought under this Article 6;
provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party (defined in Section
6.11(b)) shall relieve the Indemnifying Party from any obligation hereunder unless (and then solely to the extent) the Indemnifying
Party thereby is materially prejudiced by such delay. Notwithstanding anything in this Agreement to the contrary, the parties shall
only be obligated for those Losses to which the Indemnified Party has given the Indemnifying Party written notice thereof prior
to the expiration of the applicable survival period, if any, set forth in Section 6.1. If a party receiving a notice of
a claim of Losses incurred by the other party disputes, in writing, all or any portion of the Losses set forth in such notice within
10 days after receipt thereof, the parties shall negotiate in good faith to resolve the matter. If the parties are unable to resolve
the matter within 20 days after delivery of the written dispute notice, then each party may seek any remedy permissible under this
Agreement. 

 

(b)The
liability of a party (the “Indemnifying Party”) to an Indemnified Party under this Article 6 with
respect to Losses arising out of claims of any third party that are subject to indemnification in this Article 6 (“Third
Party Claims”) shall be governed by and contingent on the following additional terms and conditions:

 

(i)if
any third party notifies any Indemnified Party with respect to a Third Party Claim, then the Indemnified Party shall give the Indemnifying
Party notice of such Third Party Claim within 20 days after the receipt by the Indemnified Party of such notice; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying
Party from any indemnification obligation hereunder unless (and then solely to the extent) the Indemnifying Party thereby is materially
prejudiced by such delay.

 

(ii)The
Indemnifying Party will have the right to assume and control the defense of the Third Party Claim in a diligent manner at its expense
and with counsel of the Indemnifying Party’s choice (subject to the reasonable satisfaction of the Indemnified Party), so
long as the Indemnifying Party gives notice of its intention to do so to the Indemnified Party within 30 days after the receipt
of notice of such Third Party Claim from the Indemnified Party.

 

(iii)If
the Indemnifying Party assumes the defense of a Third Party Claim, (A) the Indemnified Party may retain separate co-counsel at
its sole cost and expense and participate in the defense of the Third Party Claim, and (B) the Indemnifying Party will not consent
to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the written consent of
the Indemnified Party, unless such judgment or settlement (x) includes an unconditional written release by the claimant or plaintiff
of the Indemnified Party from all liability in respect of such Third Party Claim, and (y) does not impose equitable remedies or
material obligations on the Indemnified Party other than financial obligations for which such Indemnified Party will be indemnified
hereunder. No Third Party Claim which is being defended in good faith by the Indemnifying Party in accordance with the terms of
this Agreement shall be settled by the Indemnified Party, nor shall the Indemnified Party consent to the entry of any judgment
with respect thereto, without the written consent of the Indemnifying Party.

 

    	33

    	 

    

(iv)In
the event that the Indemnifying Party does not assume the defense of a Third Party Claim, (A) the Indemnified Party may defend
against, and consent to the entry of any judgment or enter into any settlement with respect to, the Third Party Claim in any manner
it reasonably and in good faith may deem appropriate (and the Indemnified Party need not consult with, or obtain any consent from,
the Indemnifying Party in connection therewith), (B) the Indemnifying Party will reimburse the Indemnified Party promptly and periodically
for the reasonable costs of defending against the Third Party Claim (including reasonable attorneys’ fees and expenses),
and (C) the Indemnifying Party will remain responsible for any Losses the Indemnified Party may suffer arising out of or resulting
from the Third Party Claim to the fullest extent provided under this Article 6.

 

(v)Each
of the Indemnifying Party and the Indemnified Party shall cooperate with the other in the defense of a Third Party Claim and make
available all witnesses, pertinent records, materials and information in such party’s possession or under such party’s
control relating to such Third Party Claim as is reasonably requested by the other party.

 

(c)Upon
Buyer’s notice to the Shareholders or Shareholder Representative of a dispute, controversy or other matter involving Seller
that has been determined to potentially give rise to a right of indemnification on the part of any Buyer Indemnitee under this
Agreement, the Shareholders shall have the right to assume and control the handling and disposition of such dispute, controversy
or other matter (even prior to the time that such dispute, controversy or other matter is not yet a Third Party Claim) on behalf
of Seller, and Seller shall cooperate in all reasonable respect in connection with the Shareholders’ handling thereof. 

 

6.12Tax
Treatment of Indemnification. All indemnification obligations satisfied under this Agreement, whether in cash or by offset,
shall be treated by the parties as an adjustment to the purchase price for federal and state tax purposes, unless otherwise required
by law.

 

Article
7

Shareholder REPRESENTATIVE

 

7.1Appointment
of Seller Representative. Each Shareholder hereby irrevocably constitutes and appoints Seller Representative as such Shareholder’s
attorney-in-fact and agent in connection with the execution and performance of this Agreement and the other Transaction Documents.
This power is irrevocable and coupled with an interest, and shall not be affected by the death, incapacity, illness, dissolution
or other inability to act of any Shareholder. By execution of this Agreement, Dr. Potts accepts such appointment as Seller Representative,
and agrees to perform all obligations of Seller Representative as set forth herein.

 

7.2Authority
of Seller Representative. Each Shareholder hereby irrevocably grants Seller Representative full power and authority:

 

(a)to
execute and deliver, on behalf of such Shareholder, and to accept delivery of, on behalf of such Shareholder, such documents as
may be deemed by Seller Representative, in his, her, or its sole discretion, to be appropriate to consummate the Transactions;

 

    	34

    	 

    

(b)to
endorse and to deliver on behalf of such Shareholder, certificates or other Transaction Documents representing the Redeemed Shares
to be sold by such Shareholder at Closing;

 

(c)to
make decisions on behalf of Shareholders (individually and as a group) with respect to the Transactions and other matters contemplated
by this Agreement or the other Transaction Documents, including regarding indemnification claims;

 

(d)to
acknowledge receipt at Closing of the Purchase Price for the Purchased Assets or Redeemed Shares sold by Seller and such Shareholder,
to instruct Buyer as to delivery of the Purchase Price (including the Net Closing Proceeds) and to certify, on behalf of Seller
and such Shareholder, as to the accuracy and completeness of the representations and warranties of Seller and such Shareholder
under, or pursuant to the terms of, this Agreement;

 

(e)to
(i) dispute or refrain from disputing, on behalf of Seller or such Shareholder, any claim made by Buyer or any other person or
entity under this Agreement; (ii) negotiate and compromise, on behalf of Seller and such Seller, any dispute that may arise under,
and to exercise or refrain from exercising any remedies available under, this Agreement and at Law; and (iii) execute, on behalf
of Seller and such Shareholder, any settlement agreement, release or other document with respect to such dispute or remedy;

 

(f)to
waive, on behalf of Seller and such Shareholder, any closing condition contained in Article 5 of this Agreement and to give
or agree to, on behalf of such Seller, any and all consents, waivers, extensions, amendments or modifications, deemed by Seller
Representative, in his or her sole discretion, to be necessary or appropriate, under this Agreement, and, in each case, to execute
and deliver any documents that may be necessary or appropriate in connection therewith;

 

(g)to
enforce, on behalf of such Shareholder, any claim against Buyer arising under this Agreement;

 

(h)to
engage attorneys, accountants and agents at the expense of Shareholders;

 

(i)to
amend this Agreement (other than this Article 7) or any of the instruments to be delivered to Buyer by Shareholders pursuant
to this Agreement; provided that such authority is limited to such amendments that do not adversely effect in any material respect
the legal, financial or other rights and interests of such Shareholder; and

 

(j)to
give such instructions and to take such action or refrain from taking such action, on behalf of such Shareholder, as Seller Representative
deems, in its sole discretion, necessary or appropriate to carry out the provisions in this Agreement, including the exercise of
all rights granted to Shareholders under this Agreement or any other Transaction Document.

 

7.3Reliance.
Each Shareholder hereby agrees to each of the following:

 

(a)In all matters
in which action by Seller Representative is required or permitted under this Agreement, Seller Representative is authorized to
act on behalf of such Shareholder, notwithstanding any dispute or disagreement among Shareholders or between any Shareholder and
Seller Representative, and Buyer shall be entitled to rely on any and all action taken by Seller Representative under this Agreement
without any Liability to, or obligation to inquire of, any Shareholder, notwithstanding any knowledge on the part of Buyer of any
such dispute or disagreement.

 

(b)Notice to Seller
Representative, delivered in the manner provided in Section 8.6, shall be deemed to be notice to all Seller Parties for
purposes of this Agreement.

 

    	35

    	 

    

(c)The power and
authority of Seller Representative, as described in this Agreement, shall continue in full force and effect until all rights and
obligations of Seller Parties under this Agreement shall have terminated, expired or been fully performed.

 

(d)Seventy percent
(70%) of the Shareholders, acting together, shall have the right, exercisable from time to time upon written notice executed by
the requisite number of Shareholders delivered to Seller Representative and Buyer, to remove Seller Representative, with or without
cause, and to appoint Dr. Moulton to serve as Seller Representative. Dr. Moulton shall be immediately appointed, without further
action of the Shareholders, to fill any vacancy caused by the death, resignation, or removal of Seller Representative. Thereafter,
seventy percent (70%) of the Shareholders, acting together, shall have the right, exercisable from time to time upon written notice
executed by the requisite number of Shareholders delivered to the then-acting Shareholder Representative and Buyer, to remove Dr.
Moulton or such other then-acting Shareholder Representative, with or without cause. Any such or subsequent vacancy shall be filled
by the affirmative vote of a majority of the Shareholders. Any such replacement shall be effective only upon receipt of written
notice, together with reasonable evidence of such replacement, by Buyer in accordance with Section 8.6. Any successor appointed
in accordance with the foregoing shall be the “Shareholder Representative” for all purposes under this Agreement.

 

7.4Actions
by Shareholders. Each Shareholder agrees that, notwithstanding the foregoing, at the reasonable request of Buyer, such Shareholder
shall use commercially reasonable efforts to take all actions necessary or appropriate to consummate the Transactions (including
delivery of the Purchased Assets or such Shareholder’s Redeemed Shares (or documents representing the same) and acceptance
of the applicable portion of the Purchase Price therefor) individually on such Shareholder’s own behalf, and to deliver any
other documents required of such Shareholder pursuant to the terms hereof as soon as reasonably practicable.

 

7.5Indemnification
of Seller Representative. Each Shareholder shall severally indemnify Seller Representative against any Losses (except such
Losses resulting from Seller Representative’s fraud, intentional misrepresentation, gross negligence or willful misconduct)
that Seller Representative may suffer or incur in connection with any action or omission as Seller Representative. Each Shareholder
shall bear its pro rata portion of such Losses. Seller Representative shall not be liable to any Shareholder with respect to any
action or omission taken or omitted to be taken by Seller Representative pursuant to this Article 7, except for Seller Representative’s
fraud, intentional misrepresentation, gross negligence or willful misconduct.

 

7.6Indemnification
of Buyer and Its Affiliates. Shareholders, jointly and severally, shall indemnify Buyer Indemnitees against, and agree to hold
Buyer Indemnitees harmless from, any and all Losses incurred or suffered by any Buyer Indemnitee arising out of, with respect to
or incident to the operation of, or any breach of any covenant or agreement pursuant to, this Article 7, or the designation,
appointment and actions of Seller Representative pursuant to the provisions hereof, including with respect to (a) actions taken
by Seller Representative; and (b) reliance by any Buyer Indemnitee on, and actions taken by any Buyer Indemnitee in response to
or in reliance on, the instructions of, notice given by or any other action taken by Seller Representative. All of the rights to
indemnification granted to Buyer Indemnitees under this Section 7.6 shall survive the Closing.

 

7.7Survival.
All of the indemnities, immunities and powers granted to the Seller Representative under this Agreement shall survive the Closing.

 

Article
8

miscellaneous

 

    	36

    	 

    

8.1Waiver.
No failure to exercise, and no delay in exercising, any right, remedy, power or privilege under this Agreement by any party shall
operate as a waiver of such right, remedy, power or privilege, nor shall any single or partial exercise of any right, remedy, power
or privilege under this Agreement preclude any other or further exercise of such right, remedy, power or privilege. Any waiver
under this Agreement must be in writing, signed by the waiving party.

 

8.2Severability.
If any term or provision of this Agreement or any other Transaction Document is determined to be invalid, illegal or unenforceable
by any court, agency or tribunal of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any
other term or provision of this Agreement or any other Transaction Document or invalidate or render unenforceable such term or
provision in any other jurisdiction. Unless expressly provided otherwise in this Agreement or any of the other Transaction Documents,
the parties to the applicable Transaction Document shall negotiate in good faith to modify such Transaction Document so as to effect
the original intent of the parties as closely as possible in a mutually acceptable manner in order that the Transactions be consummated
as originally contemplated to the greatest extent possible.

 

8.3Third
Party Beneficiaries. This Agreement is solely for the benefit of the parties and those persons and entities specifically described
herein, and, except as for such parties, no provision in this Agreement shall be deemed to confer any remedy, claim, or right upon
any third party. 

 

8.4Amendment;
Assignment. This Agreement may not be amended except by an instrument in writing signed by Buyer and Seller Representative.
This Agreement and all provisions hereof shall be binding upon and inure to the benefit of, and be enforceable by, the parties
hereto and their respective successors and permitted assigns, but neither this Agreement nor any of the rights, interests or obligations
herein shall be assigned by any party hereto without the prior written consent of the other party; provided, however, that Buyer
may assign this Agreement or delegate the performance of its obligations to a subsidiary or Affiliate of Buyer or without the consent
of Seller so long as such assignment or delegation, in no way limits, diminishes or alters the nature or extent of Seller Parties’
rights, interests, or remedies herein. Notwithstanding anything in this Agreement to the contrary, expressed or implied, this Agreement
is not intended to confer any rights or remedies on any person other than the parties and their respective successors and permitted
assigns.

 

8.5Entire
Agreement. Except as otherwise provided in this Agreement, this Agreement, the other Transaction Documents, and that certain
Confidentiality and Mutual Nondisclosure Agreement dated January 13, 2015 by and between Buyer and Seller (the “NDA”)
collectively set forth the entire understanding of the parties with respect to the subject matter hereof and thereof and this Agreement,
the other Transaction Documents and the NDA collectively supersede all prior agreements concerning the subject matter hereof and
thereof. No party is relying upon any statement or representation of any other party except as expressly set forth herein and each
party is relying on its own judgment in connection with the execution of this Agreement and the other Transaction Documents and
the consummation of the Transactions.

 

8.6Notices.
All notices, claims, certificates, requests, demands and other communications pursuant to this Agreement or any other Transaction
Document shall be in writing and shall be deemed to have been duly given to Buyer or to Seller Representative, as the case may
be, (a) when delivered, if delivered by hand; (b) one business day after transmitted, if transmitted by a nationally-recognized
overnight courier service, (c) when sent by electronic mail, with confirmation of receipt; or (d) three business days after mailing,
if mailed by registered or certified mail, postage prepaid, return receipt requested, and in each case to the parties at the following
addresses (or at such other address for such party as shall be specified in a notice given in accordance with this Section 8.5):

    	37

    	 

    

	If to Seller Parties	 	Kevin E. Potts, MD	 
	 	 	4402 Shipyard Boulevard	 	 
	 	 	Wilmington, North Carolina 28403	 	 
	 	 	Email: kepotts@ec.rr.com	 	 
	 	 	 	 	 
	With copy to, which shall not constitute notice to Seller:
	 	 	 	 	 
	 	 	 	 	 
	 	 	Murchison, Taylor & Gibson, PLLC

                    16 North Fifth Avenue

                    Wilmington, North Carolina 28401

                    Attention: W. Berry Trice, Esq.

                    Email: btrice@murchisontaylor.com

	 	 	 	 	 
	If to Buyer:	 	ACSH Medical Management, LLC

                    1170 Peachtree Street NE, Suite 2350

                    Atlanta, Georgia 30309

                    Email: nwinland@americancaresource.com

                    Attention: Norman Winland, COO
	 
	 	 	 	 	 
	with copy to, which shall not constitute notice to Buyer:
	 	 	 	 	 
	 	 	ACSH Medical Management, LLC

                    c/o Baker, Donelson, Bearman, Caldwell & Berkowitz, P.C.

                    420 20th Street North, Suite 1400

                    Birmingham, Alabama 35203

                    Email: awinger@americancaresource.com

                    Attention: Adam S. Winger, General Counsel

 

8.7Governing
Law, Venue, Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the laws of the State
of Delaware, excluding any conflicts-of-law rules or principles that might refer the governance or construction of this Agreement
to the laws of another jurisdiction. The parties hereto hereby irrevocably submit to the jurisdiction of the courts of the State
of North Carolina, in each case located in New Hanover County, North Carolina, and appropriate appellate courts therefrom, over
any dispute arising out of or relating to this Agreement or the Transactions and each party hereby irrevocably agrees that all
claims in respect of such dispute or proceeding may be heard and determined in such courts, which courts shall be the exclusive
courts of jurisdiction and venue. The parties irrevocably waive, to the fullest extent permitted by applicable law, any objection
which they may now or hereafter have to the laying of venue of any dispute arising out of or relating to this Agreement or the
Transactions brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the parties
agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner
provided by law. This consent to jurisdiction and venue is being given solely for purposes of this Agreement and is not intended
to, and shall not, confer consent to jurisdiction or venue with respect to any other dispute in which a party to this Agreement
may become involved. EACH OF THE PARTIES WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY PROCEEDING SEEKING ENFORCEMENT
OF SUCH PARTY’S RIGHTS UNDER THIS AGREEMENT. 

 

    	38

    	 

    

8.8Costs
of Enforcement. If Buyer or Seller files suit or other action to enforce the terms of this Agreement or to obtain performance
as required in this Agreement, then the prevailing party in any such suit or action will be entitled to recover all reasonable
costs, including reasonable attorneys’ fees and costs, from the non-prevailing party as part of any judgment in such suit
or action. The term “prevailing party” will mean the party in whose favor final judgment after appeal (if any) is rendered
with respect to the claims asserted in the complaint.

 

8.9Construction
and Usage. All Schedules and Exhibits attached to this Agreement and the definitions set forth in the Preamble and Recitals
to this Agreement hereby incorporated in this Agreement as if set forth in full herein and, unless otherwise defined therein, all
terms used in any Schedule or Exhibit shall have the meanings assigned to such terms in this Agreement. The words “include,”
“includes” and “including” shall be deemed to be followed by the phrase “without limitation.”
The words “hereof,” “herein” and “hereunder” and words of similar import when used in this
Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Unless otherwise expressly
provided herein, any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred
to herein means such agreement, instrument or statute as from time to time may be amended, modified or supplemented, including
(in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor
statutes and references to all attachments thereto and instruments incorporated therein. 

 

8.10Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and shall be
valid and effective for all purposes.

 

8.11No
Requirement To Refer. Notwithstanding anything contained herein, nothing in this Agreement shall be construed to induce, encourage,
solicit or reimburse the referral of any patients or business, including any patients or business funded in whole or part by federal
or state government programs (i.e., Medicare, Medicaid, TRICARE, etc.) or to limit the freedom of any patient of Seller, Buyer
or any of their Affiliates to choose the hospital, healthcare facility or physician from whom such patient will receive medical
services. The parties acknowledge that there is no requirement under this Agreement or any other agreement between the parties
that Seller or any of their Affiliates refer patients or business to Buyer, any medical practice, walk-in clinic or urgent care
clinic managed by Buyer or its Affiliates. No payment made under this Agreement will be in return for the referral of patients
or business, including those paid in whole or part by federal or state government programs. The parties acknowledge that none of
the benefits granted Seller or any of their Affiliates hereunder are conditioned on any requirement that any such person make referrals
to, be in a position to make or influence referrals to, or otherwise generate business for Buyer, any medical practice, walk-in
clinic or urgent care clinic managed by Buyer or any of their Affiliates.

 

8.12Fair
Value. Buyer and Seller Parties acknowledge that the terms of this Agreement have been negotiated at arms’ length and
that the Purchase Price constitutes fair value for the Purchased Assets.

 

 

 

 

 

 

 

[Signature pages follow.]

 

    	39

    	 

    

IN WITNESS WHEREOF,
this Agreement has been duly executed and delivered by the duly authorized representatives of Buyer and of the Seller as of the
Effective Date.

 

	 	BUYER:	 
	 	 	 
	 	ACSH MEDICAL MANAGEMENT, LLC,
	 	a Delaware limited liability company
	 	 	 
	 	By:	 /s/ Norman B. Winland
	 	Name:	Norman B. Winland
	 	Title:	President
	 	 	 
	 	SELLER:
	 	 	 
	 	MEDAC HEALTH SERVICES, P.A.,
	 	a North Carolina professional corporation
	 	 	 
	 	By:	/s/ Michael P Moulton,
MD
	 	Name:	 Michael P. Moulton, MD
	 	Title:	President
	 	 	 
	 	SELLER REPRESENTATIVE:
	 	 	 
	 	Sign:	/s/ Kevin E. Potts,
MD
	 	Print: 	Kevin E. Potts, MD
	 	 	 
	 	SHAREHOLDERS:
	 	 	 
	 	Sign:	/s/ Stephen B. Durham,
MD
	 	Print:	 Stephen B. Durham, MD
	 	 	 
	 	Sign:	/s/ Andres J. Exposito,
MD
	 	Print:	 Andres J. Exposito, MD
	 	 	 
	 	Sign:	/s/ Kenneth S. Garm,
MD
	 	Print:	 Kenneth S. Garm, MD

 

 

[Signature page to Asset Purchase Agreement

Page 1 of 2]

    	 

    	 

    

 

	 	Sign:	/s/ Monique R. Minor, MD
	 	Print:	 Monique R. Minor, MD
	 	 	 
	 	Sign:	/s/ Stanley G. Minor,
MD
	 	Print:	 Stanley G. Minor,
MD
	 	 	 
	 	Sign:	/s/ Michael P. Moulton,
MD
	 	Print:	 Michael P. Moulton,
MD
	 	 	 
	 	Sign:	/s/ Robert A. Parr,
DO
	 	Print:	Robert A. Parr,
DO
	 	 	 
	 	Sign:	/s/ Kevin E. Potts,
MD
	 	Print:	Kevin E. Potts,
MD
	 	 	 
	 	Sign:	/s/ Matthew C. Radack,
MD
	 	Print:	Matthew C. Radack,
MD
	 	 	 
	 	Sign:	/s/ Kevin J. Reese,
MD
	 	Print:	Kevin J. Reese,
MD
	 	 	 
	 	Sign:	/s/ Theodore R. Winneberger,
MD
	 	Print:	Theodore R. Winneberger,
MD
	 	 	 
	 	Sign:	/s/ Alfred H. Woodworth,
MD
	 	Print:	Alfred H. Woodworth,
MD
	 	 	 

 

[Signature page to Asset Purchase Agreement

Page 2 of 2]

    	 

    	 

    

Exhibit A

Form of Stock Redemption Agreement

STOCK REDEMPTION AGREEMENT

This STOCK REDEMPTION AGREEMENT (this
“Agreement”) is entered into as of July                       
, 2015 (the "Effective Date"), by and among MEDAC HEALTH SERVICES, P.A., a North Carolina professional
corporation (the “Corporation”), the shareholders of Company listed on the signature page to this Agreement
(the “Redeemed Shareholders”), and KEVIN E. POTTS, MD, (in his capacity as
a Redeemed Shareholder, “Dr. Potts” and in his capacity as an authorized representative of Shareholders,
“Shareholder Representative”).

RECITALS

A.Contemporaneously
with the execution of this Agreement, the Corporation, the Redeemed Shareholders, Michael P. Moulton, M.D. (“Dr. Moulton”)
and Shareholder Representative will enter into an Asset Purchase Agreement with ACSH Medical Management, LLC, a Delaware limited
liability company (“ACSH Medical”), pursuant to which the Corporation
will sell to ACSH Medical substantially all of its assets used in connection with the Business (the “Asset Purchase
Agreement”). Capitalized terms used and not defined in this Agreement shall have the
meaning ascribed in the Asset Purchase Agreement.

B.The
Corporation has 1,200 shares of capital stock issued and outstanding (the “Shares”),
and the Redeemed Shareholders own, in equal amounts, 1,100 of the Shares (the “Redeemed Shares”).

C.In connection with the
transactions contemplated by the Asset Purchase Agreement, all of the Redeemed Shareholders, which comprise all the shareholders
of the Corporation except Dr. Moulton, desire to sell, assign and transfer their respective Redeemed Shares to the Corporation,
and the Corporation desires to purchase and redeem the Redeemed Shares from the Redeemed Shareholders, all on the terms and subject
to the conditions set forth in this Agreement.

D.The Redeemed Shareholders
have appointed Dr. Potts as their authorized representative to take certain action and to effectuate certain aspects of the Transactions
on behalf of the Redeemed Shareholders, as set forth in more detail in this Agreement and the Asset Purchase Agreement.

AGREEMENT

In consideration of the above Recitals and
the promises and provisions set forth in this Agreement, the adequacy and sufficiency of which the parties acknowledge, the parties,
intending to be bound, agree as follows:

1.                 
Redemption. At the Closing (defined herein), each Redeemed Shareholder shall sell to the Corporation, and the Corporation
shall purchase and redeem from each Redeemed Shareholder, 100 Redeemed Shares, which represents each Redeemed Shareholder’s
entire ownership interest in the Corporation.

2.                 
Purchase Price. The aggregate consideration to be paid at Closing for all the Redeemed Shares shall be One Hundred Ten Dollars
($110.00) (the "Purchase Price"). The portion of the full Purchase Price payable to each Shareholder and
the number of Redeemed Shares owned by each Redeemed Shareholder is set forth on Exhibit A to this Agreement.

3.                 
Transfer of Redeemed Shares. On the Effective Date, each Redeemed Shareholder shall either duly endorse in blank and deliver
to Shareholder Representative certificate(s) evidencing their respective Redeemed Shares in a form ready for transfer or duly execute
and deliver to Shareholder Representative an assignment separate from certificate for such Redeemed Shares in substantially the
form attached hereto as Exhibit B. Although the certificates and assignments described in this Section 3
shall be delivered to Seller Representative simultaneously with the execution of this Agreement, the consummation of the transactions
contemplated by this Agreement shall be effective only at Closing.

    	1

     

    

4.                 
Resignation and Release.

(a)               
Each Redeemed Shareholder agrees to resign as of Closing from all positions held by such Redeemed Shareholder as an officer or
director in the Corporation. Such resignation shall be effective at Closing without any further action of any party.

(b)              
At Closing, and without any further action of any party, each Redeemed Shareholder hereby waives, releases and forever discharges
the Corporation, each director, officer and shareholder of the Corporation, and their successors, assigns, heirs, officers, employees
and agents (collectively, the “Corporation Released Parties”) from and against all debts,
actions, causes of action, suits, contracts, agreements, damages and any and all claims, demands and liabilities whatsoever of
every kind or nature (collectively, the “Claims”) which such Redeemed Shareholder has or may have, or
ever had against any Corporation Released Party on account of or arising out of any cause or event occurring contemporaneously
with or prior to Closing, and whether known or unknown, contingent or otherwise, including, without limitation Claims related to
(i) Redeemed Shareholder’s capacity as a shareholder of the Corporation, (ii) the fairness or adequacy of the consideration
received or to be received under this Agreement, (iii) any claim or future claim of pre-emptive rights or dividend distributions
under applicable Law, the Articles of Incorporation, Bylaws, any other governing document of the Corporation, or any agreement
or arrangement among one or more of the shareholders, (iv) any contractual relationship between the Corporation and a Redeemed
Shareholder or an affiliate of a Redeemed Shareholder that is expressly terminated pursuant to this Agreement; provided, however,
that nothing in the foregoing release shall be deemed to release the Corporation or any other Corporation Released Party from,
and the released claims shall not be deemed for any purpose to include, (x) any obligation of the Corporation under any law or
agreement to indemnify a Redeemed Shareholder for claims by third parties (other than Buyer or any of the other Shareholders) against
such Shareholder in his or her capacity as an officer or director of the Corporation, (y) any obligation of the Corporation under
or arising out of the Asset Purchase Agreement or any other Transaction Document (as defined in the Asset Purchase Agreement);
provided, that each Redeemed Shareholder agrees that he or she has no right of contribution against the Corporation in connection
with the Shareholders’ indemnification obligations under Article 6 of the Asset Purchase Agreement, or (z) any obligation
of any Corporation Released Party to any Redeemed Shareholder which obligation has been disclosed on Schedule 2.22 of the Asset
Purchase Agreement.

(c)               
At Closing, and without any further action of any party, the Corporation hereby waives, releases and forever discharges each Redeemed
Shareholder, and such Redeemed Shareholder’s successors, assigns, heirs, and agents (collectively, the “Shareholder
Released Parties”) from and against all Claims which the Corporation has or may have, or ever had against any Shareholder
Released Party on account of or arising out of any cause or event occurring contemporaneously with or prior to Closing, and whether
known or unknown, contingent or otherwise, including, without limitation Claims related to (i) Redeemed Shareholder’s
capacity as a shareholder of the Corporation, (ii) the fairness or adequacy of the consideration received or to be received
under this Agreement, or (iii) any contractual relationship between the Corporation and a Redeemed Shareholder or an affiliate
of a Redeemed Shareholder that is expressly terminated pursuant to this Agreement; provided, however, that nothing in the foregoing
release shall be deemed to release a Redeemed Shareholder or any other Shareholder Released Party from, and the released claims
shall not be deemed for any purpose to include, any obligation of any Shareholder Released Party to the Corporation which obligation
has been disclosed on Schedule 2.22 of the Asset Purchase Agreement.

    	2

     

    

5.                 
Redeemed Shareholder’s Representations and Warranties. Each Redeemed Shareholder represents and warrants to the Corporation
as of the Effective Date and at Closing as follows with respect to such Redeemed Shareholder, but not with respect to any other
Redeemed Shareholder:

(a)               
Such Redeemed Shareholder (i) owns his or her Redeemed Shares free and clear of all pledges, liens, encumbrances, security interests,
options, claims and other charges of every kind, other than Permitted Liens (as defined in the Asset Purchase Agreement) and (ii)
has not entered into any contract or agreement, other than this Agreement, to sell or otherwise transfer any of his or her Redeemed
Shares. Except for the Shares described on Exhibit A attached hereto, such Redeemed Shareholder has no other right
or interest in or to the Corporation. Upon delivery by Seller Representative of the certificate(s) representing such Redeemed Shareholder’s
Redeemed Shares (or such other documentation referenced in Section 3 of this Agreement), at Closing, such Redeemed Shareholder
will transfer clear title to the Redeemed Shares to the Corporation.

(b)              
Such Redeemed Shareholder has full power and authority to execute this Agreement and to consummate the transactions contemplated
by this Agreement. Such Redeemed Shareholder’s execution, delivery, and performance of this Agreement has been duly authorized
by all necessary parties and action, and this Agreement is the legal, valid and binding obligation of such Redeemed Shareholder,
enforceable against such Redeemed Shareholder in accordance with its terms.

(c)               
The execution and delivery by such Redeemed Shareholder of this Agreement and the consummation of the transactions contemplated
by this Agreement will not result (i) in any violation of any Laws applicable to the Shares, the Business, or such Redeemed
Shareholder, or (ii) in any violation of, conflict with, or breach the terms, conditions or provisions of, or constitute a default
under, any Contract, or require or give to any other party any interest or rights, including rights of termination, cancellation
or acceleration, with respect to any instruments, contracts or agreements, or require any authorization, consent, approval, exemption
or other action by, or notice to or filing with, any Governmental Authority which has not been obtained or given, except as is
set forth in Schedule 2.7(b) under the Asset Purchase Agreement.

(d)              
Upon execution and delivery by such Redeemed Shareholder of this Agreement and the Asset Purchase Agreement, Seller Representative,
as attorney-in-fact of such Shareholder (as set forth in the Asset Purchase Agreement), shall be vested with the right, power,
and authority, to, among other things, consummate the transactions contemplated by this Agreement on behalf of such Redeemed Shareholder.

6.                 
Corporation’s Representations and Warranties. The Corporation represents and warrants as of the Effective Date and
at Closing to each Redeemed Shareholder as follows:

(a)               
The Corporation has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
The Corporation’s execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate
action, and this Agreement is the legal, valid and binding obligation of the Corporation, enforceable against the Corporation in
accordance with its terms.

    	3

     

    

(b)              
The Corporation presently can, and immediately following the consummation of and after giving effect to, the execution and delivery
of this Agreement will be able to, pay its known and reasonably anticipated debts as they become due in the ordinary course of
business, or has or will have total assets which are greater than the sum of its total liabilities.

(c)               
The Corporation is not redeeming the Redeemed Shares for the purpose of immediate resale nor does it have any present intention
to sell or otherwise transfer any of the Stock.

7.                 
Termination of Shareholders’ Agreement. Contemporaneously with the Closing, that certain Shareholders’ Agreement
dated May 2, 1990, by and between Eastern Carolina Emergency Physicians, P.A., Hetzal Hartley, MD, David L. Hoeppner, MD, Kenneth
C. Marburg, MD, Stanley Gill Minor, MD, Jerome T. Nolan, MD, Robert A. Parr, MD, Samuel Spicer, MD, David M. Turnbull, MD, Theodore
Winneberger, MD, and Alfred H. Woodworth, MD, as subsequently amended and/or restated, and any other agreement or arrangement among
the Shareholders relating to their relationship as shareholders of the Corporation shall automatically terminate without the consent
or any further action of any party.

8.                 
Survival. The representations and warranties contained in this Agreement shall survive the execution of this Agreement and
the execution of the documents referred to in, or executed pursuant to, this Agreement for the period set forth for Fundamental
Representations in the Asset Purchase Agreement.

9.                 
Closing. The transactions contemplated by this Agreement shall close (the “Closing”) immediately
after, and is expressly conditioned upon, the consummation of the transactions described in clauses (i) through (iii) of Paragraph
E of the Recitals under the Asset Purchase Agreement. Pursuant to the authority granted in the Asset Purchase Agreement, at Closing,
Seller Representative shall take all necessary action to consummate the transactions contemplated by this Agreement for and on
behalf of each Redeemed Shareholder.

10.             
Termination. This Agreement shall terminate immediately upon the termination of the Asset Purchase Agreement. Upon such
termination, all parties will be relieved of their obligations to consummate the transactions contemplated by this Agreement and
Shareholder Representative shall promptly return to the respective Shareholders the deliveries made by the Shareholders to the
Shareholder Representative pursuant to Section 3 of this Agreement.

11.             
Benefit and Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties, their heirs,
legal representatives, successors and assigns and no party may assign or delegate any of such party’s rights or obligations
hereunder without obtaining the prior written consent of all other parties.

12.             
Third Party Beneficiary. The parties agree that ACSH Medical is an intended third party beneficiary to this Agreement.

    	4

     

    

13.             
Further Action. Seller Representative and each Redeemed Shareholder agrees to execute any other agreements, documents or
instruments consistent with this Agreement as may be requested by Corporation to carry out the intent of the transactions contemplated
by this Agreement.

14.             
Entire Agreement. This Agreement and the Asset Purchase Agreement, including any other writing or communication delivered
pursuant to this Agreement, constitute the entire agreement and understanding between the parties and supersedes any prior agreement
or understanding relating to the subject matter of this Agreement.

15.             
Governing Law and Jurisdiction. This Agreement is entered into under, and shall be governed by and construed in accordance
with, the laws of the State of North Carolina without giving effect to any choice of law principles. The parties hereto consent
to the exclusive jurisdiction of the courts of the State of North Carolina, located in New Hanover County.

16.             
Expenses. Each party to this Agreement shall bear all expenses and costs incurred by such party in connection with the transactions
contemplated in this Agreement.

17.             
Miscellaneous. No waiver of any provision of this Agreement shall be valid unless in writing and signed by the person or
party against whom charged. No modification of this Agreement shall be binding unless in writing and signed by all of the parties
to this Agreement. This Agreement may be executed in any number of counterparts, each of which shall be taken to be an original.
This Agreement may be executed in any number of counterparts, each of which shall be taken to be an original. This Agreement is
the result of a full and complete negotiation at arm’s length by all parties. Accordingly, no prior draft of this Agreement
or its exhibits or schedules prepared by any party, shall be used to construe or interpret any provisions of the Agreement or exhibits
or schedules. The parties expressly acknowledge that this Agreement is the product of joint drafting, each party had an opportunity
to participate, and no inference shall be drawn against any party based upon the identity of the preparer of this Agreement.

18.             
No Requirement To Refer. Notwithstanding anything contained herein, nothing in this Agreement shall be construed to induce,
encourage, solicit or reimburse the referral of any patients or business, including any patients or business funded in whole or
part by federal or state government programs (i.e., Medicare, Medicaid, TRICARE, etc.) or to limit the freedom of any patient to
choose the hospital, healthcare facility or physician from whom such patient will receive medical services. The parties acknowledge
there is no requirement under this Agreement or any other agreement between the parties that any party refers patients or business
to any other party. No payment made under this Agreement will be in return for the referral of patients or business, including
those whose care is paid in whole or part by one or more federal or state government programs. The parties acknowledge that none
of the benefits granted to any party hereunder are conditioned on any requirement that such party make referrals to, be in a position
to make or influence referrals to, or otherwise generate business for any other party.

19.             
Fair Value. The Corporation and the Redeemed Shareholders acknowledge that the terms of this Agreement have been negotiated
at arms’ length and that the Purchase Price constitutes fair value for the Redeemed Shares.

 

[Signature Pages Follow]

    	5

     

    

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date and year first above written.

 

CORPORATION:

 

MEDAC HEALTH SERVICES, P.A.,

a North Carolina professional corporation

 

 

By:                                                     

Name: Michael P. Moulton, MD

Title:President

 

SELLER REPRESENTATIVE:

 

 

Sign:                                                

Print: Kevin E. Potts, MD

 

SHAREHOLDERS:

 

 

Sign:                                               

Print: Stephen B. Durham, MD

Sign:                                                  

Print: Andres J. Exposito, MD

Sign:                                                  

Print: Kenneth S. Garm, MD

Sign:                                                   

Print: Monique R. Minor, MD

Sign:                                                   

Print: Stanley G. Minor, MD

Sign:                                                    

Print: Robert A. Parr, DO

    	6

     

    

Sign:                                                      

Print: Kevin E. Potts, MD

Sign:                                                      

Print: Matthew C. Radack, MD

Sign:                                                      

Print: Kevin J. Reese, MD

Sign:                                                       

Print: Theodore R. Winneberger, MD

Sign: 

Print: Alfred H. Woodworth, MD

    	7

     

    

EXHIBIT A 

 

 

	 	
        Redeemed Shareholder 

        Name
	Number of Redeemed Shares	Pro Rata Share of Purchase Price
	1.	Stephen B. Durham, MD	100	$10
	2.	Andres J. Exposito, MD	100	$10
	3.	Kenneth S. Garm, MD	100	$10
	4.	Monique R. Minor, MD	100	$10
	5.	Stanley G. Minor, MD	100	$10
	6.	Robert A. Parr, DO	100	$10
	7.	Kevin E. Potts, MD	100	$10
	8.	Matthew C. Radack, MD	100	$10
	9.	Kevin J. Reese, MD	100	$10
	10.	Theodore R. Winneberger, MD	100	$10
	11.	Alfred H. Woodworth, MD	100	$10
	 	TOTAL	1100	$110.00

 

    	 

     

    

EXHIBIT B

 

FORM OF

ASSIGNMENT SEPARATE FROM CERTIFICATE

 

FOR VALUE RECEIVED, the undersigned does hereby sell, assign and
transfer unto:

 

MEDAC HEALTH SERVICES, P.A.

 

One Hundred (100) shares of capital stock of Medac Health Services,
P.A. (the “Company”) standing in the name of the undersigned on the books of the Company, represented
by Certificate No.         dated                     ,
and does hereby irrevocably constitute and appoint Kevin E. Potts, MD (“Seller Representative”), as such
individual’s attorney-in-fact to transfer the said shares on the books of the Company, with full power of substitution in
the premises, subject to the terms and conditions of the Stock Redemption Agreement dated as of                     ,
2015, by and among the undersigned, the other Redeemed Shareholders named therein, the Seller Representative, and the Company (the
“Stock Redemption Agreement”). Notwithstanding anything to the contrary in the Stock Redemption Agreement
or in this Assignment Separate from Certificate, if the Stock Redemption Agreement terminates in accordance with its terms, the
powers granted to Seller Representative herein shall be automatically revoked and the assignment contemplated herein shall not
be effectuated.

 

Dated                                             
2015.

Sign:                                                            

Print: [REDEEMED SHAREHOLDER]

 

 

 

 

 

 

    	 

    	 

    

Exhibit B

 

Form of Promissory Note

 

PROMISSORY NOTE

 

	$560,000	 	, 2015

 

 

FOR VALUE RECEIVED, ACSH MEDICAL MANAGEMENT, LLC, a Delaware
limited liability company (“Borrower”), hereby promises to pay to MEDAC HEALTH SERVICE, P.A.,
a North Carolina professional corporation (“Lender”), to the address  or at such other place
as may be designated in writing by Lender, the principal sum of $560,000, together with interest on the unpaid balance thereof
at the rate, on the terms and subject to the conditions set forth herein.

 

This Promissory Note (this “Note”)
is delivered by Borrower pursuant to and in accordance with the terms and conditions of that certain Asset Purchase Agreement (the
“Purchase Agreement”), dated as of July ___, 2015, by and among Borrower, Lender, each shareholder
of Lender, and Kevin E. Potts, MD, as representative of such shareholders (Lender and such shareholders, collectively, “Seller
Parties”). Capitalized terms used and not otherwise defined in this Note shall have the meanings ascribed to such
term in the Purchase Agreement.

 

1.                 
Interest Rate. The unpaid principal balance of the Note shall bear simple interest starting on the date hereof at a fixed
interest rate of 5% per annum. After the Maturity Date (defined below) or the date of an Event of Default (defined below), whichever
occurs first, the principal balance hereof and any other amounts due hereunder shall bear interest at the rate of twelve percent
(12%) per annum until paid in full. In no event shall the amount of interest due or payable under this Note exceed the maximum
rate of interest allowed by applicable law, as amended from time to time. If any payment of interest or in the nature of interest
would, under applicable Law, cause the foregoing interest rate limitation to be exceeded, then the excess payment shall be credited
as a payment of principal, unless Borrower notifies Lender that Borrower desires to have the excess sum returned to Borrower.

 

2.                 
Maturity. If not sooner prepaid pursuant to the terms of this Note, and subject to earlier acceleration in accordance with
Section 6 below, the unpaid principal balance and all accrued but unpaid interest under this Note shall be due and payable on the
date that is 18 months after the date of this Note (the “Maturity Date”); provided that if Borrower in
good faith delivers to Lender an indemnity notice pursuant to Section 6.11 of the Purchase Agreement prior to the Maturity Date,
and the matters for which indemnification is sought are unresolved on the Maturity Date, the Maturity Date for an amount equal
to the amount for which indemnification is sought shall be the date that is fifteen days after the date all such matters are finally
and fully resolved (for the avoidance of doubt, the Maturity Date for any amount in excess of the amount for which indemnification
is sought shall be unaffected by this proviso). 

 

3.                 
Prepayment. The principal amount of this Note may be prepaid in full or in part at any time without penalty. Any such prepayment
shall be first applied to accrued but unpaid interest, and the balance, if any, to principal.

 

4.                 
Security for Loan. This Note is secured by the unconditional and absolute guaranty of payment given by American CareSource
Holdings, Inc. (“Guarantor”) to Lender pursuant to the Guaranty dated of even date herewith (the “Guaranty”).

 

    	1

     

    

5.                 
Event of Default. An “Event of Default” shall occur under this Note upon the happening of any
one or more of the following events: (a) the failure of Borrower to pay all amounts when due on or before the applicable Maturity
Date determined in accordance with Section 2; (b) the making by Borrower or Gurantor of a general assignment for the benefit of
creditors; (c) the filing of a petition or the commencement of any proceeding by or against Borrower or any endorser or Guarantor
for any relief under any bankruptcy or insolvency laws, or any law relating to the relief of debtors, readjustment of indebtedness,
reorganization, consolidations or extensions; (d) Borrower’s or Guarantor’s dissolution, liquidation or bankruptcy;
(e) the suspension of the transaction of the usual business of Borrower; (f) any sale, exchange or conveyance to another person
or entity of all or substantially all of the assets of Borrower or Guarantor (excluding any assets used in connection with Guarantor’s
operation of its ancillary network business, which Lender acknowledges that Guarantor intends to sell prior to the Maturity Date)
or a sale or transfer of more than fifty percent (50%) of the ownership interest in Borrower or Guarantor, whether by sale, merger
or consolidation; and (g) in the event of a breach or default of any representation, warranty or covenant of Borrower or Guarantor
set forth in this Note or the Guaranty.

 

6.                 
Acceleration. Upon the happening of an Event of Default, the entire unpaid principal balance of this Note, together with
any accrued interest or other amounts due hereunder, shall immediately become due and payable without notice or demand.

 

7.                 
Costs of Enforcement; Cumulative Remedies. Upon an Event of Default, the holder of this Note may employ an attorney to enforce
the holder’s rights and remedies and Borrower hereby agrees to pay to the holder, in addition to the unpaid principal and
interest hereof, to the extent allowed by law, reasonable attorneys’ fees (not exceeding a sum equal to fifteen percent (15%)
of the outstanding balance owing on the Note) and costs of collection. The rights and remedies of the holder as provided in this
Note or by law shall be cumulative and may be pursued singly, successively or together.

 

8.                 
Waiver of Notice and Other Rights. Borrower hereby waives presentment for payment, demand, protest, notice of nonpayment
or dishonor, and any and all other notices and demands whatsoever, and any and all defenses on the grounds of (a) any extension
of time for payment which may be granted by the holder of this Note, (b) any release, surrender, exchange, modification or
substitution of this Note, and (c) any failure to assert any legal rights available to the holder of this Note. Borrower agrees
to remain bound until the entire indebtedness evidenced by this Note is paid in full. No waiver by Lender of any right or remedy
under this Note shall be effective unless in writing signed by Lender. Neither the failure nor the delay in enforcing any right,
power or privilege under this Note will operate as a waiver or release of any such right, power or privilege and no single or cumulative
exercise of any such right, power or privilege by Lender will preclude any other or further exercise of such right, power or privilege
or the exercise of any other right, power or privilege. To the maximum extent permitted by law, (1) no claim or right of Lender
arising out of this Note can be discharged by Lender, in whole or in part, by a waiver or renunciation of the claim or right unless
in a writing signed by Lender; (2) no waiver that may be given to Borrower will be applicable except in the specific instance for
which it is given; and (3) no notice to or demand on Borrower will be deemed to be a waiver of any obligation of Borrower or of
the right of Lender to take further action without notice or demand as provided in this Note.

 

9.                 
Method of Payment. Payments made pursuant to this Note shall be made in cash or immediately available funds to Lender at
the address provided above, or to such other address as Lender may designate to Borrower in writing from time to time.

 

10.             
Offset by Borrower. Borrower may offset undisputed amounts owed to Borrower by any Seller Party under any of the Transaction
Documents against any amount owed to Lender under this Note, whether or not such amounts are currently due under this Note; provided
that Borrower first comply with all terms and satisfy all conditions set forth in the applicable Transaction Documents.

 

11.             
Applicable Law and Dispute Resolution. The provisions set forth in Article 8 of the Purchase Agreement relating to choice
of law and dispute resolution shall govern any dispute concerning this Note.

 

    	2

     

    

12.             
Execution and Delivery. Notwithstanding anything to the contrary set forth herein, this Note shall be executed and delivered
at the location designated for Closing in the Purchase Agreement.

 

13.             
Headings. The headings of the sections, subsections, paragraphs and subparagraphs of this Note are used only for convenience
of reference and shall not be considered in construing the contents of this Note.

 

14.             
Severability. No determination by any court, agency or other Governmental Authority that any provision of this Note is invalid
or unenforceable in any instance shall affect the validity or enforceability of (a) any other such provision or (b) such provision
in any circumstance not controlled by such determination. Each such provision shall be valid and enforceable to the fullest extent
allowed by, and shall be construed wherever possible as being consistent with, applicable law.

 

15.             
Modification. This Note may be modified, amended, discharged or waived only by an agreement in writing signed by Borrower
and Lender.

 

16.             
Not a Negotiable Instrument; Assignment to [Newco]. This Note shall not be deemed to be a negotiable instrument, and the
rights and obligations under this Note may not be assigned or delegated by Borrower or any Seller Party without the prior written
consent of the other and no such assignment or delegation shall release the liability of the Borrower unless otherwise agreed by
Lender in writing. Notwithstanding the foregoing, the Purchase Agreement contemplates Lender’s assignment of this Note to
[Newco] as part of the Transactions; accordingly, Borrower’s consent shall not be required in connection with such assignment
and, following such assignment, [Newco] shall have all of the rights of Lender hereunder. This Note shall bind Borrower and Borrower’s
successors and permitted assigns, and inure to the benefit of Lender and Lender’s successors and assigns.

 

17.             
Notices. All notices and other communications provided for by this Note shall be given in the manner as set forth in the
Purchase Agreement and to the parties at their addresses.

 

18.             
Time of the Essence. Time is hereby declared to be of the essence of this Note and of every part hereof.

 

19.             
Relationship. Nothing contained in this Note shall be deemed or construed to create a partnership, tenancy-in-common, joint
tenancy, joint venture or co-ownership by or between Borrower and any Seller Party.

 

 

 

[Signature Page Follows]

 

    	3

     

    

IN WITNESS WHEREOF, the undersigned has executed
this Note in favor of Lender as of the date first written above.

 

 

 

BORROWER:

 

ACSH MEDICAL MANAGEMENT, LLC,

a Delaware limited liability company

 

 

By: ________________________ 

Name: Norman B. Winland

Title: President 

 

 

 

 

 

    	4

    	 

    

Exhibit C

Form of Escrow Agreement

 

ESCROW AGREEMENT

 

THIS ESCROW AGREEMENT (this “Escrow Agreement”)
is made effective as of _______________, 2015, by and among (i) ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability company
(“Buyer”), (ii) MEDAC HEALTH SERVICES, P.A., a North Carolina professional corporation (“Seller”),
KEVIN E. POTTS, MD (“Seller Representative”), and (iv) BRANCH BANKING AND TRUST COMPANY, a North Carolina
banking corporation (“Escrow Agent”).

 

RECITALS

 

A.Buyer, Seller, Seller’s shareholders,
and Kevin E. Potts, MD, are parties to an Asset Purchase Agreement dated as of _____, 2015 (the “Purchase Agreement”).
Capitalized terms used herein and not defined herein shall have the respective meanings given to them in the Purchase Agreement.

 

B.Pursuant to the Purchase Agreement, Buyer
acquired substantially all of Seller’s assets used in connection with the Business, effective on the date hereof (the “Transaction”).

 

C.Pursuant to Section 1.4(c) of the Purchase
Agreement, at Closing Buyer is to deposit with Escrow Agent on behalf of the Seller, out of the Purchase Price to be paid to Seller,
the sum of Six Hundred Ten Thousand Dollars ($610,000) (the “Escrow Deposit”), to be held, invested and
distributed by the Escrow Agent as provided in this Escrow Agreement. Of the Escrow Deposit, $110,000 (together with any interest
earned thereon) is referred to herein as the “Regulatory Escrow Funds”, and $500,000 (together with any
interest earned thereon) is referred to herein as the “Payor Escrow Funds” (the Regulatory Escrow Funds
and the Payor Escrow Funds, collectively, the “Escrow Funds”). The Escrow Funds shall be held by Escrow
Agent as security for the performance of the indemnity obligations of the Seller Parties that relate to
the matters for which indemnification is secured by the Payor Escrow or the Regulatory Escrow under and subject to Article
6 of the Purchase Agreement.

 

D.The parties are entering into this Escrow
Agreement to provide for, among other things, the manner in which the Escrow Funds shall be held and disbursed by Escrow Agent.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing
recitals, the agreements, covenants, representations and warranties hereinafter set forth, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.                 
APPOINTMENT OF ESCROW AGENT; ESTABLISHMENT OF ACCOUNT.

 

1.1            
Appointment of Escrow Agent. Buyer and Seller hereby appoint Branch Banking and Trust Company as Escrow Agent and Escrow
Agent hereby accepts such appointment pursuant to the terms hereof. 

 

    	

     

    

1.2            
Delivery of Escrow Funds and Establishment of Account. Simultaneously with the execution of this Agreement, Buyer shall
deposit with Escrow Agent, by wire transfer of immediately available funds, the Escrow Deposit. As promptly as practicable thereafter,
the Escrow Agent shall acknowledge receipt of such sum. Escrow Agent shall establish a separate and segregated trust account entitled
the “ACSH/Medac Escrow Account” in which the Escrow Funds shall be held. The Escrow Funds shall be invested in accordance
with Section 3 and disbursed in accordance with the provisions of Section 2.

 

2.                 
DISBURSEMENT OF ESCROW FUNDS.

 

2.1            
Disbursement Pursuant to Release Instructions. Upon receipt of joint written instructions (each set of written instructions
being hereinafter referred to as “Release Instructions”) from Buyer and Seller Representative, or receipt
of any Resolution Notice (as defined herein) in accordance with Section 2.5, Escrow Agent shall promptly disburse to Seller or
to the Buyer Indemnitee(s), as the case may be, such amount of the Escrow Funds as is directed in such Release Instructions or
Resolution Notice. Buyer and Seller Representative shall provide Release Instructions to Escrow Agent in order to cause the release
of Escrow Funds in a prompt and timely manner in accordance with the provisions of this Section 2 and the Purchase Agreement. Escrow
Agent shall have no duty or obligation to make any determination with respect to whether any party is entitled to one or more disbursements
under the Purchase Agreement, and, except as provided in Section 2.3 regarding the Termination Date distribution and Section
3.4 regarding taxes, shall not disburse or release any of the Escrow Funds to Seller or any Buyer Indemnitee unless pursuant
to a Release Instruction or Resolution Notice delivered in accordance with the terms hereof.

 

2.2            
Disbursement to Buyer of Escrow Funds. If and to the extent that any Buyer Indemnitee is from time-to-time entitled to receive
indemnity subject to satisfaction in accordance with the provisions of Section 6.8(b) or Section 6.8(c) of the Purchase Agreement,
then Buyer and Seller Representative shall deliver Release Instructions regarding the disbursement of Escrowed Funds to Buyer in
accordance with this Section 2.2.

(a)               
Disbursements from Regulatory Escrow. If and to the extent that any Buyer Indemnitee is from time-to-time entitled to receive
indemnity payments under the provisions of Section 6.2 of the Purchase Agreement for the matter described in Section 6.8(b) of
the Purchase Agreement, then Buyer and Seller Representative shall deliver Release Instructions to the Escrow Agent setting forth
the amount of the disbursement to Buyer and directing the Escrow Agent to disburse such amount to Buyer out of the Regulatory Escrow
Funds.

(b)              
Disbursements from Payor Escrow. If and to the extent that any Buyer Indemnitee is from time-to-time entitled to receive
indemnity payments under the provisions of Sections 6.2(d) and 6.8(c) of the Purchase Agreement, then Buyer and Seller Representative
shall deliver Release Instructions to the Escrow Agent setting forth the amount of the disbursement to Buyer and directing the
Escrow Agent to disburse such amount to Buyer out of the Payor Escrow Funds.

    	2

     

    

2.3            
Disbursement to Seller of Escrow Funds. Escrow Agent shall release Escrow Funds to Seller in accordance with this Section
2.3.

(a)               
Interim Disbursement. Except as otherwise provided below in this Section 2.3(a), and subject to reduction for the satisfaction
by Escrow Agent of any prior or pending Release Instructions or Resolution Notices directing one or more disbursements to any Buyer
Indemnitee out of the Payor Escrow Funds, within five (5) business days after __________, 2016 (the “Interim Disbursement
Date”) Escrow Agent shall release and disburse to Seller $250,000 (the “Interim Disbursement Amount”)
out of the Payor Escrow Funds. Notwithstanding the foregoing, if on or prior to the Interim Disbursement Date Buyer has delivered
to Escrow Agent any notice of a claim of Losses under Section 6.11 of the Purchase Agreement (a “Claims Notice”)
as to which neither Release Instructions nor a Resolution Notice has been delivered to Escrow Agent, Escrow Agent shall retain
in escrow after the Interim Distribution Date an amount equal to the amount of all Losses covered by such Claims Notice(s), up
to the full amount of the Payor Escrow, and Escrow Agent shall deliver to Seller on the Interim Distribution Date only such portion
of the Interim Disbursement Amount, if any, that is in excess of the aggregate amount set forth in such Claims Notice(s). In the
event less than all of the Interim Disbursement Amount is released to Seller on the Interim Disbursement Date due to the delivery
of one or more Claim Notices by Buyer on or prior to the Interim Disbursement Date, then, within five (5) business days after the
final resolution of the matters giving rise to the relevant Claim Notice(s), Seller Representative and Buyer shall deliver to Escrow
Agent Release Instructions or a Resolution Notice, as the case may be, regarding the disbursement to Seller of the balance of the
Interim Disbursement Amount, if any, remaining after disbursement to the Buyer Indemnitee(s) of all amounts to which it is or they
are entitled.

(b)              
Termination Disbursement. Except as otherwise provided below in this Section 2.3(b), and subject to reduction for the satisfaction
by Escrow Agent of any prior or pending Release Instructions or Resolution Notices directing one or more disbursements to any Buyer
Indemnitee out of the Escrow Funds, within five (5) business days after __________, 2017 (the “Termination Date”)
Escrow Agent shall release all remaining Escrow Funds to Seller. Notwithstanding the foregoing, if prior to the Termination Date
Buyer has delivered to Escrow Agent any Claims Notices as to which neither Release Instructions nor a Resolution Notice has been
delivered to Escrow Agent, Escrow Agent shall retain in escrow after the Termination Date from the Payor Escrow Funds, the Regulatory
Escrow Funds, or both, as appropriate, an amount equal to the amount of all Losses covered by such Claims Notice(s), up to the
full amount remaining of the Payor Escrow Funds, the Regulatory Escrow Funds, or both, as appropriate, and Escrow Agent shall deliver
to Seller on the Termination Date only such portion of the then remaining Payor Escrow Funds or Regulatory Escrow Funds, if any,
that exceeds the amount covered by such Claims Notice(s). In the event less than all of the remaining Escrow Funds are released
to the Seller on the Termination Date due to the delivery of one or more Claim Notices by Buyer on or prior to the Termination
Date, then, within five (5) business days after the final resolution of the matters giving rise to the relevant Claim Notice(s)
relating thereto, Seller Representative and Buyer shall deliver to Escrow Agent Release Instructions or a Resolution Notice, as
the case may be, regarding the disbursement to Seller of the balance of the Escrow Funds remaining after disbursement to the Buyer
Indemnitee(s) of all amounts to which it is or they are entitled.

 

    	3

     

    

2.4            
Provisions Regarding Disbursements to the Seller. Pursuant to the terms of the Purchase Agreement, after Closing Seller
shall assign and distribute (the “Assignment”) all of its rights and obligations under this Escrow Agreement
to a limited liability company formed by Seller’s shareholders to receive such rights and obligation on their behalf (“Seller’s
LLC”). Immediately following the Assignment, this Agreement shall be amended automatically without further action
of any party, such that each use of the term “Seller” herein shall be substituted with the term “Seller’s
LLC.” Any amount released to Seller pursuant to Release Instructions or a Resolution Notice shall be distributed to Seller’s
LLC as set forth in the Release Instructions or a Resolution Notice. Escrow Agent shall be responsible only for mailing or sending
by wire transfer any amounts due the Seller’s LLC under this Section 2.4 to the address or wire instructions indicated on
Exhibit A or such other address as the Seller Representative may request in writing. Seller’s Representative may make
other wire transfer or similar alternative arrangements with Escrow Agent; such alternate arrangements shall be requested in writing,
at Seller’s LLC’s expense.

 

2.5            
Disagreements Regarding Release of Escrow Funds. In the event of a dispute or disagreement between Buyer and Seller Representative
with respect to the release or the failure to release any portion of the Escrow Funds or relating to the failure by any party to
issue or join in the execution of Release Instructions that the other party believes are required to be executed in accordance
with this Escrow Agreement or the Purchase Agreement, such dispute or disagreement shall be resolved in accordance with Section
8.7 of the Purchase Agreement and any other relevant provision of the Purchase Agreement regarding the resolution of disputes.
Until such dispute or disagreement is finally resolved, Escrow Agent shall not deliver or otherwise dispose of the Escrow Funds
or any part thereof or to otherwise act hereunder, unless and until (i) the rights of such parties have been finally (that is,
following the exhaustion of all appeals or the expiration of all applicable periods for appeals) settled by binding arbitration
or duly adjudicated in a court having jurisdiction of the parties and the Escrow Funds and Escrow Agent shall have received a copy
of the resulting final, non-appealable arbitration award or final, non-appealable judgment; or (ii) the parties have reached a
written agreement resolving their differences and have notified Escrow Agent in writing of such agreement (any such notice of a
final arbitration award, final judgment, or written agreement a “Resolution Notice”).

 

3.                 
DUTIES OF ESCROW AGENT.

 

3.1            
Scope. Escrow Agent undertakes to perform only such duties as are expressly set forth herein, and no additional duties or
obligations shall be implied hereunder. In performing its duties under this Escrow Agreement, or upon the claimed failure to perform
any of its duties hereunder, Escrow Agent shall not be liable to anyone for any damages, losses or expenses which may be incurred
as a result of Escrow Agent so acting or failing to so act; provided, however, Escrow Agent shall not be relieved
from liability for damages arising out of its proven gross negligence or willful misconduct under this Escrow Agreement. Escrow
Agent shall in no event incur any liability with respect to (i) any action taken or omitted to be taken in good faith upon advice
of legal counsel, which may not be counsel to any party hereto, given with respect to any question relating to the duties and responsibilities
of Escrow Agent hereunder or (ii) any action taken or omitted to be taken in reliance upon any instrument delivered to Escrow Agent
and reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties. Escrow Agent shall
not be bound in any way by any agreement or contract by, between or among Buyer, Seller and Seller Representative, whether or not
Escrow Agent has knowledge of any such agreement or contract.

    	4

     

    

3.2            
Investment; Interest and Earnings. Escrow Agent shall invest and reinvest the Escrow Funds in Authorized Investments (as
defined herein). Interest or other income and net gains, if any, realized on any assets held in the Escrow Funds shall be added
to and become a part of the Escrow Funds, shall from time to time be reinvested by Escrow Agent in Authorized Investments as promptly
as practicable, and shall be disbursed in accordance with the provisions of Section 2. Escrow Agent may refrain from investing
the Escrow Funds until it receives such written investment instructions as it may reasonably request.

 

3.3            
Authorized Investments. For purposes hereof, “Authorized Investments” shall mean: [(i) The Goldman
Sachs Treasury Investments Fund, #524, (ii) Goldman Sachs Financial Square Treasury Instruments Fund, or (iii) any other investments
specified to Escrow Agent by written investment instruction signed by Seller Representative and Buyer]. [TO BE DETERMINED]

 

3.4            
Federal Tax Withholding; Tax Reporting; Payment of Taxes. Escrow Agent shall have no obligation, duty or responsibility
to withhold from any payment to any Buyer Indemnitee or Seller any amounts for tax purposes except to the extent any such amounts
are required to be withheld under United States federal income tax laws. Escrow Agent shall report to the Internal Revenue Service,
as of each calendar year-end, all income earned from the investment of the Escrow Funds against Seller, whether or not said income
has been distributed during such year, as and to the extent required by law. Any taxes payable on any such income shall be paid
by Seller, whether or not said income was distributed by Escrow Agent during any particular year. 

 

3.5            
Reporting. Escrow Agent shall not be obligated to perform tax reporting functions with respect to Buyer or Seller, except
as specifically provided in Section 3.4 above. In accord with the requirements of the Patriot Act, all parties to this Escrow Agreement
must provide Escrow Agent with a fully executed IRS Form W-9 upon execution hereof.

 

4.                 
SECURITY INTERESTS. Buyer and Seller each warrant to and agree with Escrow Agent
that, except as otherwise expressly set forth herein, there is no security interest in the Escrow Funds or any part of the Escrow
Funds; no financing statement under the Uniform Commercial Code of any jurisdiction is on file in any jurisdiction claiming a security
interest in or describing, whether specifically or generally, any part of the Escrow Funds; and Escrow Agent shall have no responsibility
at any time to ascertain whether or not any security interest exists in any part of the Escrow Funds or to file any financing statement
under the Uniform Commercial Code of any jurisdiction with respect to the Escrow Funds or any part thereof. 

    	5

     

    

5.                 
PERFORMANCE OF ESCROW AGENT’S DUTIES. When Escrow Agent has taken all
of the actions required by this Escrow Agreement, including the disbursement of all of the Escrow Funds in accordance with this
Agreement, Escrow Agent shall thereupon and thereafter be freed and discharged of all obligations and liabilities hereunder.

 

6.                 
DUTY OF CARE. Escrow Agent (i) shall not be under any duty to give the Escrow
Funds any greater degree of care than it gives its own similar property and (ii) except as otherwise expressly provided herein,
does not have and will not have any interest in the Escrow Funds but is a mere holder thereof. Escrow Agent shall be under no obligation
to institute or defend any actions, suit or legal proceeding in connection herewith or to take any other action likely to involve
it incurring any expense unless first indemnified to its satisfaction.

 

7.                 
COMPENSATION OF ESCROW AGENT. Subject to Section 11, Buyer and Seller hereby
agree to each pay one-half of the fees of Escrow Agent as compensation for the services to be rendered pursuant to this Escrow
Agreement, which fees are set forth on Exhibit B. The parties also shall each reimburse Escrow Agent within fifteen (15)
days of written request by Escrow Agent for one-half of the reasonable out of pocket expenses incurred by Escrow Agent in rendering
services hereunder, including, but not limited to, the actual cost of legal services in the event Escrow Agent deems it necessary
to retain counsel in connection with the interpretation or implementation of this Agreement. The parties shall pay their respective
share of such expenses to Escrow Agent within fifteen (15) days following receipt by the parties of a written statement setting
forth such expenses. Except as otherwise provided in Section 10, the parties agree that, in the event any controversy arises under
or in connection with this Escrow Agreement or the Escrow Funds or if Escrow Agent is made a party to or intervenes in any litigation
pertaining to this Escrow Agreement or the Escrow Funds, the parties shall each pay to Escrow Agent one half of the reasonable
compensation for Escrow Agent’s extraordinary services and each shall reimburse Escrow Agent for one-half of all costs and
expenses associated with such controversy or litigation. Escrow Agent agrees that Buyer and Seller are severally, but not jointly,
liable for the fees and expenses described in this Section 7, and agrees to look to each of Buyer and Seller for only their respective
one-half share of such fees and expenses.

 

8.                 
DOCUMENTS PRESENTED TO ESCROW AGENT. Escrow Agent may act in reliance upon any
instrument or signature believed to be genuine and may assume that any person purporting to give any written notice, advice or
instruction in connection with the provisions hereof has been duly authorized to do so. Escrow Agent may request such certificates,
opinions or other documents evidencing such authorizations as it deems reasonably necessary.

 

9.                 
NO REPRESENTATIONS BY ESCROW AGENT. Escrow Agent makes no representation as
to the validity, value, genuineness, negotiability or collectibility of any security or other document or instrument held by or
delivered to or by it.

 

10.            
INDEMNIFICATION.

 

10.1        
Indemnification of Escrow Agent.

    	6

     

    

 

(a)               
Escrow Agent shall have no obligation to take any legal action in connection with this Escrow Agreement or towards its enforcement,
or to appear in, prosecute or defend any action or legal proceeding which would or might involve it in any cost, expense, loss
or liability unless security and indemnity, as provided in this Section 10, shall be furnished.

 

(b)              
Buyer and Seller each agree to severally, but not jointly, indemnify, to the extent of one half of the Escrow Funds, Escrow Agent,
and its officers, directors, employees and agents from and against any and all Claims (as defined herein) and Losses (as defined
herein) which may be incurred by Escrow Agent, or its officers, directors, employees and agents as a result of any Claims asserted
against Escrow Agent, and its officers, directors, employees and agents, and Escrow Agent agrees to look to each of Buyer and Seller
for only their respective one-half share of such Claims and Losses. “Claims” shall mean all claims, lawsuits,
causes of action or other legal actions and proceedings of whatever nature brought against (whether by way of direct action, counterclaim,
cross action or impleader) Escrow Agent or any such officer, director, employee or agent, even if groundless, false or fraudulent,
so long as the claim, lawsuit, cause of action or other legal action or proceeding is alleged or determined, directly or indirectly,
to arise out of, result from, relate to or be based upon, in whole or in part: (a) the acts or omissions of Buyer or Seller, (b)
the appointment of Escrow Agent as escrow agent under this Escrow Agreement, or (c) the performance by Escrow Agent of its powers
and duties under this Escrow Agreement. “Losses” shall mean losses, costs, damages and liabilities suffered
by Escrow Agent and its officers, directors, employees and agents resulting from or arising out of Claims. Upon the written request
of Escrow Agent or any such officer, director, employee or agent (each referred to hereinafter as an “Indemnified Party”),
the parties hereto, to the extent of the Escrow Funds, agree to assume the investigation and defense of any Claim, including the
employment of counsel acceptable to the applicable Indemnified Party and the payment of all reasonable expenses related thereto
and, notwithstanding any such assumption, the Indemnified Party shall have the right, and the parties, to the extent of the Escrow
Funds, agree to pay the cost and expense thereof, to employ separate counsel with respect to any such Claim and participate in
the investigation and defense thereof in the event that such Indemnified Party shall have been advised by counsel that there may
be one or more legal defenses available to such Indemnified Party which are different from or additional to those available to
Seller. The parties hereto hereby agree that the indemnifications and protections afforded Escrow Agent in this Section 10 shall
survive the termination of this Escrow Agreement.

 

10.2        
Escrow Agent’s Security Interest. To secure the obligations of Buyer and Seller to indemnify Escrow Agent for Claims
or Losses, Buyer and Seller grant Escrow Agent a security interest in the Escrow Funds.

 

11.            
RESIGNATION. Escrow Agent may resign at any time from its obligations hereunder
by providing written notice to the parties hereto. Such resignation shall be effective on the date set forth in such written notice
which shall be no earlier than thirty (30) days after such written notice has been given. In the event that Escrow Agent resigns
without cause under this Section 11 within eighteen (18) months after the date hereof, Escrow Agent shall repay to the parties
one-eighteenth (1/18) of the fee paid by the parties to Escrow Agent under Section 7 for each such month of said eighteen (18)
month term for which Escrow Agent does not continue as escrow agent hereunder, with one-half of such fees payable to each of Buyer
and Seller. In the event no successor escrow agent has been appointed on or prior to the date such resignation is to become effective,
Escrow Agent shall be entitled to tender into the custody of a court of competent jurisdiction all assets then held by it hereunder
and shall thereupon be relieved of all further duties and obligations hereunder. Escrow Agent shall have no responsibility for
the appointment of a successor escrow agent hereunder.

    	7

     

    

 

12.            
MISCELLANEOUS PROVISIONS.

 

12.1        
Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given
(a) when delivered, if delivered by hand; (b) one business day after transmitted, if transmitted by a nationally-recognized overnight
courier service, (c) when sent by electronic mail, with confirmation of receipt; or (d) three business days after mailing, if mailed
by registered or certified mail, postage prepaid, return receipt requested, and in each case to the parties at the following addresses
(or at such other address for such party as shall be specified in a notice given in accordance with this Section 12.1):

 

If to Buyer, then to:

 

ACSH Medical Management, LLC 

1170 Peachtree Street NE, Suite 2350

Atlanta, Georgia 30309

Attention: Norman Winland, COO

Email: nwinland@americancaresource.com

 

If to the Seller or Seller Representative, then
to:

 

Kevin E. Potts, MD

4402 Shipyard Boulevard

Wilmington, North Carolina 28403

Email: kepotts@ec.rr.com

 

If to Escrow Agent, then to:

 

Branch Banking and Trust Company

Attention: Corporate Trust Services

223 West Nash Street

Wilson, North Carolina 27893

Email:

 

12.2        
Attorneys’ Fees. In the event of any suit, action, or any other proceeding between any of the parties (whether in
law or equity, and whether administrative, trial, appellate or otherwise) arising out of or related to this Escrow Agreement, the
non-prevailing or unsuccessful party shall pay all of the prevailing or successful party’s costs and expenses incurred in
connection with such proceeding, including (without limitation) court costs and reasonable attorneys’ fees, whether or not
such proceeding is prosecuted to judgment.

    	8

     

    

 

12.3        
Successors and Assigns. This Escrow Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. 

 

12.4        
Amendment. This Escrow Agreement may not be amended except in writing signed by all of the parties hereto.

 

12.5        
Governing Law. This Escrow Agreement shall be governed by and construed in accordance with the law of the State of North
Carolina, without regard to choice of law and conflicts of law rules.

 

12.6        
Entire Agreement. This Escrow Agreement, together with the Purchase Agreement, constitutes the entire agreement, and supersedes
all prior agreements and understandings (whether oral or written), among the parties hereto with respect to the subject matter
hereof.

 

12.7        
Exhibits. The exhibits referred to in this Escrow Agreement are hereby incorporated herein and made a part of this Escrow
Agreement.

 

12.8        
Headings; Sections. The titles and captions of the sections and subdivisions of this Escrow Agreement are for convenience
of reference only, and shall be given no effect in the construction or interpretation of this Escrow Agreement. All references
to “Section” or “Sections” refer to the corresponding Section or Sections of this Escrow Agreement, unless
expressly provided otherwise, and the words “herein”, “hereof”, “hereto” and “hereunder”
shall be deemed to refer to the entire Escrow Agreement.

 

12.9        
Severability. If any provision of this Escrow Agreement is held by a court of competent jurisdiction to be prohibited or
unenforceable in any jurisdiction, the remainder of this Escrow Agreement shall remain in full force and effect, and such holding
shall not affect this Escrow Agreement or any provision hereof in any other jurisdiction.

 

12.10   
Counterparts. This Escrow Agreement may be executed in any number of counterparts, each of which shall be an original with
the same effect as if the signatures thereto and hereto were upon the same instrument, but all of which together shall constitute
one and the same instrument.

 

[Signatures on following page]

 

    	9

     

    

 

 

IN WITNESS WHEREOF, the parties hereto have executed
this Escrow Agreement under seal effective as of the date first above written.

 

 

 

	BUYER:	 	ACSH MEDICAL MANAGEMENT, LLC
	 	 	 
	 	 	 
	 	 	By:	/s/
	 	 	Name:	Norman B. Winland
	 	 	Title:	President
	 	 	 	 
	 	 	 	 
	SELLER:	 	MEDAC HEALTH SERVICES, P.A.
	 	 	 	 
	 	 	By:	 
	 	 	Name:	Michael P. Moulton, MD
	 	 	Title:	President
	 	 	 	 
	 	 	 	 
	SELLER REPRESENTATIVE:	 	Sign:	 
	 	 	Print:	Kevin E. Potts, MD
	 	 	 	 
	 	 	 	 
	ESCROW AGENT:	 	BRANCH BANKING AND TRUST COMPANY
	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	 	 	 
	 	 	 

 

[Signature Page – Escrow Agreement]

    	

     

    

EXHIBIT A

 

 

 

	
         

        Seller

         
	
         

        Instructions for Disbursements

	
        Medac Health Services, P.A.

        4402 Shipyard Boulevard

        Wilmington, North Carolina 28403

         
	Address:                                                  
                                                   
                                                   
     

    ____________________________________________

    ____________________________________________

    ____________________________________________

    

    

    Wire Instructions:                  

    ____________________________________________

    ____________________________________________

    ____________________________________________ 

 

 

 

 

 

 

 

    	

     

    

EXHIBIT B

 

 

FEES PAYABLE TO ESCROW AGENT

 

Escrow Agent Fee:                                                                         $1,800.00*

 

*Fee due upon execution of the Escrow Agreement.

 

 

Unless otherwise indicated, the above fees relate to the establishment
of one escrow account.

 

 

    	 

    	 

    

Exhibit D

 

Form of Restrictive Covenant Agreements

 

[FORM FOR PHYSICIANS NOT RENDERING SERVICES
FOR BENEFIT OF SELLER AT TIME OF CLOSING]

 

RESTRICTIVE
COVENANT AGREEMENT

This
RESTRICTIVE COVENANT AGREEMENT (the “Agreement”),
dated effective as of , 2015, (the “Effective Date”), is by and between ACSH MEDICAL MANAGEMENT,
LLC, a Delaware limited liability company (“Buyer”), MEDAC HEALTH SERVICES, P.A. (“Seller”),
and [SHAREHOLDER NAME], MD, a resident of the State of North Carolina (“Physician”).

RECITALS

A.             
Pursuant to that certain Asset Purchase Agreement dated as of , 2015 (the “Purchase Agreement”)
by and among Buyer, Seller, and each of the shareholders of Seller, (collectively, the “Seller Parties”),
on the Effective Date, Seller Parties sold, transferred and assigned, and Buyer purchased, substantially all of the assets used
or held for use in connection with the operation of the Business. Capitalized terms used and not defined herein shall have the
meaning ascribed thereto in the Purchase Agreement. 

B.             
Physician has intimate knowledge of the Business which knowledge, if improperly used, directly or indirectly, by Physician in
contravention of this Agreement, would seriously, adversely and irreparably affect the ability of Buyer to realize the benefits
of its acquisition and protect and secure, among other things, (1) certain trade secrets of the Business; (2) valuable confidential
and professional information of the Business; (3) relationships between the Seller and existing patients; (4) and the goodwill
associated with the Business and Purchased Assets.

AGREEMENT

In
consideration of the above Recitals, the Purchase Price and the promises and provisions set forth in this Agreement, the adequacy
and sufficiency of which the parties acknowledge, the parties, intending to be bound, agree as follows:

1.                 
Acknowledgements and Conditional Effectiveness.Physician acknowledges that the covenants contained in this Agreement
are an essential part of the Purchase Agreement and that, but for Physician’s agreement to comply with such covenants, Buyer
would not have entered into the Purchase Agreement. Physicians further acknowledge that the terms and provisions of this Agreement
are incorporated by reference into the Purchase Agreement, and that certain of such terms and provisions are intended to inure
to the benefit of both Buyer and Seller. Although this Agreement shall be executed by Physician and delivered to Seller Representative
simultaneously with the execution and delivery of the Purchase Agreement, the effectiveness and enforceability of the terms and
conditions of this Agreement shall be conditioned on the Closing of the Transactions. 

2.                 
Defined Terms. For purposes of this Agreement (and not the Purchase Agreement), the following terms shall have the respective
meanings indicated below:

(a)               
“Buyer Parties” means collectively, Buyer and its Affiliates, and any of their respective directors,
officers, members, owners, employees, personnel, agents and representatives.

(b)              
“Cause” means (i) the good faith determination of Seller that Physician is not providing adequate patient
care or that the health, safety or welfare of patients is jeopardized by the continued engagement or employment of Physician;
(ii) the denial or termination of Physician’s participation in any governmental reimbursement program (Medicare, Medicaid,
and TriCare), any commercial payor, or any other third party reimbursement program in which Seller participates or desires to
participate; (iii) the occurrence of any of the following events: (A) the Physician’s use of drugs or alcohol in a manner
that Seller reasonably determines could impede or impair Physician’s ability to competently carry out Physician’s
patient care duties; (B) Physician’s gross neglect of, or reckless disregard for, applicable professional or ethical standards;
(C) Physician's dishonesty, theft, fraud, embezzlement, or Physician’s conviction of a felony or a crime involving moral
turpitude; (D) Physician’s continued failure to be available for work when requested by Seller, which failure is not corrected
following written notice to Physician providing Physician with a reasonable opportunity to cure; (E) Physician’s material
breach of Sections 3, 4 or 5 of this Agreement, which breach is not corrected following written notice to Physician providing
Physician with a reasonable opportunity to cure.

 

    	 

    	 

    

(c)               
“Covered Period” means the period beginning on the Effective Date and ending on the Expiration Date.

(d)              
“Expiration Date” means (i) the third anniversary of the Closing Date, with respect to the restrictions
on the direct or indirect ownership of a facility that engages in Prohibited Services (ii) the second anniversary of the Closing
Date with respect to the restrictions on providing Prohibited Urgent Care Services and (iii) the first anniversary of the Closing
Date with respect to the restrictions on providing Prohibited Primary Care Services. In the event Physician becomes a Clinical
Provider, and the Seller subsequently terminates or causes to be terminated, without Cause, Physician’s right to render
services at any of the Centers (due to employment termination or termination of independent contractor engagement without a contemporaneous
offer of employment), then the Expiration Date for purposes of clauses (ii) and (iii) shall be the date such termination occurs.

(e)               
 “Prohibited Primary Care Services” means, collectively, the clinical services involved in the care
rendered in an appointment-based setting to established patients of a third party. 

(f)               
“Prohibited Urgent Care Services” means, collectively, the clinical services involved in the practice
of urgent care, occupational care, or convenient ambulatory care. 

(g)               
“Prohibited Services” means, collectively, Prohibited Urgent Care Services and Prohibited Primary Care
Services.  For the avoidance of doubt, the term Prohibited Services shall not include hospice care or emergency
medical services rendered in a free-standing or hospital-based emergency department, hospice facility or any other clinic not
serving as a place of treatment for patients seeking any of the Prohibited Services.

(h)              
“Protected Radius” means the 25-mile area surrounding any medical clinic, center or facility that is
(a) owned or managed by Buyer, Seller, or any of their Affiliates on the Effective Date, (b) located in the State of North Carolina,
and (c) that serves as a place of treatment for patients seeking any of the Prohibited Services. For the avoidance of doubt, such
clinic, centers and facilities referenced in the preceding sentence shall not include a free-standing or hospital-based emergency
department, hospice facility, or any other clinic not serving as a place of treatment for patients seeking any of the Prohibited
Services. 

    	2

    	 

    

(i)                
 “Separation Date” means the date Physician ceases to perform services, directly or indirectly, for
or on behalf of Buyer in any capacity, including as an employee, independent contractor, or employee or contractor of an independent
contractor.

3.                 
Non-Competition. During the Covered Period, and except on behalf or for the benefit of Seller, Physician shall not, directly
or indirectly, for Physician’s own account or for others, (a) perform any Prohibited Services within the Protected Radius,
or (b) operate, manage, consult for, or own (directly or indirectly) any interest in any business or entity that renders Prohibited
Services within the Protected Radius. The foregoing is not intended nor shall it be interpreted to prohibit Physician from working
for or on behalf of Seller or from referring any patient for any goods or services to any clinic, facility or health care center
that, in such Physician’s independent medical judgment, is in the best interests of such patient. 

4.                 
Non-Solicitation. For two years after the Closing Date, Physician shall not, directly or indirectly, for Physician’s
own account or for others, (a) hire, attempt to hire, contact or solicit with respect to hiring, any employee or independent contractor
of Buyer or Seller who was an employee or independent contractor of Buyer or Seller on the Closing Date; or (b) call upon, solicit,
divert or take away, any (i) patient who has received treatment or (ii) client whose employees or agents have received treatment
or testing, during the 12 months preceding the Closing Date at any clinic, center or facility owned or managed by Buyer or Seller,
except to the extent such a restriction would be in violation of applicable Law (including the regulations of the North Carolina
Medical Board).

5.                 
Confidentiality. Except as necessary in the performance of services for or on behalf of the Seller and unless otherwise
jointly authorized by Buyer and Seller, Physician will hold and keep confidential all Confidential Information (as defined below)
to which Physician, at any time shall have become informed, and Physician will not, directly or indirectly, disclose any Confidential
Information to any person, firm, corporation or entity, or use the same, or permit the same to be disclosed or used. “Confidential
Information” as used herein means proprietary information of Buyer or Seller relating to the Business, whether involving
any Buyer Party, any Seller Party or that which is developed exclusively by or for the benefit of any Buyer Party or any Seller
Party in connection with the Business or the Transactions. Confidential Information, and may include, without limitation, the
following types of information: corporate information, including business information, plans, strategies, tactics, or policies;
marketing information, including strategies, tactics, methods, customer and patient lists, prospects, and market research data;
financial data or forecasts; policies or procedures; know-how and ideas; operational information, including trade secrets; and
technical information, including designs, drawings and specifications. Confidential Information is limited to that information
which is not generally known to or accessible by the public (other than as a result of unauthorized disclosure by any Seller Party)
or within the industry in which the Business is operated. This restriction on disclosure of Confidential Information shall
terminate three years after the Closing Date and shall not apply to the extent that (a) Physician is compelled by subpoena, court
order or other lawful process to provide such Confidential Information, provided Physician gives Seller reasonable notice of any
such subpoena, court order or other lawful process and an opportunity to oppose the disclosure or (b) the Confidential Information
is disclosed to the public through no fault of Physician.

6.                 
Non-Disparagement. Physician will not make any public statements, written or verbal, (or statements that are reasonably
likely to become public) that are defamatory, derogatory, or disparaging about, or that may adversely affect the Business, any
Buyer Party, Seller, or any other Seller Party (provided that with respect to comments relating to Seller Parties other than Seller
(other Shareholders), such prohibition shall apply only to public statements that may adversely affect the Business). This includes,
but is not limited to, making such statements on any internet site, blog or social media page, including Facebook, Google Plus,
Twitter, LinkedIn, or other internet sites, electronic medium or other public forum or medium. This prohibition applies to statements
made under false names, anonymously, or through third parties or other business entities. The terms “derogatory” or
“disparaging” as used in this Agreement are intended to cover any utterances or writings by Physician or at Physician’s
instruction that could be reasonably regarded by an objective person as tending to deprecate, discredit, demean, lower or diminish
the regard or reputation of or otherwise adversely affect the Business or the Buyer Entities as a result. Notwithstanding the
foregoing provisions of this Section 6, but subject to the confidentiality provisions set forth in Section 5, the
prohibitions contained in this Section 6 shall not prevent or preclude the Physician from exercising any rights or duties
Physician may have under applicable law, including the right to engage in protected concerted activity, the right and/or duty
to report and assist in the investigation of any violations of law or Seller’s employment policies, and the duty to respond
to any subpoena, court order or other lawful process, and any such activity shall not constitute a violation of this provision.

    	3

    	 

    

7.                 
Compliance.Physician acknowledges that compliance by Physician with the terms of this Agreement is necessary for (a)
Seller to continue operating at levels comparable to that existing at Closing, (b) for Buyer to realize the benefits of the Transactions,
and (c) for both Buyer and Seller to protect and secure, among other things (1) trade secrets of the Business; (2) valuable confidential
and professional information of the Business; (3) Seller’s relationships with existing patients; and (4) the goodwill associated
with the Business and the Purchased Assets purchased by Buyer under the Purchase Agreement. Further, Physician acknowledges and
agrees that irreparable injury, for which the remedy at law would be inadequate, will result to Buyer and Seller in the event
of a breach of this Agreement. Accordingly, Physician agrees that Buyer will be entitled, in addition to any other remedies and
damages available, including reasonable attorney fees incurred in the enforcement of the covenants and restrictions contained
in this Agreement, to an injunction to restrain the violation of the terms of this Agreement.

8.                 
Reasonableness; Severability. Physician acknowledges and agrees that the restrictions placed on Physician and the rights
and remedies conferred on Seller are reasonable in time, scope, and territory and are fully required to protect the legitimate
business interests of Buyer without a disproportionate detriment to Physicians. If any provision of this Agreement shall, for
any reason, be adjudged by any court of competent jurisdiction to be invalid or unenforceable (a) such provision shall remain
in force and effect to the maximum extent allowable, if any, and (b) such judgment shall not affect, impair, or invalidate the
remainder of this Agreement, but shall be confined in its operation to the provision of this Agreement directly involved in the
controversy in which such judgment shall have been rendered, and (c) and the enforceability or validity of the remaining provisions
of this Agreement shall not be affected thereby. If a court finds that any provision of this Agreement is invalid or unenforceable,
but that modification of such provision will make it valid or enforceable, then such provision shall be deemed to be so modified.

9.                 
Damage Limitation. Notwithstanding that Physician’s breach of any negative covenant in this Agreement could foreseeably
give rise to losses by both Buyer and Seller, any liability for damages under this Agreement shall be determined without duplication
of recovery by such parties.

 

    	4

    	 

    

10.             
Miscellaneous. This Agreement shall be construed and enforced in accordance with, and governed by, the laws of the State
of North Carolina (without regard to the conflicts of laws principles thereof). This Agreement embodies the entire agreement and
understanding between Seller, Buyer and Physician with respect to the subject matter hereof and supersedes all prior and contemporaneous
agreements and relating to the subject matter hereof. Except as expressly set forth in this Agreement, this Agreement may not
be modified or amended or any term or provision hereof waived or discharged except in writing signed by the party against whom
such amendment, modification, waiver, or discharge is sought to be enforced. All of the terms of this Agreement shall be binding
upon the parties hereto and their respective successors and assigns and shall inure to the benefit of and be enforceable by the
parties hereto, the Buyer Parties and their respective successors and assigns. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including .pdf) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 

 

[Signature Page Follows]

 

 

 

 

 

    	5

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have duly executed this Agreement as of the Effective Date.

 

 

BUYER:

 

ACSH MEDICAL MANAGEMENT, LLC,

a Delaware limited liability company

 

By:________________________

Name:Norman B. Winland

Title:President

 

SELLER:

 

MEDAC HEALTH SERVICES, P.A.,

a North Carolina professional corporation

 

By:________________________

Name: Michael P. Moulton, MD

Title:President

 

 

PHYSICIAN:

 

Sign:________________________

Print: [Physician Name]

 

 

[Signature Page – Restrictive Covenant
Agreement]

 

    	 

    	 

    

[FORM FOR PHYSICIANS RENDERING SERVICES FOR BENEFIT OF SELLER AT TIME
OF CLOSING]

 

 

RESTRICTIVE COVENANT
AGREEMENT

This RESTRICTIVE
COVENANT AGREEMENT (the “Agreement”), dated effective as of , 2015, (the
“Effective Date”), is by and between ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability
company (“Buyer”), MEDAC HEALTH SERVICES, P.A. (“Seller”), and [SHAREHOLDER
NAME], MD, a resident of the State of North Carolina (“Physician”).

RECITALS

A.             
Pursuant to that certain Asset Purchase Agreement dated as of , 2015 (the “Purchase Agreement”)
by and among Buyer, Seller, and each of the shareholders of Seller, (collectively, the “Seller Parties”),
on the Effective Date, Seller Parties sold, transferred and assigned, and Buyer purchased, substantially all of the assets used
or held for use in connection with the operation of the Business. Capitalized terms used and not defined herein shall have the
meaning ascribed thereto in the Purchase Agreement.

B.             
Physician has intimate knowledge of the Business which knowledge, if improperly used, directly or indirectly, by Physician in contravention
of this Agreement, would seriously, adversely and irreparably affect the ability of Buyer to realize the benefits of its acquisition
and protect and secure, among other things, (1) certain trade secrets of the Business; (2) valuable confidential and professional
information of the Business; (3) relationships between the Seller and existing patients; (4) and the goodwill associated with the
Business and Purchased Assets.

AGREEMENT

 

In consideration of the above Recitals, the
Purchase Price and the promises and provisions set forth in this Agreement, the adequacy and sufficiency of which the parties acknowledge,
the parties, intending to be bound, agree as follows:

1.                 
Acknowledgements and Conditional Effectiveness.Physician acknowledges that the covenants contained in this Agreement
are an essential part of the Purchase Agreement and that, but for Physician’s agreement to comply with such covenants, Buyer
would not have entered into the Purchase Agreement. Physicians further acknowledge that the terms and provisions of this Agreement
are incorporated by reference into the Purchase Agreement, and that certain of such terms and provisions are intended to inure
to the benefit of both Buyer and Seller. Although this Agreement shall be executed by Physician and delivered to Seller Representative
simultaneously with the execution and delivery of the Purchase Agreement, the effectiveness and enforceability of the terms and
conditions of this Agreement shall be conditioned on the Closing of the Transactions.

2.                 
Defined Terms. For purposes of this Agreement (and not the Purchase Agreement), the following terms shall have the respective
meanings indicated below:

(a)               
“Buyer Parties” means collectively, Buyer and its Affiliates, and any of their respective directors,
officers, members, owners, employees, personnel, agents and representatives.

(b)              
“Cause” means (i) the good faith determination of Seller that Physician is not providing adequate patient
care or that the health, safety or welfare of patients is jeopardized by the continued engagement or employment of Physician;
(ii) the denial or termination of Physician’s participation in any governmental reimbursement program (Medicare, Medicaid,
and TriCare), any commercial payor, or any other third party reimbursement program in which Seller participates or desires to
participate; (iii) the occurrence of any of the following events: (A) the Physician’s use of drugs or alcohol in a manner
that Seller reasonably determines could impede or impair Physician’s ability to competently carry out Physician’s
patient care duties; (B) Physician’s gross neglect of, or reckless disregard for, applicable professional or ethical standards;
(C) Physician's dishonesty, theft, fraud, embezzlement, or Physician’s conviction of a felony or a crime involving moral
turpitude; (D) Physician’s continued failure to be available for work when requested by Seller, which failure is not corrected
following written notice to Physician providing Physician with a reasonable opportunity to cure; (E) Physician’s material
breach of Sections 3, 4 or 5 of this Agreement, which breach is not corrected following written notice to Physician providing
Physician with a reasonable opportunity to cure.

     

     

    

(c)               
“Covered Period” means the period beginning on the Effective Date and ending on the Expiration Date.

(d)              
“Expiration Date” means (i) the third anniversary of the Effective Date, with respect to the restrictions
on the direct or indirect ownership of a facility that engages in any Prohibited Services, (ii) the later of the second anniversary
of the Effective Date or the first anniversary of the Separation Date with respect to the restrictions on providing Prohibited
Urgent Care Services, and (iii) the later of the first anniversary of the Effective Date and the first anniversary of the Separation
Date with respect to the restrictions on providing Prohibited Primary Care Services. Notwithstanding the foregoing, if the Seller
terminates or causes to be terminated, without Cause, Physician’s right to render services at any of the Centers (due to
employment termination or termination of independent contractor engagement without a contemporaneous offer of employment), then
the Expiration Date for purposes of clauses (ii) and (iii) shall be the date such termination occurs.

(e)               
“Prohibited Primary Care Services” means, collectively, the clinical services involved in the care rendered
in an appointment-based setting to established patients of a third party.

(f)               
“Prohibited Urgent Care Services” means, collectively, the clinical services involved in the practice
of urgent care, occupational care, or convenient ambulatory care.

(g)               
“Prohibited Services” means, collectively, Prohibited Urgent Care Services and Prohibited Primary Care
Services.  For the avoidance of doubt, the term Prohibited Services shall not include hospice care or emergency medical
services rendered in a free-standing or hospital-based emergency department, hospice facility or any other clinic not serving as
a place of treatment for patients seeking any of the Prohibited Services.

(h)              
“Protected Radius” means the 25-mile area surrounding any medical clinic, center or facility that is
(a) owned or managed by Buyer, Seller, or any of their Affiliates (including any clinic, center or facility which any of such
parties is committed to owning, opening or managing) on the Separation Date, (b) located in the State of North Carolina, and (c)
that serves as a place of treatment for patients seeking any of the Prohibited Services. For the avoidance of doubt, such clinic,
centers and facilities referenced in the preceding sentence shall not include a free-standing or hospital-based emergency department,
hospice facility, or any other clinic not serving as a place of treatment for patients seeking any of the Prohibited Services.

    2 

     

    

(i)                
“Separation Date” means the date Physician ceases to perform services, directly or indirectly, for or
on behalf of Buyer in any capacity, including as an employee, independent contractor, or employee or contractor of an independent
contractor.

3.                 
Non-Competition. During the Covered Period, and except on behalf or for the benefit of Seller, Physician shall not, directly
or indirectly, for Physician’s own account or for others, (a) perform any Prohibited Services within the Protected Radius,
or (b) operate, manage, consult for, or own (directly or indirectly) any interest in any business or entity that renders Prohibited
Services within the Protected Radius. The foregoing is not intended nor shall it be interpreted to prohibit Physician from working
for or on behalf of Seller or from referring any patient for any goods or services to any clinic, facility or health care center
that, in such Physician’s independent medical judgment, is in the best interests of such patient.

4.                 
Non-Solicitation. From the Closing Date until two years after the Separation Date, Physician shall not, directly or indirectly,
for Physician’s own account or for others, (a) hire, attempt to hire, contact or solicit with respect to hiring, any employee
or independent contractor of Buyer or Seller who was an employee or independent contractor of Buyer or Seller on the Separation
Date; or (b) call upon, solicit, divert or take away, any (i) patient who has received treatment or (ii) client whose employees
or agents have received treatment or testing, during the 12 months preceding the Separation Date at any clinic, center or facility
owned or managed by Buyer or Seller, except to the extent such a restriction would be in violation of applicable Law (including
the regulations of the North Carolina Medical Board).

5.                 
Confidentiality. Except as necessary in the performance of services for or on behalf of the Seller and unless otherwise
jointly authorized by Buyer and Seller, Physician will hold and keep confidential all Confidential Information (as defined below)
to which Physician, at any time shall have become informed, and Physician will not, directly or indirectly, disclose any Confidential
Information to any person, firm, corporation or entity, or use the same, or permit the same to be disclosed or used. “Confidential
Information” as used herein means proprietary information of Buyer or Seller relating to the Business, whether involving
any Buyer Party, any Seller Party or that which is developed exclusively by or for the benefit of any Buyer Party or any Seller
Party in connection with the Business or the Transactions. Confidential Information, and may include, without limitation, the following
types of information: corporate information, including business information, plans, strategies, tactics, or policies; marketing
information, including strategies, tactics, methods, customer and patient lists, prospects, and market research data; financial
data or forecasts; policies or procedures; know-how and ideas; operational information, including trade secrets; and technical
information, including designs, drawings and specifications. Confidential Information is limited to that information which is not
generally known to or accessible by the public (other than as a result of unauthorized disclosure by any Seller Party) or within
the industry in which the Business is operated. This restriction on disclosure of Confidential Information shall terminate
three years after the Separation Date and shall not apply to the extent that (a) Physician is compelled by subpoena, court order
or other lawful process to provide such Confidential Information, provided Physician gives Seller reasonable notice of any such
subpoena, court order or other lawful process and an opportunity to oppose the disclosure or (b) the Confidential Information is
disclosed to the public through no fault of Physician.

6.                 
Non-Disparagement. Physician will not make any public statements, written or verbal, (or statements that are reasonably
likely to become public) that are defamatory, derogatory, or disparaging about, or that may adversely affect the Business, any
Buyer Party, Seller, or any other Seller Party (provided that with respect to comments relating to Seller Parties other than Seller
(other Shareholders), such prohibition shall apply only to public statements that may adversely affect the Business). This includes,
but is not limited to, making such statements on any internet site, blog or social media page, including Facebook, Google Plus,
Twitter, LinkedIn, or other internet sites, electronic medium or other public forum or medium. This prohibition applies to statements
made under false names, anonymously, or through third parties or other business entities. The terms “derogatory” or
“disparaging” as used in this Agreement are intended to cover any utterances or writings by Physician or at Physician’s
instruction that could be reasonably regarded by an objective person as tending to deprecate, discredit, demean, lower or diminish
the regard or reputation of or otherwise adversely affect the Business or the Buyer Entities as a result. Notwithstanding the
foregoing provisions of this Section 6, but subject to the confidentiality provisions set forth in Section 5, the
prohibitions contained in this Section 6 shall not prevent or preclude the Physician from exercising any rights or duties
Physician may have under applicable law, including the right to engage in protected concerted activity, the right and/or duty
to report and assist in the investigation of any violations of law or Seller’s employment policies, and the duty to respond
to any subpoena, court order or other lawful process, and any such activity shall not constitute a violation of this provision.

    3 

     

    

7.                 
Compliance.Physician acknowledges that compliance by Physician with the terms of this Agreement is necessary for (a)
Seller to continue operating at levels comparable to that existing at Closing, (b) for Buyer to realize the benefits of the Transactions,
and (c) for both Buyer and Seller to protect and secure, among other things (1) trade secrets of the Business; (2) valuable confidential
and professional information of the Business; (3) Seller’s relationships with existing patients; and (4) the goodwill associated
with the Business and the Purchased Assets purchased by Buyer under the Purchase Agreement. Further, Physician acknowledges and
agrees that irreparable injury, for which the remedy at law would be inadequate, will result to Buyer and Seller in the event of
a breach of this Agreement. Accordingly, Physician agrees that Buyer will be entitled, in addition to any other remedies and damages
available, including reasonable attorney fees incurred in the enforcement of the covenants and restrictions contained in this Agreement,
to an injunction to restrain the violation of the terms of this Agreement.

8.                 
Reasonableness; Severability. Physician acknowledges and agrees that the restrictions placed on Physician and the rights
and remedies conferred on Seller are reasonable in time, scope, and territory and are fully required to protect the legitimate
business interests of Buyer without a disproportionate detriment to Physicians. If any provision of this Agreement shall, for any
reason, be adjudged by any court of competent jurisdiction to be invalid or unenforceable (a) such provision shall remain in force
and effect to the maximum extent allowable, if any, and (b) such judgment shall not affect, impair, or invalidate the remainder
of this Agreement, but shall be confined in its operation to the provision of this Agreement directly involved in the controversy
in which such judgment shall have been rendered, and (c) and the enforceability or validity of the remaining provisions of this
Agreement shall not be affected thereby. If a court finds that any provision of this Agreement is invalid or unenforceable, but
that modification of such provision will make it valid or enforceable, then such provision shall be deemed to be so modified.

9.                 
Damage Limitation. Notwithstanding that Physician’s breach of any negative covenant in this Agreement could
foreseeably give rise to losses by both Buyer and Seller, any liability for damages under this Agreement shall be determined without
duplication of recovery by such parties.

    4 

     

    

 

10.             
Miscellaneous. This Agreement shall be construed and enforced in accordance with, and governed by, the laws of the State
of North Carolina (without regard to the conflicts of laws principles thereof). This Agreement embodies the entire agreement and
understanding between Seller, Buyer and Physician with respect to the subject matter hereof and supersedes all prior and contemporaneous
agreements and relating to the subject matter hereof. Except as expressly set forth in this Agreement, this Agreement may not be
modified or amended or any term or provision hereof waived or discharged except in writing signed by the party against whom such
amendment, modification, waiver, or discharge is sought to be enforced. All of the terms of this Agreement shall be binding upon
the parties hereto and their respective successors and assigns and shall inure to the benefit of and be enforceable by the parties
hereto, the Buyer Parties and their respective successors and assigns. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including .pdf) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

    5 

     

    

 

IN WITNESS WHEREOF, the parties hereto have duly
executed this Agreement as of the Effective Date.

 

 

	 	BUYER:	 
	 	 	 	 
	 	ACSH MEDICAL MANAGEMENT, LLC, 
	 	a Delaware limited liability company
	 	 	 	 
	 	 	 	 
	 	By:	 	 
	 	Name:   Norman B. Winland	 
	 	Title:   President	 
	 	 	 	 
	 	 	 	 
	 	SELLER:	 
	 	 	 	 
	 	MEDAC HEALTH SERVICES, P.A.,
	 	a North Carolina professional corporation 
	 	 	 	 
	 	 	 	 
	 	By:	 	 
	 	Name:   Michael P. Moulton, MD
	 	Title:   President	 
	 	 	 	 
	 	 	 	 
	 	PHYSICIAN:	 
	 	 	 	 
	 	 	 	 
	 	Sign: 	 	 
	 	Print: [Physician Name] 

 

 

 

 

 

 

 

 

 

[Signature Page – Restrictive
Covenant Agreement]

 

    	 

    	 

    

Exhibit E

 

Form of Bill of Sale

 

 

BILL OF SALE

 

1.                 
Sale and Transfer of Purchased Assets. For good and valuable consideration, the receipt, adequacy and legal sufficiency
of which are hereby acknowledged, and as contemplated by that certain Asset Purchase Agreement dated as of, 2015 (the
“Purchase Agreement”), by and among ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability
company (“Buyer”), MEDAC HEALTH SERVICES, P.A., a North Carolina professional corporation (“Seller”),
each of the shareholders of Seller, and KEVIN E. POTTS, MD, Seller hereby sells, assigns, transfers, conveys and delivers
to Buyer, effective as of 11:59 p.m. Atlanta, Georgia time on , 2015 (the “Closing Date”), all of Seller’s
right, title and interest in and to the Purchased Assets. Capitalized terms used and not defined herein shall have the meaning
ascribed thereto in the Purchase Agreement.

 

2.                 
Terms of the Purchase Agreement. The terms and conditions of the Purchase Agreement, including, without limitation, the
representations, warranties, covenants, agreements and indemnities are incorporated herein by this reference. In the event of any
conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, except with respect to the transfer
described in Paragraph 1 above, the terms of the Purchase Agreement shall govern.

 

3.                 
Further Assurances. Seller for itself and its successors and assigns, hereby covenants and agrees that, at any time and
from time to time upon the written request of Buyer, Seller will do, execute, acknowledge and deliver or cause to be done, executed,
acknowledged and delivered, all such further acts, deeds, assignments, transfers, conveyances, powers of attorney and assurances
as may be reasonably required by Buyer in order to assign, transfer, set over, convey, assure and confirm unto and vest in Buyer,
its successors and assigns, title to the Purchased Assets.

4.                 
Governing Law. This Bill of Sale shall be governed by and construed in accordance with the law of the State of North Carolina.

 

 

[Signature Page Follows]

 

 

    	 

     

    

IN WITNESS WHEREOF, Seller has duly executed
this Bill of Sale as of the Closing Date.

 

 

SELLER:

 

MEDAC HEALTH SERVICES, P.A.,

a North Carolina professional corporation

 

 

By: _______________________________ 

Name: Michael P. Moulton, MD

Title:President

 

    	 

    	 

    

Exhibit F

 

Form of Assignment and Assumption Agreement

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (the “Agreement”),
is made and entered into as of , 2015 (the “Closing Date”), by and among ACSH MEDICAL
MANAGEMENT, LLC, a Delaware limited liability company (“Buyer”) and MEDAC HEALTH SERVICES, P.A.,
a North Carolina professional corporation (“Seller”), and all of the shareholders of the Seller
(the “Shareholders” and together with Seller, “Seller Parties”).

 

RECITALS:

A.                
Seller Parties and Buyer, among others, are party to that certain Asset Purchase Agreement dated as of , 2015 (the “Purchase
Agreement”). Capitalized terms used and not defined herein shall have the meaning ascribed thereto in the Purchase
Agreement.

B.                
Each Shareholder has appointed Kevin E. Potts, MD (“Seller Representative”) as its agent, attorney-in-fact
and authorized representative to, among other things, enter into this Agreement on such Shareholder’s behalf.

C.                
Subject to the terms and conditions of the Purchase Agreement, Seller Parties have agreed to assign all of their respective right,
title and interest in, to and under the Assumed Contracts, to Buyer, and Buyer has agreed to assume and perform certain Liabilities
under the Assumed Contracts as set forth herein.

AGREEMENT

In consideration of the above Recitals and the
promises and provisions set forth in this Agreement, the adequacy and sufficiency of which the parties acknowledge, the parties,
intending to be bound, agree as follows:

 

1.                 
Recitals. The above Recitals are incorporated into this Agreement by reference.

 

2.                 
Assignment and Assumption of Assumed Contracts. Seller Parties, to the extent permitted by applicable Law, hereby assign
to Buyer all of Seller Parties' right, title and interest in, to and under the Assumed Contracts and Buyer hereby assumes and agrees
to pay, perform, fulfill and otherwise discharge when due all payment and/or performance obligations and all other Liabilities
of Seller Parties relating to or arising out of any Assumed Contract, but only to the extent such Liabilities do not relate to
or arise from (a) a breach or failure to perform when due any of the terms of the Assumed Contracts prior to Closing or (b) any
action, omission or occurrence taking place prior to Closing. 

 

3.                 
No Other Assumption. Buyer does not assume any of the Retained Liabilities.

 

4.                 
Binding Effect. This Agreement shall bind and inure to the benefit of parties
hereto and their respective successors and permitted assigns. No provision of this Agreement is intended to, or shall, confer any
third party beneficiary or other rights or remedies upon any person other than the parties hereto.

 

5.                 
Terms of Purchase Agreement. Nothing in this Agreement is intended to modify, amend, or alter in any respect the rights
and obligations of the parties under the Purchase Agreement. In the event of any conflict or inconsistency between the terms of
the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern

 

    	1

     

    

6.                 
Governing Law. This Agreement, and any and all claims arising hereunder,
shall be governed by, and construed in accordance with, the laws of the State of North Carolina, without giving effect to principles
of conflicts of laws.

 

7.                 
Further Assurances. Buyer and Seller Parties shall execute and deliver all such other instruments and agreements and take
all such further actions as may be reasonably required to carry out the Transactions.

 

8.                 
Counterparts. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including .pdf) or other transmission method approved by the receiving party,
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 

 

 

 

[Signature Page Follows]

    	 

     

    

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the Closing Date.

 

 

BUYER:

 

ACSH MEDICAL MANAGEMENT, LLC,

a Delaware limited liability company

 

 

By: ________________________ 

Name:  ______________________

Title:  _______________________

 

 

SELLER PARTIES:

 

MEDAC HEALTH SERVICES, P.A.,

a North Carolina professional corporation

 

 

By:  ________________________

Name: Michael P. Moulton, MD

Title: President

 

 

On Behalf of Each Shareholder 

 

 

 

Sign:  ________________________

Print: Kevin E. Potts, MD, attorney-in-fact

 

 

    	 

    	 

    

Exhibit G

 

Form of Closing Certificate

 

 

CLOSING CERTIFICATE OF BUYER

 

ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited liability
company (“Buyer”), hereby certifies, represents and warrants as of , 2015 to MEDAC HEALTH
SERVICES, P.A., a North Carolina professional corporation (“Seller”) and  as
follows:

 

1.                 
Each of the representations and warranties made by Buyer in that certain Asset Purchase Agreement dated as of July ___, 2015, by
and among Buyer and Seller Parties (the “Purchase Agreement”), which representations and warranties are
incorporated herein as though set out in full herein, (A) were true, accurate and complete in all respects (subject to any express
qualifications as to materiality contained therein) on and as of the Effective Date, and (B) are true, accurate and complete in
all respects (subject to any express qualifications as to materiality contained therein) and not breached as of Closing except,
in both cases, for such representations and warranties that speak as of a specific date or time, which were true, accurate and
complete as of such date or time. Capitalized terms used and not defined herein shall have the meaning ascribed thereto in the
Purchase Agreement.

 

2.                 
Each covenant and obligation required to be performed by Buyer prior to or at Closing pursuant to the Purchase Agreement has been
performed in all material respects, unless expressly waived by or on behalf of Seller.

 

3.                 
The undersigned acknowledges that this Closing Certificate is being delivered to Seller Parties pursuant to the Purchase Agreement
and that Seller Parties will rely on this Closing Certificate in closing the Transactions.

 

 

 

[Signature Page Follows]

 

    	1

     

    

IN WITNESS WHEREOF, this Closing Certificate has been executed as
of the Closing Date.

 

 

BUYER:

 

ACSH MEDICAL MANAGEMENT, LLC,

a Delaware limited liability company

 

 

By: __________________________

Name: Norman B. Winland

Title: President

 

 

 

 

 

 

 

 

 

[Signature Page to Closing Certificate of Buyer]

    	 

     

    

CLOSING CERTIFICATE OF SELLER PARTIES 

 

MEDAC HEALTH SERVICES, P.A., a North Carolina professional
corporation (“Seller”), and all of the shareholders of Seller (the “Shareholders”
and together with Seller and the Seller Representative (defined below), “Seller Parties”) hereby, jointly
and severally, certify, represent and warrant as of , 2015 to ACSH MEDICAL MANAGEMENT, LLC, a Delaware limited
liability company (“Buyer”) as follows:

 

1.                 
Each of the representations and warranties made by Seller Parties in that certain Asset Purchase Agreement dated as of July ___,
2015, by and among Buyer and Seller Parties (the “Purchase Agreement”), which representations and warranties
are incorporated herein as though set out in full herein, (A) were true, accurate and complete in all respects (subject to any
express qualifications as to materiality contained therein) on and as of the Effective Date, and (B) are true, accurate and complete
in all respects (subject to any express qualifications as to materiality contained therein) and not breached as of Closing, except,
in both cases, for such representations and warranties that speak as of a specific date or time, which were true and accurate (in
all respect or all material respects, as the case may be) as of such date or time. Capitalized terms used and not defined herein
shall have the meaning ascribed thereto in the Purchase Agreement.

 

2.                 
Each Shareholder has appointed Kevin E. Potts, MD (“Seller Representative”) as its agent, attorney-in-fact
and authorized representative to, among other things, sign this Closing Certificate on such Shareholder’s behalf. The power
and authority granted to Seller Representative by the Shareholders in the Purchase Agreement remains in full force and effect,
and no Shareholder has taken any action or given any notice of such Shareholder’s intent to revoke, suspend or modify such
power and authority.

 

3.                 
Each covenant and obligation required to be performed by any Seller Party prior to or at Closing pursuant to the Purchase Agreement
has been performed in all material respects, unless expressly waived by Buyer.

 

4.                 
The undersigned acknowledges that this Closing Certificate is being delivered to Buyer pursuant to the Purchase Agreement and that
Buyer will rely on this Closing Certificate in closing the Transactions.

 

 

 

[Signature Page Follows]

 

 

 

    	 

     

    

IN WITNESS WHEREOF, this Closing Certificate
has been executed as of the Closing Date.

 

 

 

SELLER PARTIES:

 

MEDAC HEALTH SERVICES, P.A.,

a North Carolina professional corporation

 

 

By: ______________________

Name: Michael P. Moulton, MD

Title:President

 

 

On Behalf of Each Shareholder 

 

 

 

Sign:  ______________________

Print: Kevin E. Potts, MD, attorney-in-fact

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]